

**Wednesday, 18. October 2023***Pre-conference workshop/course*

09:30 - 13:30

MAZUREK

**WAVE workshop - Sex, drugs and data gaps***Pre-conference workshop/course*

09:30 - 09:40

MAZUREK

**Opening and update***Chair:* Annette Haberl, DE**Opening and update**

09:30 - 09:40

*Speaker:* Yvonne Gilleece, GB*Pre-conference workshop/course*

09:30 - 15:00

ETIUDA

**EACS pre-educational course***Pre-conference workshop/course*

09:30 - 09:35

ETIUDA

**Introduction****Introduction**

09:30 - 09:35

*Speaker:* Tristan Barber, GB*Speaker:* Jose I Bernardino, ES*Speaker:* Laura Waters, GB*Pre-conference workshop/course*

09:35 - 10:35

ETIUDA

**Achieving zero by 2023: Approaches to HIV testing***Chair:* Jose I Bernardino, ES*Chair:* Oana Sandulescu, RO**Achieving zero by 2023: Approaches to HIV testing**

09:35 - 10:05

*Speaker:* Raquel Martin-Iguacel, DK*Speaker:* Daniel Simões, PT*Speaker:* Takashi Muramatsu, JP*Pre-conference workshop/course*

09:40 - 10:20

MAZUREK

**It's a heartache - CVD risks in women living with HIV***Chair:* Dagny Krankowska, PL**It's a heartache - CVD risks in women living with HIV**

09:40 - 10:20

*Speaker:* Chris Longenecker, US*Discussant:* Annette Haberl, DE*Discussant:* Yvonne Gilleece, GB*Pre-conference workshop/course*

10:00 - 12:30

SONATA

**EATG STEPS 9 "A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection"****Welcome & Introduction**

10:00 - 10:15

*Speaker:* Brian West, BE**Approaches to a cure - clades and latency reversing agents**

10:15 - 10:35

*Speaker:* Kathryn S. Hensley, NL

<b>Shrinking the reservoir with early treatment and using latency-reversing agents</b>	10:35 - 10:55
<i>Speaker:</i> Henrieke Prins, NL	
<b>Break</b>	10:55 - 11:15
<b>Different approaches to cure including the use of mRNA technology</b>	11:15 - 11:35
<i>Speaker:</i> Mario Ostrowski, CA	
<b>The impact of cure research on people living with HIV</b>	11:35 - 11:55
<i>Speaker:</i> Grzegorz Jezierski, PL	
<b>Q&amp;A Session</b>	11:55 - 12:20
<i>Moderator:</i> Brian West, BE	
<b>Closing notes and next steps</b>	12:20 - 12:30
<i>Speaker:</i> Brian West, BE	
<i>Pre-conference workshop/course</i> 10:20 - 10:50	MAZUREK
<b>Walking on the milky way - breastfeeding and HIV</b>	
<i>Chair:</i> Fiona Lyons, IE	
<b>Walking on the milky way - breastfeeding and HIV</b>	10:20 - 10:50
<i>Speaker:</i> Amy Keane, IE	
<i>Discussant:</i> Annette Haberl, DE	
<i>Discussant:</i> LeaSuwanna Griffith, GB	
<i>Pre-conference workshop/course</i> 10:35 - 10:55	ETIUDA
<b>Break</b>	
<i>Pre-conference workshop/course</i> 10:50 - 11:20	MAZUREK
<b>Break</b>	
<i>Pre-conference workshop/course</i> 10:55 - 11:45	ETIUDA
<b>HIV and HPV - where are we in 2023?</b>	
<b>HIV and HPV - where are we in 2023?</b>	10:55 - 11:45
<i>Speaker:</i> Déborah Konopnicki, BE	
<i>Case Presenter:</i> Owen Cachia, MT	
<i>Pre-conference workshop/course</i> 11:20 - 11:50	MAZUREK
<b>Girls just wanna have fun - PrEP in women living with HIV</b>	
<i>Chair:</i> María Jesús Pérez Elías, ES	
<b>Girls just wanna have fun - PrEP in women living with HIV</b>	11:20 - 11:50
<i>Speaker:</i> Naomi Fitzgerald, GB	
<i>Discussant:</i> Lella Cosmaro, IT	
<i>Discussant:</i> Yvonne Gilleece, GB	
<i>Pre-conference workshop/course</i> 11:45 - 12:35	ETIUDA
<b>PrEP practicalities: managing complexity with limited options</b>	
<b>PrEP practicalities: managing complexity with limited options</b>	11:45 - 12:35

*Speaker:* Bartosz Szetela, PL  
*Case Presenter:* Sashini Payagala, GB

*Pre-conference workshop/course*

11:50 - 12:20

MAZUREK

**Should I stay or should I go? HPV in women living with HIV**

*Chair:* Karoline Aebi-Popp, CH

**Should I stay or should I go? HPV in women living with HIV**

11:50 - 12:20

*Speaker:* Dagny Krankowska, PL

*Discussant:* Yvonne Gilleece, GB

*Industry sponsored session*

12:00 - 13:00

POLONEZ

**Industry sponsored session**

*Pre-conference workshop/course*

12:20 - 12:50

MAZUREK

**Hot stuff - menopause in women living with HIV**

*Chair:* Ellen Moseholm, DK

**Hot stuff - menopause in women living with HIV**

12:20 - 12:50

*Speaker:* Emma Graham, DK

*Discussant:* Harriet Langanke, DE

*Discussant:* Anna Hachfeld, CH

*Pre-conference workshop/course*

12:35 - 13:05

ETIUDA

**Lunch**

*Pre-conference workshop/course*

12:50 - 13:20

MAZUREK

**I'm every woman - HIV testing and care in migrant women**

*Chair:* Marta Vasylyev, UA

**I'm every woman - HIV testing and care in migrant women**

12:50 - 13:20

*Speaker:* Dagny Krankowska, PL

*Discussant:* Panagiota Lourida, GR

*Discussant:* Eliane Becks Nininahazwe, BI

*Meeting*

13:00 - 14:00

SONATA

**Improving access to PrEP and continuity of care in sex workers and other highly mobile populations: an initiative of SwissPrEPared in cooperation with the European Sex Workers' Rights Alliance (ESWA)**

*Chair:* Benjamin Hampel, CH

**Collaborative workshop**

13:00 - 14:00

*Pre-conference workshop/course*

13:05 - 13:55

ETIUDA

**Advances in HIV cure**

**Advances in HIV cure**

13:05 - 13:55

*Speaker:* Beatriz Mothe, ES

*Case Presenter:* Jesper Gunst, DK

*Pre-conference workshop/course*

13:20 - 13:30

MAZUREK

**Closing notes and next steps****Closing notes and next steps**

13:20 - 13:30

*Speaker:* Annette Haberl, DE*Pre-conference workshop/course*

13:55 - 14:45

ETIUDA

**Using novel antiretrovirals novel strategies wisely****Using novel antiretrovirals novel strategies wisely**

13:55 - 14:45

*Speaker:* Jürgen Rockstroh, DE*Case Presenter:* Bogusz Jan Aksak-Wąs, PL*Meeting*

14:30 - 16:00

SONATA

**PrEP, from pills to long-acting injectables: the current state of policy, marketing, and implementation in Eastern Europe and Central Asia (EECA)***Moderator:* Stela Bivol, CH*Moderator:* Nadiya Yanhol, UA**WHO birds' eye view on PrEP in EECA**

14:30 - 14:45

*Speaker:* Ioannis Mameletzis, UA**Challenges and opportunities of PrEP in Ukraine**

14:45 - 15:00

*Speaker:* US CDC / PEPFAR, UA**Policy environment and strategies for a broader implementation of PrEP in EECA based on SoS 2.0 project experience**

15:00 - 15:20

*Speaker:* Sergiy Philippovych, UA**Roll-out of PrEP in Ukraine: current status of PrEP programme in the context of war**

15:20 - 15:30

*Speaker:* Ioannis Mameletzis, UA**Discussion**

15:30 - 16:00

*Pre-conference workshop/course*

14:45 - 14:50

ETIUDA

**YIP****YIP**

14:45 - 14:50

*Speaker:* Casper Rokx, NL*Pre-conference workshop/course*

14:50 - 14:57

ETIUDA

**The Western-Eastern European Partnership Initiative on HIV, Viral Hepatitis and TB (WEEPI)****A foundation to improve quality of care through support of clinical or implementation research projects**

14:50 - 14:57

*Speaker:* Manuel Battegay, CH*Pre-conference workshop/course*

14:55 - 15:02

ETIUDA

**Summary and Close**

*Industry sponsored session*

15:00 - 16:30

POLONEZ

**Industry sponsored session***Meeting*

15:45 - 16:15

ETIUDA

**EACS press conference***Industry sponsored session*

16:30 - 17:30

MAZUREK

**Industry sponsored session***Industry sponsored session*

16:30 - 17:30

ETIUDA

**Industry sponsored session***Ceremony*

17:45 - 18:45

POLONEZ

**Opening ceremony****Introduction to the 19th European AIDS Conference**

17:45 - 18:00

*Speaker:* Esteban Martínez, EACS President, EACS Conference Co-Chair, ES*Speaker:* Justyna Kowalska, Local Conference Co-chair, PL*Speaker:* Magdalena Ankiersztejn-Bartczak, Local Community Co-Chair, PL**Welcome address**

18:00 - 18:05

**There and back again - HIV epidemic in Central Eastern Europe 20 years later**

18:05 - 18:20

*Speaker:* Justyna Kowalska, Local Conference Co-chair, PL**EACS Award 2023**

18:20 - 18:35

*Speaker:* Peter Reiss, EACS Award Chair, NL**Welcome to Warsaw**

18:35 - 18:40

**Thursday, 19. October 2023***Meet-the-expert*

07:30 - 08:30

MAZUREK

**MTE1 - Progress in liver diseases (HBV+HDV; HCV; NAFLD+NASH)***Moderator:* Arjan Harxhi, AL**What you need to know about HBV/HDV**

07:30 - 07:40

*Speaker:* Kathrin Van Bremen, DE**HCV: What remains to be done**

07:40 - 07:50

*Speaker:* Mojca Maticic, SI**NAFLD+NASH: The next challenge in people living with HIV**

07:50 - 08:00

*Speaker:* Patrick Ingiliz, FR**Roundtable discussion**

08:00 - 08:30

*Meet-the-expert*

07:30 - 08:30

ETIUDA

**MTE2 - Controversies around breastfeeding***Moderator:* Magdalena Marczyńska, PL**Controversies in breastfeeding - South Africa**

07:30 - 07:40

*Speaker:* Anna Coutoudis, ZA**Controversies in breastfeeding - Switzerland**

07:40 - 07:50

*Speaker:* Christian Kahlert, CH**Controversies in breastfeeding - Ireland**

07:50 - 08:00

*Speaker:* Fiona Lyons, IE**A pilot trial on initial treatment of HIV-infected pregnant women with 3TC/DTG: The PREGNANT Study**

08:00 - 08:10

*Oral Presenter:* Carlos Brites, BR**Does the COVID-19 vaccination impact on breastfeeding?**

08:10 - 08:20

*Oral Presenter:* Aleksandra Wesołowska, PL**Panel discussion**

08:20 - 08:30

*Meet-the-expert*

07:30 - 08:30

SONATA

**MTE3 - Quality of life of people living with HIV***Chair:* Lisa Power, GB**HIV justice**

07:30 - 07:40

*Speaker:* Timur Abdullaev, UZ**Drivers of satisfaction and health-related quality of life of people living with HIV within Europe: findings from a real-world survey of people living with HIV**

07:40 - 07:50

*Oral Presenter:* Paul O'Brien, GB**Discussion**

07:50 - 08:30

*Plenary lecture*

09:00 - 09:30

POLONEZ

**Going beyond HIV and STI with PrEP and PEP***Chair:* Deniz Gökengin, TR

**Going beyond HIV and STI with PrEP and PEP**

09:00 - 09:30

*Speaker:* Jean-Michel Molina, FR*ePosters*

09:00 - 18:00

**ePoster Exhibition****A. Basic & translational sciences**

09:00 - 09:00

**Targeting emtricitabine to HIV reservoir in mesenteric lymph nodes using lipophilic prodrug approach and lipidic formulation**

09:00 - 09:00

*Poster Presenter:* Graziamarina Sinatra, GB**Bictegravir and Dolutegravir influence leukocytes and/or platelets in a way that promotes a proinflammatory milieu which favors cardiovascular toxicity**

09:00 - 09:00

*Poster Presenter:* Juan V Esplugues, ES**Benefits of a change of ART to BIC/FTC/TAF in an HIV clinic in northern Mexico**

09:00 - 09:00

*Poster Presenter:* Luis Gerardo Castillo, MX**Cardiovascular disease prevalence in a cohort of HIV positive (PLWH) patients, over 50 years of age, in the era of the INSTI based regimen: a proof of concept retrospective analysis**

09:00 - 09:00

*Poster Presenter:* Marco Di Gregorio, IT**Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong**

09:00 - 09:00

*Poster Presenter:* Man Chun, Jacky Chan, HK**Fostemsavir in association with doravirine for the treatment of heavily treatment-experienced (HTE) PLWH with multi-drug resistant (MDR) HIV-1 infection: data from clinical practice**

09:00 - 09:00

*Poster Presenter:* Pierluigi Francesco Salvo, IT**Comparison of rapid ART versus delayed ART in viral load reduction and loss to follow-up in a cohort of naïve migrants living with HIV in a single tertiary care center in Florence, Italy**

09:00 - 09:00

*Poster Presenter:* Sasha Trevisan, IT**Real life evidence on dual therapy with dolutegravir and lamivudine**

09:00 - 09:00

*Poster Presenter:* Ana Caroline Coutinho Iglessias, BR**Bictegravir/Emtricitabine/Tenofovir Alafenamide use significantly improves CD4/CD8 ratio in women living with HIV over a 48-week treatment, with good safety and effectiveness**

09:00 - 09:00

*Poster Presenter:* Manuela Ceccarelli, IT**Assessment of the impact of the new blister packaging of Biktarvy® (B/F/TAF) on treatment satisfaction, in the treatment of people living with HIV-1**

09:00 - 09:00

*Poster Presenter:* Filipa Palha, PT**A shot in the dark: a review one year on after initiation of injectable HIV Treatment in a UK HIV outpatient clinic**

09:00 - 09:00

*Poster Presenter:* Jonathan Roberts, GB**CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine Fixed Dose Combination (FDC) in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France. One-year interim analysis results**

09:00 - 09:00

*Poster Presenter:* Patrick Philibert, FR

<b>Bikswitch study: effectiveness and safety of switching to a bictegravir-based antiretroviral therapy regimen from non-integrase inhibitor-based therapies in virologically suppressed HIV-infected patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> Francisco Jover, ES	
<b>Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks</b>	09:00 - 09:00
<i>Poster Presenter:</i> Christina Katerina Psomas, FR	
<b>Intermittent three-drug regimens (i-3DR) as maintenance ART: a meta-analysis including individual participant data</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jean-Jacques Parienti, FR	
<b>DoraVIH: Observational study of the reasons for switch to Doravirine-based regimen in patients with virological success and the choice of a treatment correlated to PRO</b>	09:00 - 09:00
<i>Poster Presenter:</i> Olivier Robineau, FR	
<b>HIV-2 in Germany: An observational study on the situation of people living with HIV-2 infection (PLHIV2) in Germany ("H2O")</b>	09:00 - 09:00
<i>Poster Presenter:</i> Dirk Berzow, DE	
<b>Investigation of the Causes of Suboptimal CD4 Cell Response in Advanced Stage HIV Patients Receiving Antiretroviral Therapy</b>	09:00 - 09:00
<i>Poster Presenter:</i> HÜLYA Özkan Özdemir, TR	
<b>Real-world 2-year weight changes among people with sustained HIV suppression : A multicenter French retrospective cohort study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Arnaud De La Blanchardiere, FR	
<b>Bictegravir versus Dolutegravir-based three-drug regimen in the setting of Rapid ART Initiation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Adriana Cervo, IT	
<b>DoDo: Real Life Experience with an Alternative Antiretroviral 2-Drug Regimen of Doravirine and Dolutegravir</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ulrich Seybold, DE	
<b>Weight and Body mass index gain among people living with HIV-1 switching to a single tablet of bictegravir /emtricitabine/tenofovir alafenamide</b>	09:00 - 09:00
<i>Poster Presenter:</i> Luiz Buzón, ES	
<b>Effectiveness and safety of a generic formulation of dolutegravir in clinical practice in a Latin American cohort: 18-month real-world data</b>	09:00 - 09:00
<i>Poster Presenter:</i> Diego Martin Cecchini, AR	
<b>Effectiveness and timing of viral load measurement in real-world use of long-acting cabotegravir-rilpivirine in people with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jose I Bernardino, ES	
<b>CAB + RPV long-acting antiretroviral therapy: real world data from an Italian single center in Rome</b>	09:00 - 09:00
<i>Poster Presenter:</i> Valentina Iannone, IT	
<b>Inflammation in HIV positive subjects on antiretroviral therapy: two-drug DTG based vs triple standard antiretroviral therapy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Claudio Ucciferri, IT	
<b>Changes in inflammation biomarkers after switching to TAF/FTC/BIC in experienced, virally suppressed People Living with HIV (PLHIV). Real world data</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vasilis Petrakis, GR	



<b>DOR-based therapy effectiveness as a switch regimen, real world study in Mexican population</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Antonio Mata-Marín, MX	
<b>Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people living with HIV who start a regimen with DTG/ABC/3TC compared to those who start BIC/FTC/TAF at 48-week follow-up at the Hospital de Infectología CMN "La Raza": a preliminary analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Antonio Mata-Marín, MX	
<b>Predictive capacity of the 7-item I-Score, a patient-reported measure of barriers to ART adherence for HIV care</b>	09:00 - 09:00
<i>Poster Presenter:</i> Bertrand Lebouché, CA	
<b>Bictegravir/emtricitabine/tenofovir alafenamide vs. other regimens for initial therapy in late presenters with AIDS-defining conditions.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ignacio Perez Valero, ES	
<b>Effects of albuvirtide intensification on CD4 T cell reconstitution in acquiring HIV clients with incomplete immune reconstitution</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ping Ma, CN	
<b>Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Maria Mazzitelli, GB	
<b>Potential Post Treatment HIV Controllers Have a Lower Burden of Comorbidities and of Non-antiretroviral Co-medications</b>	09:00 - 09:00
<i>Poster Presenter:</i> Micol Ferrara, IT	
<b>Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vani Vannappagari, US	
<b>HIV molecular epidemiology and resistance profiles in HIV-infected refugees from Ukraine in Hamburg, Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Anna Koval, UA	
<b>Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: findings from a University Hospital in Paris, France</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jade Ghosn, FR	
<b>Final results of <u>VICDOR</u>: Effectiveness of Switching to <u>DOR</u>-based antiretroviral therapy under real-world conditions in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Christoph Wyen, DE	
<b>Acceptability and health-related quality of life among HIV patients switching to a dual therapy with DTG/3TC: results from PROBI study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Martin Duracinsky, FR	
<b>Who wants to switch to injectables? Patients' preferences, perceptions and knowledge in the Swiss HIV Cohort Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Yonas Martin, CH	
<b>The two sides of doravirine-based regimens: a descriptive study focusing on kidney function and lipidic profile</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marianna Menozzi, IT	
<b>Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Nicholas Brian Bana, IT	

<b>Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People With HIV-1 (PWH) Aged ≥50 Years</b>	09:00 - 09:00
<i>Poster Presenter:</i> Emilio Letang, ES	
<b>Dolutegravir + lamivudine 2-drug regimen is highly effective and well-tolerated in a real-world clinical setting in Europe: data from the COMBINE-2 Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Cristina Mussini, IT	
<b>Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naive People With HIV-1 (PWH) and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review</b>	09:00 - 09:00
<i>Poster Presenter:</i> Emilio Letang, ES	
<b>Assessing the effectiveness and safety of lamivudine/dolutegravir versus bictegravir/emtricitabine/tenofovir alafenamide fumarate in adults living with Human immunodeficiency virus: one retrospective observational cohort study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Chien-Yu Cheng, TW	
<b>EFFECTIVENESS, SAFETY AND TOLERABILITY OF DOLUTEGRAVIR/LAMIVUDINE VERSUS TENOFOVIR ALAFENAMIDE/EMTRICITABINE/BICTEGRAVIR IN A REAL-LIFE COHORT OF HIV-1 VIROLOGICALLY SUPPRESSED TREATMENT EXPERIENCED PEOPLE LIVING WITH HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sara Tordi, IT	
<b>Clinical Characteristics and Antiretroviral Treatment Patterns in HIV-2 Infected Patients: Insights from a Tertiary Hospital in Portugal</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carmela Piñeiro, PT	
<b>Prospective assessment of viral rebound and associated risk factors in people living with HIV after achieving viral suppression in rural Tanzania</b>	09:00 - 09:00
<i>Poster Presenter:</i> Amina Nyuri, TZ	
<b>DOLAM-500: Efficacy and safety of Dolutegravir (DTG) plus Lamivudine (3TC) in ART-naive PLWH with baseline viral load ≥500.000 copies/ml</b>	09:00 - 09:00
<i>Poster Presenter:</i> Asuman Inan, TR	
<b>UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Kyle Ring, GB	
<b>Performance of hepatic steatosis serological scores and lipid profile safety in a virologically suppressed population in DTG/3TC</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marcello Trizzino, IT	
<b>Comparing lamivudine+dolutegravir and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve HIV-infected patients: preliminary results from clinical practice</b>	09:00 - 09:00
<i>Poster Presenter:</i> Hai Long, CN	
<b>Total HIV-DNA trend in complex ART-experienced PLWH switching to CAB+RPV long-acting injectable: 28-week results in a home-care assistance setting</b>	09:00 - 09:00
<i>Poster Presenter:</i> Valentina Iannone, IT	
<b>Real-world data on metabolic profile and renal function in a Latin American cohort of people living with HIV starting or switching to bictegravir/emtricitabine/tenofovir alafenamide fixed dose</b>	09:00 - 09:00

**combination: 48-week follow-up***Poster Presenter:* Diego Martin Cecchini, AR**Informing the design of HIV cure trials including antiretroviral treatment interruptions: the voices of people living with HIV**

09:00 - 09:00

*Poster Presenter:* Ming Jie Lee, GB**Lipid profile in people living with HIV after one year of antiretroviral therapy**

09:00 - 09:00

*Poster Presenter:* Agnieszka Lembas, PL**ORANGE STUDY: HIV Patients frOm UkRAine - ContiNuum of Care in Germany**

09:00 - 09:00

*Poster Presenter:* Annette Haberl, DE**Real-life data of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults living with VIH-1. 48-96 weeks results of RETROBIC study**

09:00 - 09:00

*Poster Presenter:* Jesús Troya, ES**BIC/FTC/TAF in PLWH with persistent low-level viremia: results of 48-96 weeks after switching**

09:00 - 09:00

*Poster Presenter:* Ignacio Santos, ES**Real-life data of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed women with VIH-1.**

09:00 - 09:00

*Poster Presenter:* Guillermo Pousada, ES**Real-world effectiveness and tolerability of doravirine-based antiretroviral therapy in people with HIV: a nationwide matched cohort study**

09:00 - 09:00

*Poster Presenter:* Patrick G. A. Oomen, NL**Fostemsavir use in the OPERA cohort: immunologic and virologic response**

09:00 - 09:00

*Poster Presenter:* Vani Vannappagari, US**Marginalization related to material deprivation and ethnic concentration among patients receiving injectable ART at academic HIV clinics in Toronto**

09:00 - 09:00

*Poster Presenter:* Ashan Wijesinghe, CA**Distinct lipidomic signatures in people living with HIV treated with EVG/c/FTC/TAF or BIC/FTC/TAF: a real-world prospective cohort study**

09:00 - 09:00

*Poster Presenter:* Biao Zhu, CN**Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection**

09:00 - 09:00

*Poster Presenter:* Nicholas Brian Bana, IT**3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-treated People Living With HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort**

09:00 - 09:00

*Poster Presenter:* Sebastian Noe, DE**Durability of two-drug antiretroviral regimens as maintenance therapy in people living with HIV and reasons for switch to a three-drug regimen: a real-life cohort study**

09:00 - 09:00

*Poster Presenter:* Emmanuelle Bontemps, FR**HIV viremias among patients who discontinued Cabotegravir(CAB)/ Rilpivirine(RPV) Long acting(LA) intramuscular(IM) in real-life setting**

09:00 - 09:00

*Poster Presenter:* Sophie Seang, FR

<b>Real life data on clinical and laboratory outcomes of long acting cabotegravir and rilpivirine in people with HIV</b> <i>Poster Presenter:</i> Maria Mazzitelli, GB	09:00 - 09:00
<b>REAL-WORLD EXPERIENCE OF TAF/FTC/BIC IN PEOPLE WITH HIV-2</b> <i>Poster Presenter:</i> Catarina Rodrigues, PT	09:00 - 09:00
<b>REAL-WORLD DATA ON PERSONS LIVING WITH HIV (PLWH) SWITCHING TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (BIC/FTC/TAF) WHILE VIROLOGICALLY SUPPRESSED: 96-WEEK DATA FROM THE ICONA COHORT</b> <i>Poster Presenter:</i> Antonella d'Arminio Monforte, IT	09:00 - 09:00
<b>Real-life experience on dolutegravir and lamivudine as initial or switch treatment in a silver population living with HIV</b> <i>Poster Presenter:</i> Maria Mazzitelli, GB	09:00 - 09:00
<b>Comparative observational study of darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus bicitegravir/emtricitabine/tenofovir alafenamide in high-risk non-adherent people living with HIV</b> <i>Poster Presenter:</i> Hernando Knobel, ES	09:00 - 09:00
<b>Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatment-naïve (TN) and -experienced (TE) people with HIV (PWH): 3-year effectiveness and safety outcomes in the BICSTaR observational cohort</b> <i>Poster Presenter:</i> Michael Sabranski, DE	09:00 - 09:00
<b>Comparative efficacy and safety of TAF/FTC/BIC, TAF/FTC+DTG, and TDF/FTC+DTG in naive people with HIV: results from the SCOLTA cohort</b> <i>Poster Presenter:</i> Andrea De Vito, IT	09:00 - 09:00
<b>Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virologically Suppressed Adults With HIV-1 Infection: a Multicenter, Randomized Controlled Study</b> <i>Poster Presenter:</i> Yueming Shao, CN	09:00 - 09:00
<b>Bictegravir/Emtricitabine/Tenofovir Alafenamide comparing with Tenofovir/Lamivudine/Efavirenz as an initial regimen in late presenters of Chinese HIV patients: a 24-week randomised multicentered clinical trial study</b> <i>Poster Presenter:</i> Wei Lyu, CN	09:00 - 09:00
<b>Efficacy and Safety of Fixed-dose Combination Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV-1: a Systematic Review and Meta-analysis</b> <i>Poster Presenter:</i> Wenjing Wang, CN	09:00 - 09:00
<b>Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1</b> <i>Poster Presenter:</i> Jason Hindman, US	09:00 - 09:00
<b>A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat</b> <i>Poster Presenter:</i> Arnold Xhikola, GB	09:00 - 09:00
<b>Evaluation of the viral reservoirs in people with HIV who start dual therapy: Results from the ANDES trial</b> <i>Poster Presenter:</i> Yanina Ghiglione, AR	09:00 - 09:00
<b>Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: week 49</b>	09:00 - 09:00

**results from a phase 3 trial***Poster Presenter:* Wayne Greaves, US**Subgroup analysis of week 48 efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily as initial HIV-1 treatment in a double-blind phase 3 trial**

09:00 - 09:00

*Poster Presenter:* Mary Pisculli, US**Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHT Study Through Week 240**

09:00 - 09:00

*Poster Presenter:* Antonella Castagna, IT**Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHT Study**

09:00 - 09:00

*Poster Presenter:* Josep M. Llibre, ES**Switching to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance - a Phase IV randomised, open-label pilot study (PIBIK study)**

09:00 - 09:00

*Poster Presenter:* Collins Iwuji, GB**Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial**

09:00 - 09:00

*Poster Presenter:* Jean-Michel Molina, FR**Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial**

09:00 - 09:00

*Poster Presenter:* Mary Pisculli, US**Virologic Outcomes of Lamivudine/Dolutegravir in Virologically suppressed persons with expected or confirmed resistance to Lamivudine (VOLVER clinical trial-GESIDA 11820)**

09:00 - 09:00

*Poster Presenter:* Rosa De Miguel, ES**Bictegravir/Emtricitabine/Tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial**

09:00 - 09:00

*Poster Presenter:* Carmen Hidalgo-Tenorio, ES**Pharmacokinetics/Pharmacodynamics and Virological Activity of VH3810109 (N6LS) in Antiretroviral-Naïve Viremic Adults From the Phase IIa BANNER Study**

09:00 - 09:00

*Poster Presenter:* A. Yin Edwards, US**Cabotegravir + Rilpivirine long-acting efficacy and safety outcomes by sex at birth, age and race: a subgroup analysis of the CARISEL study**

09:00 - 09:00

*Poster Presenter:* Kai Hove, GB**Efficacy, safety and implementation outcomes of Cabotegravir + Rilpivirine long-acting by country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL)**

09:00 - 09:00

*Poster Presenter:* Celia Jonsson-Oldenbüttel, DE**Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3 trials**

09:00 - 09:00

*Poster Presenter:* Jean-Michel Molina, FR

<b>No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials</b>	09:00 - 09:00
<i>Poster Presenter:</i> Parul Patel, US	
<b>Follow-up of injection site reactions in clinical studies of people using lenacapavir every 6 months for HIV treatment</b>	09:00 - 09:00
<i>Poster Presenter:</i> Antonella Castagna, IT	
<b>SOLAR 12-Month European Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ignacio Santos, ES	
<b>ANRS 177 DUETTO randomized, open-label and multicentric trial evaluating the non-inferiority of maintenance antiretroviral dual therapy taken 4 consecutive days per week versus dual therapy 7/7 days per week.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Roland Landman, FR	
<b>Analysis of transmitted HIV drug resistance and phylogenetic clusters in Bulgaria (2012-2020)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ivailo Alexiev, BG	
<b>The Efficacy and Tolerability of Latency Reversing Agents in Reactivating the HIV-1 Reservoir in Clinical Studies: a Systematic Review</b>	09:00 - 09:00
<i>Poster Presenter:</i> Kathryn S. Hensley, NL	
<b>Comparing viral re-suppression rates following antiretroviral therapy interruption in cure-related clinical studies: a systematic review and meta-analysis of intervention vs. non-intervention trials</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ming Jie Lee, GB	
<b>IMPACT OF ADMINISTRATION OF A LATENCY REVERSAL AGENT DURING INITIATION OF ANTIRETROVIRAL TREATMENT ON THE HIV RESERVOIR SIZE</b>	09:00 - 09:00
<i>Poster Presenter:</i> Erick De La Torre Tarazona, ES	
<b>Identification of therapeutic targets for HIV cure through high-throughput screening in novel <i>in vitro</i> non-clonal HIV-1 latency models</b>	09:00 - 09:00
<i>Poster Presenter:</i> Edurne Garcia-Vidal, ES	
<b>No Differences in HIV-1 Proviral Landscapes over 10 Years in Treated and Suppressed Individuals with Distinct HIV-1 Reservoir Dynamics</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jasmin Tschumi, CH	
<b>Performance Evaluation of two new molecular platforms for HIV-1 RNA measurement: the COBAS HIV-1 5800 and the NeuMoDx 96</b>	09:00 - 09:00
<i>Poster Presenter:</i> Eleni Papachristou, GR	
<b>Heparin-Binding Protein as a proinflammatory biomarker in people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Agnieszka Lembas, PL	
<b>Longitudinal immunophenotyping analysis of peripheral blood cells in PLWH on long-acting injectable HIV antiretroviral</b>	09:00 - 09:00
<i>Poster Presenter:</i> Raffaella Marocco, IT	
<b>Characterization of specific T-cell responses to a Three-Doses nonavalent HPV Vaccine Schedule in people living with HIV (PLWH) on antiretroviral therapy (ART)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Miriam Lichtner, IT	

<b>Mycobacterium tuberculosis infection associated immune perturbations correlate with antiretroviral immunity</b>	09:00 - 09:00
<i>Poster Presenter:</i> Katharina Kusejko, CH	
<b>Platelet responses are comparable in participants taking BIC/F/TAF or DRV/c/F/TAF in context of HIV test-and-treat</b>	09:00 - 09:00
<i>Poster Presenter:</i> Akif A. Khawaja, GB	
<b>Association of Susceptibility to Broadly Neutralizing Antibodies and Presence of Capsid CTL Epitopes During Acute HIV-1 Infection</b>	09:00 - 09:00
<i>Poster Presenter:</i> Laurie A. VanderVeen, US	
<b>T-cell responses to an original/BA.4-5 bivalent 4<sup>th</sup> mRNA vaccine dose in people living with HIV (PLWH) on efficacious cART</b>	09:00 - 09:00
<i>Poster Presenter:</i> Matteo Augello, IT	
<b>Development of highly conserved HIV-specific multiple CTL epitope vaccines based on the mRNA vaccine platform</b>	09:00 - 09:00
<i>Poster Presenter:</i> Zhihang Zheng, CN	
<b>B1. Clinical science - Antiretroviral therapy</b>	09:00 - 09:00
<b>Switching to bictegravir/emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Daniel Podzamczar, ES	
<b>Surveillance programme to identify and reduce Drug-Drug Interactions (DDI) with Protease Inhibitors (PI) in PLHIV and darunavir/cobicistat (DRV/c) based ART. HIPI Cohort</b>	09:00 - 09:00
<i>Poster Presenter:</i> Veronica Rico Gonzalez, ES	
<b>Outcomes of drug interactions between antiretrovirals and over-the-counter drugs: a real-world study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jose Molto, ES	
<b>A study of pharmacist antiretroviral stewardship in relation to drug-drug interaction (DDI) checking</b>	09:00 - 09:00
<i>Poster Presenter:</i> Arlene Heekin, IE	
<b>Polypharmacy, anticholinergic burden, and drug-drug interaction assessment in people living with HIV harboring a 4-class resistance: data from the PRESTIGIO Registry</b>	09:00 - 09:00
<i>Poster Presenter:</i> Maria Mazzitelli, GB	
<b>Virological rebound and the use of dietary supplements in people living with HIV: results of a survey</b>	09:00 - 09:00
<i>Poster Presenter:</i> Adriana Cervo, IT	
<b>Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naïve Ethiopians</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mulugeta Kiros, ET	
<b>Drug resistance mutations conferring resistance to integrase inhibitors among HIV patients in Tel Aviv, between 2010-2020, prevalence and risk factors</b>	09:00 - 09:00
<i>Poster Presenter:</i> Dan Turner, IL	
<b>Assessing the Utilization of HIV Genotype Resistance Testing: Insights from Italian Infectious Diseases Units</b>	09:00 - 09:00
<i>Poster Presenter:</i> Andrea De Vito, IT	
<b>Prevalence of doravirine (DOR) resistance associated mutations (RAMs) by algorithm in persons living with HIV (PLWH) and a history of failing a non-nucleoside reverse transcriptase inhibitor</b>	09:00 - 09:00

**(NNRTI) in Haiti***Poster Presenter:* Rafael Campo, US**Prevalence of Doravirine Resistance-Associated Mutations in Pregnant Women Living with HIV**

09:00 - 09:00

*Poster Presenter:* Javier Alejandro Sfalcin, AR**A cross-sectional analysis of HIV genotypic mutations and treatment efficacy; data from the All Ireland ID (AIID) Cohort**

09:00 - 09:00

*Poster Presenter:* Daragh Matthew McGee, IE**Real-world data on the use of the antiretroviral treatment (ART) regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c) and dolutegravir (DTG)**

09:00 - 09:00

*Poster Presenter:* Amy Keane, IE**Prevalence of Resistance-Associated Mutations in Treatment-Naïve people with HIV-1 (PWH) Amid the Era of Integrase-Strand Transfer Inhibitors in Taiwan**

09:00 - 09:00

*Poster Presenter:* Guan-Jhou Chen, TW**Prevalence and Profile of Drug Resistance Mutations Among Irregular Migrants From Latin America Living With HIV**

09:00 - 09:00

*Poster Presenter:* Samuel Manzano, ES**Sensitive HIV-1 DNA pol next generation sequencing (NGS) for the characterisation of archived antiretroviral drug resistance**

09:00 - 09:00

*Poster Presenter:* Johannes C Botha, GB**Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-naïve patients**

09:00 - 09:00

*Poster Presenter:* José Luis Blanco Arévalo, ES**Assessing phenotypic effect of integrase strand transfer inhibitor (INSTI)-based resistance substitutions linked to failures on cabotegravir**

09:00 - 09:00

*Poster Presenter:* Michelle L. D'Antoni, US**Unlocking Antiretroviral Treatment Potential: use of doravirine (DOR) in PLHIV with past NNRTI resistance associated mutations (RAMs)**

09:00 - 09:00

*Poster Presenter:* Basma Abdi, FR**Dolutegravir/rilpivirine (DTG/RPV) therapy as a maintenance treatment in PLWH with past virological failures and resistance-associated mutations to NNRTIs and INSTIs**

09:00 - 09:00

*Poster Presenter:* Romain Palich, FR**High levels of resistance among HIV-1 treatment-naïve PLHIV in Greece: Evidence for ongoing NNRTI transmitted resistance within local transmission networks**

09:00 - 09:00

*Poster Presenter:* Evangelia-Georgia Kostaki, GR**3-year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study)**

09:00 - 09:00

*Poster Presenter:* Anne-Geneviève Marcelin, FR**Resistance to doravirine after virologic failure to a first-line Non-Nucleoside Reverse Transcriptase Inhibitor based regimen: Data from a real life cohort in a Latin American country**

09:00 - 09:00

*Poster Presenter:* Maria Veronica Mingrone, AR**Do minority resistant variants in HIV-DNA predict virological**

09:00 - 09:00



	<b>rebound in highly treatment experienced PLWH under virological control? Data from the PRESTIGIO Registry</b>	
	<i>Poster Presenter:</i> Daniele Armenia, IT	
	<b>Proviral DNA for detection of HIV-1 subtype A drug resistance mutations</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Tal Levinson, IL	
	<b>DORAVIR: a French national survey of people with HIV-1 treated by an antiretroviral regimen including Doravirine</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Cathia Soulie, FR	
	<b>Comparative analysis of drug resistance among treatment-naïve Polish individuals and migrants living with HIV-1</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Kaja Scheibe, PL	
	<b>EFFICACY AND DURABILITY OF FOSTEMSAVIR-, IBALIZUMAB-, OR LENACAPAVIR-INCLUDING REGIMENS IN PEOPLE LIVING WITH A MULTIDRUG RESISTANT HIV: RESULTS FROM THE PRESTIGIO REGISTRY</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Vincenzo Spagnuolo, IT	
	<b>Transmitted drug resistance (TDR) surveillance in Croatia in period before and during COVID-19 pandemic</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Ana Planinic, HR	
	<b>Real life CABOTEGRAVIR (CAB) and RILPIVIRINE (RPV) pharmacokinetics among PLHIV treated with CAB RPV Long Acting (LA IM)</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Sophie Seang, FR	
	<b>Cabotegravir/Rilpivirin based long acting therapy with insufficient drug levels in routine drug monitoring</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Robert Ehret, DE	
	<b>Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Jean-Michel Molina, FR	
	<b>Tenofovir plasma and intracellular pharmacokinetics IN Insti-based regimens</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Micol Ferrara, IT	
	<b>IMPACT OF DIFFERENT ANTIRETROVIRAL DRUGS ON ADIPOCYTE DIFFERENTIATION</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Maria Aurora Carleo, IT	
	<b>Use of the data mining algorithms for the analysis of adverse event risks associated with antiretroviral treatment</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Przemysław Kłęsk, PL	
	<b>Subjective sleep quality evolution in patients starting or switching to dolutegravir or cabotegravir: a real-world longitudinal study</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Peter Messiaen, BE	
	<b>Dolutegravir discontinuation due to neuropsychiatric adverse events: a pharmacogenetic case-control study</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Julien De Greef, BE	
eP.B1.032	<b>Integrase strand-transfer inhibitor resistance in a tertiary hospital in Portugal</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Josefina Méndez, PT	
	<b>B2. Clinical science - Co-morbidities and ageing</b>	09:00 - 09:00

<b>Lipid changes and its impact on CV risk after hepatitis C virus eradication in HIV-HCV co-infected persons</b>	09:00 - 09:00
<i>Poster Presenter:</i> Anna Castelli, ES	
<b>Role of optical coherence tomography to assess cognitive impairment in person living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Agnès Libois, BE	
<b>Nonalcoholic fatty liver disease among people living with HIV (PLWH): a monocentric cross-sectional analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Benedetto Maurizio Celesia, IT	
<b>The role of CYP450 families in the management of dyslipidemia in PLWHIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Elio Gentilini Cacciola, IT	
<b>Low levels of cortisol in people living with HIV infection in the OVER50 Cohort: a hormonal substudy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Diana Hernandez-Sanchez, ES	
<b>Study of the Cardiovascular Disease Risk in People Living with HIV-1 in Portugal</b>	09:00 - 09:00
<i>Poster Presenter:</i> Isabel Casella, PT	
<b>Neuregulin 4 could be a new serum marker of insulin resistance, diabetes and lipid disorders development in people living with HIV on suppressive antiretroviral therapy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mariusz Sapała, PL	
<b>Cardiovascular risk assessment with SCORE, SCORE2 and D:A:D in people living with HIV with high prevalence of cardiovascular risk factors</b>	09:00 - 09:00
<i>Poster Presenter:</i> Inês Pintassilgo, PT	
<b>Prevalence and predictors of non-alcoholic fatty liver disease (NAFLD) among Egyptian people living with HIV: a cross-sectional study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Rahma Mohamed, EG	
<b>Prevalence and predictors of erectile dysfunction in a contemporary cohort of greek people living with HIV (PLHIV) - a single center experience</b>	09:00 - 09:00
<i>Poster Presenter:</i> Konstantinos Protopapas, GR	
<b>Prevalence of Cardiovascular Disease Risk Factors and Calculation of Cardiovascular Disease Risk in a Cohort of People Living with HIV in Lebanon</b>	09:00 - 09:00
<i>Poster Presenter:</i> Remie El Helou, LB	
<b>Cognitive trajectories among people with HIV attending a dedicated memory clinic for people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jaime Vera, GB	
<b>Characterization of transient elastography findings among Egyptian people living with HIV: a spotlight on steatotic liver disease</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ahmed Cordie, EG	
<b>Awareness and acceptability of herpes zoster vaccination in people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Christian Motet, BE	
<b>ATTITUDE TOWARDS ALCOHOL INTAKE IN PLWHA: IMPLICATION FOR DIETITIAN COUNSELLING</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giancarlo Orofino, IT	

<b>The CYP2B6 Gene Polymorphism Is Associated with An Increased Risk of Cardiovascular Disease and Weight Gain in People Living with HIV on Antiretroviral Therapy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Yuan-Ti Lee, TW	
<b>Humoral response 24 months after first COVID-19 vaccination in PWH with and without diabetes mellitus</b>	09:00 - 09:00
<i>Poster Presenter:</i> Louise Bering, DK	
<b>Incidence of bacterial respiratory infection and pneumonia in people with HIV with and without airflow limitation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Safura-Luise Heidari, DK	
<b>Is there evidence for immunological alterations with GLP-1 agonists in people living with HIV?</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sebastian Noe, DE	
<b>Socio-economic and demographic determinants of medication prescription in the Swiss HIV Cohort Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Chloé Pasin, CH	
<b>Intensive care unit treatment in people living with HIV in Croatia: a single Centre 25-year experience</b>	09:00 - 09:00
<i>Poster Presenter:</i> Filip Glavac, HR	
<b>Unmasking the Invisible Threat: Evaluating Cardiovascular Risks Among Smokers Living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Bogusz Jan Aksak-Wąs, PL	
<b>The first two lung transplants in persons living with HIV at Puerta de Hierro Hospital (Madrid, Spain)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Alberto Díaz-de Santiago, ES	
<b>Longitudinal Analysis of Cerebrospinal Fluid HIV RNA in Untreated People with HIV: Identification of Cerebrospinal fluid Controllers</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mattia Trunfio, US	
<b>Incidence of Metabolic Syndrome in People living with HIV Starting ART with a Dolutegravir Based-Regimen vs Bictegravir Based-Regimen After 24 Weeks in Mexico</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jose Antonio Mata Marín, MX	
<b>Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carmela Pinnetti, IT	
<b>CORRELATION OF ANTHROPOMETRIC PARAMETERS TO EPICARDIAL AND VISCERAL FAT IN PATIENTS RECEIVING ANTIRETROVIRAL TREATMENT</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vanja Andric, RS	
<b>Statins and acetylsalicylic acid (ASA) use and LDL cholesterol value below 70 mg/dl in people living with HIV (PLWH): there is a gap between European AIDS Clinical Society guidelines and clinical practice</b>	09:00 - 09:00
<i>Poster Presenter:</i> Benedetto Maurizio Celesia, IT	
<b>The interplay between adipose tissue properties and levels of NT-proBNP in people with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mads-Holger Bang Jacobsen, DK	
<b>Infectious disease events in people with HIV receiving kidney transplantation - analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Katharina Kusejko, CH	

<b>Weight gain and loss and stable weight in relation to fat and lean mass in PWH</b>	09:00 - 09:00
<i>Poster Presenter:</i> Nicole Barp, IT	
<b>LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giorgia Carrozzo, IT	
<b>Associations between multimorbidity burden and objective and patient-reported health outcomes among people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Caroline Sabin, GB	
<b>Bictegravir and Dolutegravir have no impact on glucose levels 12 months after initiation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Nicola Squillace, IT	
<b>Divergent effects of SSRIs and SNRIs on blood and cerebrospinal fluid inflammatory markers in virally suppressed people with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mattia Trunfio, US	
<b>Comparing the performance of cardiovascular risk models for a multicentre cohort of people living with HIV from the UK in an era of modern ART</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ming Jie Lee, GB	
<b>NEW RISK FACTORS FOR FRAGILITY FRACTURES MUST BE CONSIDERED IN OLDER ADULTS WITH HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Fátima Brañas, ES	
<b>The influence of COVID-19 pandemic on HIV care in Izmir, Türkiye</b>	09:00 - 09:00
<i>Poster Presenter:</i> Arzu Nazli, TR	
<b>Going virtual: Experience with conducting an HIV research study virtual visits during COVID-19 Lockdown in Kampala Uganda</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sylvia Namanda, UG	
<b>Spike-specific CD8+ T cell responses after SARS-CoV-2 mRNA vaccination in people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Matthias Müller, DE	
<b>Immune response to routine COVID-19 vaccination amongst immunocompromised HIV patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ludwig Apers, BE	
<b>The impact of COVID -19 pandemic on HIV national testing treatment and care services in the country of Georgia</b>	09:00 - 09:00
<i>Poster Presenter:</i> Otar Chokoshvili, GE	
<b>PREDICTORS OF SARS-COV2 INFECTION IN TREATMENT-EXPERIENCED PLWHIV: CASE-CONTROL STUDY</b>	09:00 - 09:00
<i>Poster Presenter:</i> Valentina Iannone, IT	
<b>Comparative analysis of primary and monovalent booster SARS-CoV-2 vaccination coverage in adults with and without HIV in Catalonia, Spain</b>	09:00 - 09:00
<i>Poster Presenter:</i> Daniel Kwakye Nomah, ES	
<b>CELLULAR AND HUMORAL RESPONSE AFTER mRNA SARS-CoV-2 VACCINATION IN KIDNEY TRANSPLANT RECIPIENTS LIVING WITH HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Daniel Kwakye Nomah, ES	
<b>Immunogenicity of a bivalent Omicron BA.1 COVID-19 booster vaccination in people with HIV in the Netherlands</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marlou J Jongkees, NL	

<b>Humoral immunogenicity of mRNA SARS-COV-2 vaccines among people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Daniel Kwakye Nomah, ES	
<b>Interferon (IFN)-<math>\gamma</math> release assay (IGRA) as a practical tool to measure SARS-CoV-2 specific cellular immunity and guide the management of people with a history of advanced HIV infection</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ludovica Ferrari, IT	
<b>People living with HIV during the COVID-19 pandemic: Significant sex differences in health related quality of life - Results from the ANITA study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Johann Fabian Eberhardt, DE	
<b>The effect of the COVID-19 epidemic on the epidemiological course of the HIV infection in Greece</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giota Touloumi, GR	
<b>The mid-term effect of SARS-COV-2 on immune-oncology checkpoint inhibitors disruption in people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Celia Crespo-Bermejo, ES	
<b>Project 90 day ideal lifestyle modification onestep closer to the fourth 90</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ku Hsin Yen, TW	
<b>Prevalence of and risk factors associated with poor quality of sleep in people living with HIV and the correlation of quality of sleep and CD4+ T lymphocyte reconstitution: cross-sectional study from Turkey</b>	09:00 - 09:00
<i>Poster Presenter:</i> Özge Eren Korkmaz, TR	
<b>HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH HIV WITH LOW CD4+ CELL COUNTS. CHANGES IN THE LAST 25 YEARS AROUND THE WORLD. A SYSTEMATIC REVIEW AND METAANALYSIS</b>	09:00 - 09:00
<i>Poster Presenter:</i> Joaquin Portilla, ES	
<b>Prevalence and Correlates of Depression among HIV-Positive Ethiopian Migrants in Israel</b>	09:00 - 09:00
<i>Poster Presenter:</i> Hila Elinav, IL	
<b>Sleep disorders and Inflammation Biomarkers in People Living with HIV (PLHIV) monitored in a tertiary University Hospital of Greece</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vasilis Petrakis, GR	
<b>The Prevalence of Stigma, Depression and Anxiety in a Cohort of Treatment Controlled People Living with HIV in Lebanon: A Cross Sectional Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Remie El Helou, LB	
<b>Insomnia Assessment in PLWH: Utilizing the Soldatos Athens Insomnia Scale</b>	09:00 - 09:00
<i>Poster Presenter:</i> Georgios Adamis, GR	
<b>Health-related Quality of Life in Long-Term AIDS Survivors. A Co-Ris Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Joaquin Portilla, ES	
<b>Validation of a mobile health app as a health-related quality of life assessment instrument for people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Joanna Cano-Smith, ES	
<b>NO CHANGES IN THE IMPACT OF AIDS DIAGNOSIS IN HEALTH RELATED QUALITY OF LIFE DURING THE LAST 25 YEARS. A SYSTEMATIC REVIEW AND METAANALYSIS</b>	09:00 - 09:00

*Poster Presenter:* Joaquin Portilla, ES

**The relationship of interleukin-6, cystatin C, D-dimer levels with depression and anxiety in people living with HIV** 09:00 - 09:00

*Poster Presenter:* Melike Nur Kultur, TR

**Switching to bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study** 09:00 - 09:00

*Poster Presenter:* Stefan Esser, DE

**Patient reported outcomes in a Slovenian national cohort of people living with HIV; results of a cross-sectional study** 09:00 - 09:00

*Poster Presenter:* Jerca Ambrožič, SI

**WELL-BEING IN PEOPLE LIVING WITH HIV (PLWH) STARTING LONG-ACTING THERAPY** 09:00 - 09:00

*Poster Presenter:* Francesca Alberton, IT

**Implementing an electronic Patient-Reported Outcomes (ePROs) system for PLWH: experience of Icona cohort** 09:00 - 09:00

*Poster Presenter:* Antonella d'Arminio Monforte, IT

**Screening for neurocognitive impairment in people living with HIV (PLHIV) through patient-reported outcome measures (PROMs) and cognitive assessment** 09:00 - 09:00

*Poster Presenter:* Marie-Angélique De Scheerder, BE

**Patient-reported outcomes among people living with HIV on bicitgravir/emtricitabine/tenofovir alafenamide fixed-dose combination: real-world data from Latin America** 09:00 - 09:00

*Poster Presenter:* Diego Martin Cecchini, AR

**Symptomatic and "Asymptomatic" HIV-associated neurocognitive impairment, adherence to antiretroviral therapy, and viral control: a four-year observational study** 09:00 - 09:00

*Poster Presenter:* Elisa Vuaran, IT

**A quality of life indicator for HIV care beyond viral suppression in Spain** 09:00 - 09:00

*Poster Presenter:* Carlos Iniesta, ES

**The impact of the COVID-19 pandemic on cervical screening and outcomes for women living with HIV (WLHIV)** 09:00 - 09:00

*Poster Presenter:* Harriet Mortimer, GB

**Could DOL/LAM be a valid Dual-Therapy option even in onco-haematological patients? Data from a retrospective analysis** 09:00 - 09:00

*Poster Presenter:* Layla Pagnucco, IT

**Results of a survey conducted among Italian oncologists and infectious disease specialists evaluating the awareness about cancer in people living with HIV** 09:00 - 09:00

*Poster Presenter:* Eva Massari, IT

**Lung cancer screening with loose dose CT scan in persons living with HIV** 09:00 - 09:00

*Poster Presenter:* Alberto Díaz-de Santiago, ES

**HIV-aviremic PLHIV with Kaposi's Sarcoma (KS) are prone to KS relapses and chemotherapy failure and toxicities: results from the French CancerVIH Network** 09:00 - 09:00

*Poster Presenter:* Sophie Bacquart, FR

**Increasing numbers of scabies in people living with HIV** 09:00 - 09:00

Poster Presenter: Oğuzhan Acet, TR

**Epidemiological features of viral hepatitis among patients with HIV/AIDS** 09:00 - 09:00

Poster Presenter: Olena Zubach, UA

**The use of polymerase chain reaction (PCR) and cycle threshold values in the diagnosis of *Pneumocystis jirovecii* pneumonia** 09:00 - 09:00

Poster Presenter: Karen Olshtain Pops, IL

**Identification of transdiagnostic HIV-related Cryptococcosis by machine learning** 09:00 - 09:00

Poster Presenter: Xuemin Fu, DE

**Seroprevalence of Monkeypox (MPX) IgG antibodies in a cohort of PLWH in Rome, during the 2022 outbreak** 09:00 - 09:00

Poster Presenter: Pierluigi Francesco Salvo, IT

**Syphilis in the Ege University HIV cohort: what was the impact of the pandemic?** 09:00 - 09:00

Poster Presenter: Oğuzhan Acet, TR

**Sexually transmitted dermatophytes may cause severe infection among men who have sex with men as *tinea genitalis*** 09:00 - 09:00

Poster Presenter: David Chromy, AT

**Incidence of syphilis among HIV-infected men in Busan, Korea, 2005-2022: a retrospective cohort study** 09:00 - 09:00

Poster Presenter: Sun Hee Lee, KR

**Azithromycin-resistant *Mycoplasma genitalium* is frequently detected in men who have sex with men in Austria** 09:00 - 09:00

Poster Presenter: David Chromy, AT

**Mpox-associated complications during the 2022 outbreak in Buenos Aires, Argentina: a case series in a referral HIV clinic** 09:00 - 09:00

Poster Presenter: Julián Vega, AR

**Lymphogranuloma venereum: the relevance of asymptomatic patients** 09:00 - 09:00

Poster Presenter: Cristina Gómez-Ayerbe, ES

**Clinical manifestations of Ocular Syphilis in people living with HIV at a specialized primary care clinic** 09:00 - 09:00

Poster Presenter: Andrea Calderón Suárez, MX

**Prevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), and syphilis co-infection among people living with HIV (PLHIV): An Egyptian cross-sectional study** 09:00 - 09:00

Poster Presenter: Rahma Mohamed, EG

**Recently acquired hepatitis C virus (RAHCV) infection in men who have sex with men (MSM) in Southern Spain** 09:00 - 09:00

Poster Presenter: Cristina Gómez-Ayerbe, ES

**Clinical Characteristics and Treatment Outcomes of Neurosyphilis in People Living with HIV: A Multicentric Retrospective Cohort Study** 09:00 - 09:00

Poster Presenter: Giulia Moi, IT

**Trends of sexually transmitted infections among MSM individuals over 2022 in a large teaching hospital in Milan, Italy** 09:00 - 09:00

Poster Presenter: Davide Moschese, IT

**Current patterns of unprotected sex, drug use, and prevalence of STIs among MSM on HIV care or taking PrEP in the region of** 09:00 - 09:00

**Madrid***Poster Presenter:* Pablo Rayn, ES**Mycoplasma genitalium treatment and detection of 23S rRNA macrolide resistance mutations in PLWHIV and HIV-negative persons**

09:00 - 09:00

*Poster Presenter:* Alberto Díaz-de Santiago, ES**Diagnostic armamentaria for AIDS Defining Illnesses remains insufficient in the Central Eastern European region - data from ECEE Network Group**

09:00 - 09:00

*Poster Presenter:* Botond Lakatos, HU**Prevalence and clinical characteristics of late HIV presenters among persons who are enrolled in care at our clinic: an Egyptian cross-sectional study**

09:00 - 09:00

*Poster Presenter:* Rahma Mohamed, EG**Pneumocystis jirovecii pneumonia - Immune reconstitution inflammatory syndrome: Evidence based therapeutic recommendations to fill the void**

09:00 - 09:00

*Poster Presenter:* Natasha Marcella Vaselli, AU**Risk factors for incident tuberculosis among people living with HIV after starting TB preventive therapy in South Africa, Mozambique, and Ethiopia**

09:00 - 09:00

*Poster Presenter:* Felex Ndebele, ZA**Latent tuberculosis infection screening and treatment in people living with HIV in a low tuberculosis incidence country**

09:00 - 09:00

*Poster Presenter:* Inès Charachon, FR**Risk factor predictions for three-year mortality among HIV-related patients with disseminated Cryptococcosis**

09:00 - 09:00

*Poster Presenter:* Xuemin Fu, DE**Rilpivirine-based ART ameliorates liver fibrosis in persons with HIV (PWH) with MASLD (Metabolic dysfunction-associated steatitic liver disease) over a two-year period**

09:00 - 09:00

*Poster Presenter:* Maria Luisa Montes, ES**Clinical and laboratory features, and antiretroviral therapy in men living with HIV with hepatitis A**

09:00 - 09:00

*Poster Presenter:* Šime Zekan, HR**Changes in the prevalence of hepatitis B virus infection in people living with HIV in Seville from 2011 to 2022**

09:00 - 09:00

*Poster Presenter:* Marta Santos, ES**Spontaneous clearance of HCV and its chronic infection alters the immunophenotypical T-cell profile in PLWH**

09:00 - 09:00

*Poster Presenter:* Manuel Llamas-Adán, ES**To the liver and beyond: the impact of HCV clearance with direct antiviral agents in people living with HIV/HCV**

09:00 - 09:00

*Poster Presenter:* Mauro Bertolini, AR**THE SHIP: Testing Hepatitis E Seroprevalence among PLWHIV**

09:00 - 09:00

*Poster Presenter:* Karolina Akinosoglou, GR**Efficacy of Tenofovir Alafenamide- or Tenofovir Disoproxil Fumarate-containing Regimens in Adults with HIV-HBV Coinfection**

09:00 - 09:00

*Poster Presenter:* Fehmi Tabak, TR**The status of hepatitis C micro-elimination among people living**

09:00 - 09:00



**with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group**

*Poster Presenter:* Agata Skrzat-Klapaczyńska, PL

**Molecular and serological survey of rat hepatitis E virus (*Rocahepevirus rattii*) in people living with HIV in Spain**

09:00 - 09:00

*Poster Presenter:* Antonio Rivero-Juarez, ES

**Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany**

09:00 - 09:00

*Poster Presenter:* Patrick Ingiliz, DE

**Prevalence of NAFLD and risk factors associated with liver fibrosis in a cohort of people with HIV in Barcelona (Spain)**

09:00 - 09:00

*Poster Presenter:* Alberto Foncillas López, ES

**Long-term durability of immune response to hepatitis A vaccination among people living with HIV**

09:00 - 09:00

*Poster Presenter:* Takashi Muramatsu, JP

**Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: a cross-sectional study**

09:00 - 09:00

*Poster Presenter:* Patrick G. A. Oomen, NL

**FibroScan screening on detecting NAFLD in PLWH: the prevalence in our cohort and the role of high BMI as risk factor**

09:00 - 09:00

*Poster Presenter:* Caterina Candela, IT

**Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study**

09:00 - 09:00

*Poster Presenter:* Antonella Castagna, IT

**Evidence generation on ageing women living with HIV in Zimbabwe. An investment case to close the gap in ending AIDS**

09:00 - 09:00

*Poster Presenter:* Tendayi Westerhof, ZW

**The prevalence and prognostic of poor immunological recovery in viral suppressed elderly HIV-infected individuals**

09:00 - 09:00

*Poster Presenter:* Ping Ma, CN

**Frailty and quality of life for people with HIV in Cyprus: re-visiting the cascade of care**

09:00 - 09:00

*Poster Presenter:* Konstantina Stavrogianni, GR

**"Everyone seems already satisfied because people with HIV do not die from AIDS": iCOPE HIV's stakeholder survey to identify the unmet needs of ageing and older people living with HIV globally**

09:00 - 09:00

*Poster Presenter:* Mario Cascio, IT

**Predictors of Quality of Life among Older People Living with HIV in Kampala, Uganda**

09:00 - 09:00

*Poster Presenter:* Elizabeth Senkoro, TZ

**Neurocognitive impairment, and anxiety symptoms may influence the development of prefrailty/frailty in Japanese people living with HIV aged over 40 years**

09:00 - 09:00

*Poster Presenter:* Hideta Nakamura, JP

**One-year frailty transitions among persons living with HIV aged 70 years or more on ART**

09:00 - 09:00

*Poster Presenter:* Clotilde Allavena, FR

**B3. Clinical science - Sex, gender and sexuality**

09:00 - 09:00

<b>SEXUALLY TRANSMITTED INFECTIONS (STIs) IN OROPHARYNGEAL MUCOSA of ASYMPTOMATIC PEOPLE LIVING WITH HIV (PLHIV)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carmen Hidalgo-Tenorio, ES	
<b>Asymptomatic extragenital gonorrhea among transgender women: prevalence, bacterial resistance and clonal types involved</b>	09:00 - 09:00
<i>Poster Presenter:</i> Pedro Cahn, AR	
<b>How are trans women doing with HIV care and the UNAIDS 95-95-95 targets? A Look back at twelve years of data</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mauro Bertolini, AR	
<b>EFFECTS OF A SPECIALIZED HEALTHCARE PROGRAM FOR WOMEN WITH HIV ON THEIR RETENTION</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jessica Mejía-Castrejón, MX	
<b>HIV infection in female patients from Ukraine in Wroclaw, Poland</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mateusz Bożejko, PL	
<b>Efficacy and safety of doravirine-based regimens by sex and race: long-term results from three phase 3 clinical trials</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sharon Walmsley, CA	
<b>B4. Clinical science - Pregnancy, children and adolescents</b>	09:00 - 09:00
<b>Anthropometric characteristics of infants born to HIV-infected mothers</b>	09:00 - 09:00
<i>Poster Presenter:</i> E.N. Serhiyenka, BY	
<b>Pediatric participation in HIV cure research: a systematic review of clinical studies</b>	09:00 - 09:00
<i>Poster Presenter:</i> Yusuf Hassan Wada, NG	
<b>Efficacy of raltegravir for virological suppression at delivery in HIV positive pregnant women: a systematic review and meta-analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Huanmei Wu, CN	
<b>Before and after transition to adult care: the path of people living with perinatally acquired HIV in an upper middle-income country</b>	09:00 - 09:00
<i>Poster Presenter:</i> Julián Vega, AR	
<b>Sources of information on HIV knowledge for youth living with HIV in a refugee setting in Uganda</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mackline Hope, UG	
<b>C1. Epidemiology / public health / models of care</b>	09:00 - 09:00
<b>Comparison between patients who interrupted ART and those with late HIV diagnosis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Dagny Krankowska, PL	
<b>COCOVIIH: New data on cascade of care in France up to 2019. Fewer PLWHIV treated than expected</b>	09:00 - 09:00
<i>Poster Presenter:</i> Catherine Majerholc, FR	
<b>Implementation of telemedicine for HIV care in the public health system of Buenos Aires: A study based on surveys of physicians to assess the acceptability of this strategy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tomas Kierszenowicz, AR	
<b>HCV cascade of care in HIV/HCV coinfecting individuals: missed opportunities for micro-elimination</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giota Touloumi, GR	
<b>Reducing HIV-related maternal mortality through strengthening</b>	09:00 - 09:00

**Maternal Surveillance and Response (MPDSR) systems in Uganda***Poster Presenter:* Brenda Kharono, UG**Influence of indicator conditions on the late presenter and all-cause mortality among PLWH: a nationwide, retrospective cohort study from 2009 to 2015**

09:00 - 09:00

*Poster Presenter:* Chun-Yuan Lee, TW**Late presenters among people newly diagnosed with HIV infection during the COVID-19 pandemic**

09:00 - 09:00

*Poster Presenter:* Adriana Violeta Topan, RO**Survival of late HIV-presenters on DTG-based regimen ART in Ukraine**

09:00 - 09:00

*Poster Presenter:* Olena Marchenko, UA**Anchor drug associated with the odds of immunological recovery: a nation-wide register-based study between 2000 and 2022**

09:00 - 09:00

*Poster Presenter:* Josefin Nilsson, SE**Evolving trends in mortality patterns and predictors among people living with HIV in Catalonia and the Balearic Islands, Spain, 1998-2020: a multisite cohort study**

09:00 - 09:00

*Poster Presenter:* Sergio Moreno-Fornés, ES**Suicide mortality trends and predictors in the PISICS cohort of people living with HIV in Catalonia and the Balearic Islands, Spain**

09:00 - 09:00

*Poster Presenter:* Daniel Kwakye Nomah, ES**Trends of HIV mortality rate and its associated factors among people who inject drugs in Mizoram, Northeast India**

09:00 - 09:00

*Poster Presenter:* Lucy Ngaihbanglovi, AU**Evolution of causes of death in people living with HIV: a retrospective single-center observational study**

09:00 - 09:00

*Poster Presenter:* Giorgia Carrozzo, IT**Comparative analysis of abnormal cervical cytology among HIV positive & negative women in a Tertiary Hospital in Southern Nigeria**

09:00 - 09:00

*Poster Presenter:* Abuchi Okpara, NG**Estimation of the time of infection and missed opportunities for an early HIV diagnosis in Greece: The MORFEAS Program**

09:00 - 09:00

*Poster Presenter:* Mina Psychogiou, GR**Differential characteristics of newly diagnosed HIV cases since COVID-19 pandemic**

09:00 - 09:00

*Poster Presenter:* Tsz Ho Kwan, HK**Risk factors associated with non-condom use among people living with HIV in Brazzaville, Republic of Congo**

09:00 - 09:00

*Poster Presenter:* Martin Herbas Ekat, CG**HIV subtypes**

09:00 - 09:00

*Poster Presenter:* Claudia Afonso, PT**Analysis HIV-1 genetic diversity among MSM living in Russia in 2008-2023**

09:00 - 09:00

*Poster Presenter:* Anastasia Shlykova, RU**First regional HIV recent infection surveillance in Krasnodar region, Russia, 2021**

09:00 - 09:00

*Poster Presenter:* Anastasia Shlykova, RU**ACUTE HIV INFECTION IN GREECE: RESULTS FROM THE**

09:00 - 09:00

**"MORFEAS" PROJECT (Missed OpporTunities For an Early diAgnosis)***Poster Presenter:* Mina Psychogiou, GR**CQI Institutionalization to achieve optimal HIV Recency Testing Targets amidst COVID 19 resurgence: Busia HC IV Experience-Busia District**

09:00 - 09:00

*Poster Presenter:* Edward Mawejje, UG**HIV transmission dynamics networks - a molecular epidemiology study in Hong Kong between 2016 and 2022**

09:00 - 09:00

*Poster Presenter:* Tsz Ho Kwan, HK**Unveiling Patient Profiles: Insights into Functionality and Switching Perspectives of HIV Patients**

09:00 - 09:00

*Poster Presenter:* Roberto Caldera, IT**Late Diagnosis in HIV with New and Old Definitions; Data from a Regional Hospital in Turkey**

09:00 - 09:00

*Poster Presenter:* Yesim Tasova, TR**Molecular investigation of HIV-1 transmission patterns among people who inject drugs in Thessaloniki: Evidence for a recent outbreak in Greece**

09:00 - 09:00

*Poster Presenter:* Evangelia-Georgia Kostaki, GR**HIV care in Ukrainian migrants in two European countries-all the same?**

09:00 - 09:00

*Poster Presenter:* Kathrin Van Bremen, DE**Integration of HIV Recent Infection Testing Algorithm into HIV surveillance among Key Populations Across Six United States Agency for International Development (USAID) supported States in Nigeria: An Observational Study**

09:00 - 09:00

*Poster Presenter:* Ughweroghene Kingston Omo-Emmanuel, NG**Clinical characteristics, epidemiological trends and prognostic factors among people with HIV admitted to ICU due to an OI in Spain: a retrospective study**

09:00 - 09:00

*Poster Presenter:* Alberto Foncillas, ES**Pretreatment HIV-1 Resistance in Argentina: results from the second surveillance study following WHO guidelines (2019-2021)**

09:00 - 09:00

*Poster Presenter:* Sergio Martini, AR**Self-reported HIV diagnoses among trans and/or non-binary participants of the TASG study, a participatory study in Germany**

09:00 - 09:00

*Poster Presenter:* Uwe Koppe, DE**High proportion of post-migration HIV acquisition in immigrant men who have sex with men receiving HIV care in France, and association with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study**

09:00 - 09:00

*Poster Presenter:* Romain Palich, FR**Usability of a mobile health app aimed at people living with HIV to prepare for the next physician's visit**

09:00 - 09:00

*Poster Presenter:* Joanna Cano-Smith, ES**VAX-EMPOWERMENT PROJECT: IDENTIFYING PLWHA GROUP AT GREATEST RISK OF NON-ADHERENCE TO BEST ADAPT VACCINE HESITANCY INTERVENTIONS**

09:00 - 09:00

*Poster Presenter:* Giancarlo Orofino, IT**Impact of methadone substitution therapy on antiretroviral treatment efficacy. Ewa Pietraszkiewicz, Andrzej Horban, Ewa Firląg-**

09:00 - 09:00

**Burkacka, Justyna Kowalska***Poster Presenter:* Ewa Pietraszkiewicz, PL**Study on the Quality of Life of people living with HIV in Romania**

09:00 - 09:00

*Poster Presenter:* Mariana Mardarescu, RO**Clinical complexity of a cohort of PLWH based on Spanish Gesida/National Policy stratification system**

09:00 - 09:00

*Poster Presenter:* Ines Armenteros, ES**Management of metabolic syndrome by HIV physicians in the Central and Eastern Europe**

09:00 - 09:00

*Poster Presenter:* Daniela Maric, RS**Building a HIV combination prevention services checklist to assess their availability and access by key populations**

09:00 - 09:00

*Poster Presenter:* Ann Isabelle von Lingen, BE**Unleashing the power of proximity: early ART initiation in East Kazakhstan's remote regions**

09:00 - 09:00

*Poster Presenter:* Nadezhda Ryapolova, KZ**Levels of tetanus seroprotection in a cohort of Ukrainian PLWHA**

09:00 - 09:00

*Poster Presenter:* Kateryna Lytvyn, UA*Poster Presenter:* Heorhii Revenko, UA**HIV Testing in the Emergency Department: an effective strategy to increase new diagnoses**

09:00 - 09:00

*Poster Presenter:* Francesco Romano, IT**Preferences, motivations, and barriers to HIV self-testing uptake among men and women enrolled in a six-month PrEP dispensing program in Kenya**

09:00 - 09:00

*Poster Presenter:* Esther Rugendo, DE**Delay between primary care access and antiretroviral therapy initiation in the most precarious people living with HIV in Northern France: a monocentric study**

09:00 - 09:00

*Poster Presenter:* Ava Diarra, FR**HIV infection and linkage to care in migrants settling in Northern France: Data from associations providing initial health and social care services**

09:00 - 09:00

*Poster Presenter:* Ava Diarra, FR**Improving HIV Self-Test (HVST) Coverage and Case Finding among Adolescents in an OVC Preventive Program in Akwa-Ibom State**

09:00 - 09:00

*Poster Presenter:* Oluwaseyi Adeyemi, NG**HIV-positive patients with chronic total occlusion (CTO) face the dilemma of percutaneous coronary interventions**

09:00 - 09:00

*Poster Presenter:* H.S Natraj Setty, IN**Percutaneous Transvenous Mitral Commissurotomy (PTMC) in HIV positive patients with severe Mitral Stenosis (MS) - challenges and dilemmas**

09:00 - 09:00

*Poster Presenter:* H.S Natraj Setty, IN**Fostering Patient-Clinician communication to promote rapid HIV, HBV, and HCV diagnostic testing: the conceptual development of a multilingual application**

09:00 - 09:00

*Poster Presenter:* Martin Duracinsky, FR**Evaluation of the information level and attitude of people living with HIV, towards conduction of tele-health systems in healthcare,**

09:00 - 09:00

**and its relationship with their sociodemographic attributes***Poster Presenter:* Hayat Kumbasar Karaosmanoğlu, TR**Insights and experiences from the CAPELLA trial: perspectives of healthcare professionals and study coordinators on lenacapavir use amongst heavily treatment-experienced people with HIV**

09:00 - 09:00

*Poster Presenter:* Megan Dunbar, US**Treatment outcomes among children and adolescents living with HIV (CALHIV) receiving 1,3,6 months ART refills: a program data review in Eastern Uganda**

09:00 - 09:00

*Poster Presenter:* Bridget Ainembabazi, UG**ART access programme at Checkpoint BLN: High rate of late presentation among people living with HIV without health insurance in Berlin, Germany**

09:00 - 09:00

*Poster Presenter:* Christoph Weber, DE**Vaccination against COVID-19 among Healthcare Workers as a Cocoon Strategy for HIV-Positive Patients**

09:00 - 09:00

*Poster Presenter:* Agata Skrzat-Klapaczyńska, PL**The burden of CHEMSEX in Normandy, France: results of a systematic screening of drugs use in STI centers**

09:00 - 09:00

*Poster Presenter:* Guillemette Unal, FR**Benefit of a systematic health checkup for migrants at arrival: the example of Ukrainian refugees in Rouen, France**

09:00 - 09:00

*Poster Presenter:* Anaïs Lesourd, FR**Engagement of Role Model Fathers to improve male partner participation in the prevention of mother-to-child transmission of HIV in Tanzania**

09:00 - 09:00

*Poster Presenter:* Neema Makyao, TZ**A Prospective Assessment From Kenya of The HIV Enhanced Access Testing in the Emergency Department (HEATED) Program: A Pragmatic Evidence-based Approach to Increased Service Delivery Among High-Risk Groups For HIV**

09:00 - 09:00

*Poster Presenter:* Joshua Smith-Sreen, US**Temporal trends in the pattern of antiretroviral therapy prescription before and during COVID-19, Croatia, 2017-2022**

09:00 - 09:00

*Poster Presenter:* Šime Zekan, HR**Telemedicine Implementation in Buenos Aires during COVID-19 outbreak: implementation outcomes using implementation facilitation as a core strategy**

09:00 - 09:00

*Poster Presenter:* Tomas Kierszenowicz, AR**Barriers to HIV testing and possible interventions to improve healthcare among migrants, especially migrant women, in Europe**

09:00 - 09:00

*Poster Presenter:* Dagny Krankowska, PL**COCOVIIH: decrease in healthcare consumption by French PLHIV in 2019 over the last decade, comparison with other European countries**

09:00 - 09:00

*Poster Presenter:* François PrevotEAU du Clary, FR**Integrated assessment and management of non-communicable diseases (NCDs): a survey of HIV centers in the WHO European Region**

09:00 - 09:00

*Poster Presenter:* Christian Kraef, DK**Ensuring the continuity of ART during significant internal migration and disruption of the sustainable functioning of HCFs in**

09:00 - 09:00

	<b>the frontline and occupied territories of Ukraine</b>	
	<i>Poster Presenter:</i> Serhii Riabokon, UA	
	<b>What impact does ART packaging have on the daily lives of PLWH: results from the French national survey CONCERTO</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Romain Palich, FR	
	<b>ART access programme at Checkpoint BLN: High prevalence of sexually transmitted infections among people living with HIV without health insurance in Berlin, Germany</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Christoph Weber, DE	
	<b>Improving HIV testing and treatment using non-health facility HIV service: a mixed-methods study from Yogyakarta, Indonesia</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Yanri Wijayanti Subronto, ID	
	<b>Role of the Advanced Pharmacist Practitioner (APP)</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Marta Boffito, GB	
	<b>Management of Sexually Transmitted Infections in Central and Eastern Europe: Route to Improvement</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Deniz Gökengin, TR	
eP.C1.077	<b>Time to ART initiation: temporal trends and challenges from a single-center cohort</b>	09:00 - 09:00
	<b>Impact of hiding HIV positive status on PLWH treatment with ART: results from the French national survey CONCERTO</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Romain Palich, FR	
	<b>Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: a prospective study in out-patient clinics of the Parisian region.</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Agnieszka Kolakowska, FR	
	<b>Experience and barriers of counseling, testing and prevention of HIV in the practice of general practitioners in Ukraine</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Yulia Kvasnevskaya, UA	
	<b>What is the profile of patients on the same oral ART for over 10 years: results from the French national survey CONCERTO</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Romain Palich, FR	
	<b>MSM seeking care in free STI / HIV testing Checkpoints in Ukraine and Germany: comparative analysis of clinical and epidemiological characteristics</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Yaroslav Basarab, UA	
	<b>Predictors of retention in care among people living with HIV: an Egyptian cross-sectional study</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Ahmed Cordie, EG	
	<b>Access to care among asylum seekers living with HIV</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Pablo Ryan, ES	
	<b>Impact of Rapid ART initiation amongst people newly diagnosed with HIV on retention in care and time to HIV viral load suppression in a diverse London cohort</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Jozef Shaw, GB	
	<b>Screening of HPV-related anogenital cancers in women living with HIV in Europe: results from a systematic review</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Dagny Krankowska, PL	
	<b>C2. Combination prevention</b>	09:00 - 09:00

<b>Co-developing a novel campaign for Amsterdam's MSM at risk of late diagnosis of HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Muhammad Sharjeel, NL	
<b>AEGIDA: An Intervention to Support Uptake of HIV Self-testing and PrEP among Women who Exchange Sex and/or Use Substances in Kazakhstan</b>	09:00 - 09:00
<i>Poster Presenter:</i> Victoria Frye, US	
<b>Improving HIV testing efficiency and New Positive identification through Sexual Index Case Testing and Tracking Recency Outcome Across Three United States for International Development (USAID) Supported States in Nigeria.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ughweroghene Kingston Omo-Emmanuel, NG	
<b>Evaluating the impact of strategic weekend approach to HIV testing, Kwara State, North Central, Nigeria experience</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ikenna Onyejiaka, NG	
<b>The Impact of Empirical quantification for implementing partners (EQUIP) tool on human resources for health for HIV case finding, Kwara State, North Central, Nigeria</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ikenna Onyejiaka, NG	
<b>Free HIV, HCV and syphilis testing in Warsaw. Who is tested at stationary checkpoints and who at social and cultural events?</b>	09:00 - 09:00
<i>Poster Presenter:</i> Agnieszka Świdarska, PL	
<b>HIV prevalence among females and males in 26 potential HIV indicator conditions in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Frederik Valbert, DE	
<b>Recent real-life data of non- occupational (NO) post-exposure prophylaxis(PEP) from 4 Greek HIV clinics and national gaps in HIV prevention</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giota Lourida, GR	
<b>Blood and body fluids exposure, post-exposure prophylaxis, and HIV self-testing among healthcare workers in northern Nigeria</b>	09:00 - 09:00
<i>Poster Presenter:</i> Muktar Aliyu, US	
<b>VICTIMS OF SEXUAL VIOLENCE, POST-EXPOSURE PROPHYLAXIS: 7 YEARS EXPERIENCE AT THE CONDESA SPECIALIZED IZTAPALAPA CLINIC</b>	09:00 - 09:00
<i>Poster Presenter:</i> Teresita de J. Cabrera López, MX	
<b>Improving Oral PreP initiation and continuation using EPOA and Pre-appointment reminders among female sex workers in Busia - East Central Uganda</b>	09:00 - 09:00
<i>Poster Presenter:</i> Edward Mawejje, UG	
<b>Willingness to participate in a long-acting injectable cabotegravir pre-exposure prophylaxis study among men who have sex with men followed in the French ANRS-PREVENIR cohort</b>	09:00 - 09:00
<i>Poster Presenter:</i> Luis Sagaon-Teyssier, FR	
<b>A collaborative approach for introducing pre-exposure prophylaxis for HIV (PrEP) in the Western Balkans: case studies from North Macedonia and Bosnia and Herzegovina</b>	09:00 - 09:00
<i>Poster Presenter:</i> Pietro Leone Giovanni Vinti, DK	
<b>Reimbursed PrEP is not enough: what are the continuing barriers to PrEP accessibility in Italy? Lessons from community-led monitoring</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marco Stizioli, IT	



<b>Disparities in HIV PrEP engagement and continuum of care among cisgender males, and transgender and cisgender women who engage in prostitution</b> <i>Poster Presenter:</i> Jorge Valencia, ES	09:00 - 09:00
<b>Uptake of PrEP among MSM in a city without formal PrEP access: comparison of PrEP-experienced and naïve MSM in case-control analysis</b> <i>Poster Presenter:</i> Ngai Sze Wong, HK	09:00 - 09:00
<b>Drivers of discontinuation of oral PrEP within Europe: Findings from a real-world survey of PrEP use</b> <i>Poster Presenter:</i> Paul O'Brien, GB	09:00 - 09:00
<b>Knowledge, attitude, and willingness towards HIV Pre-Exposure Prophylaxis (PrEP) among men who have sex with men (MSM) in Yogyakarta, Indonesia</b> <i>Poster Presenter:</i> Dwi Kartika Rukmi, ID	09:00 - 09:00
<b>Factors influencing the willingness to use bi-monthly long-acting injectable PrEP among MSM using oral PrEP: results from a mixed-method study in Belgium</b> <i>Poster Presenter:</i> Thijs Reyniers, BE	09:00 - 09:00
<b>Nurse-Led PrEP with tenofovir alafenamide fumarate/emtricitabine (TAF/FTC) achieves better outcomes compared to physician-led PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) among cis-gender women in Zambia at 24 weeks: results from the NLPREP Trial</b> <i>Poster Presenter:</i> Lloyd Mulenga, ZM	09:00 - 09:00
<b>Complex PrEP: outcomes from a complex clinical PrEP referral service in the UK</b> <i>Poster Presenter:</i> Rachel Gallagher, GB	09:00 - 09:00
<b>Extremely limited knowledge and moderate interest in HIV pre-exposure prophylaxis among people who inject drugs in Madrid, Spain</b> <i>Poster Presenter:</i> Jorge Valencia, ES	09:00 - 09:00
<b>What we know about knowledge, attitudes and use of Pre-exposure prophylaxis (PrEP) among MSM in the Russian Federation: Data from the European MSM Internet Survey</b> <i>Poster Presenter:</i> Rigmor C Berg, NO	09:00 - 09:00
<b>Perceived impact of digital health instruments on the uptake of HIV Pre-Exposure Prophylaxis among gay, bisexual, and other men who have sex with men in the UK. A discrete choice experiment on the use of digital health for PrEP initiation.</b> <i>Poster Presenter:</i> Igor Kuchin, AT	09:00 - 09:00
<b>HIV home testing in Poland - underappreciated approach despite huge potential</b> <i>Poster Presenter:</i> Bartosz Szetela, PL	09:00 - 09:00
<b>Early pre-exposure prophylaxis users in Belgium, their PrEP use trajectories and incidence of HIV and STI: a cohort analysis of insurance claims data from 2017 to 2019</b> <i>Poster Presenter:</i> Anke Rotsaert, BE	09:00 - 09:00
<b>Looking forward in Pre-Exposure Prophylaxis (PrEP): comparing preference and acceptability of novel modalities in a cohort of men who have sex with men (MSM) in a community centre in Barcelona, Spain</b> <i>Poster Presenter:</i> Jose Miguel Cabrera Guarin, ES	09:00 - 09:00

<b>Prevalence and factors associated with pre-exposure prophylaxis uptake among men who have sex with men</b> <i>Poster Presenter:</i> Tsz Ho Kwan, HK	09:00 - 09:00
<b>Pre-exposure prophylaxis in men who have sex with men and new HIV infections in Croatia</b> <i>Poster Presenter:</i> Šime Zekan, HR	09:00 - 09:00
<b>Informal PrEP for HIV prevention: The case of Greece</b> <i>Poster Presenter:</i> Konstantinos Protopapas, GR	09:00 - 09:00
<b>Outcomes of a PrEP service model from 56 Dean Street</b> <i>Poster Presenter:</i> Victoria Tittle, GB	09:00 - 09:00
<b>Pre-exposure prophylaxis for HIV in Austria: a prospective observational study</b> <i>Poster Presenter:</i> David Chromy, AT	09:00 - 09:00
<b>C3. Social sciences</b>	09:00 - 09:00
<b>An hospital-based integrated Healthy Life Programme among PLWH: preliminary data from a service including Infectious Disease specialist, nutritionist, personal trainer and psychologist at "D. Cotugno" hospital, Naples, Italy</b> <i>Poster Presenter:</i> Francesco Maria Fusco, IT	09:00 - 09:00
<b>Favorable effect of karate on self-esteem, anxiety, anger and fatigue in people living with HIV: a pilot study</b> <i>Poster Presenter:</i> Lucia Grandiere Perez, FR	09:00 - 09:00
<b>Assessment of Anti-Pneumococcal Vaccination Health Beliefs Among Patients Living With HIV and Viral Hepatitis In Constanta, Romania</b> <i>Poster Presenter:</i> Ana-Maria Schweitzer, RO	09:00 - 09:00
<b>Efficacy and safety of bariatric surgery in people living with HIV: a retrospective matched cohort analysis</b> <i>Poster Presenter:</i> Leena Zino, NL	09:00 - 09:00
<b>Tracking of PLHIV who had a clinical missed ART due to Russia's war with Ukraine based on data from the medical information system</b> <i>Poster Presenter:</i> Olha Klymova, UA	09:00 - 09:00
<b>Characterization of new HIV diagnoses in the migrant population in a tertiary hospital in Portugal</b> <i>Poster Presenter:</i> Maria João Miguel, PT	09:00 - 09:00
<b>Migrants' (un)equal access to health: Where do national policies of European countries stand?</b> <i>Poster Presenter:</i> Varsha Srivatsan, US	09:00 - 09:00
<b>Patients' fears and expectations related to HIV infection and its treatment in Poland. A Positive Perspective 2 (PP2) substudy</b> <i>Poster Presenter:</i> Maciej Moskwa, PL	09:00 - 09:00
<b>COVID 19 effects: how young people living with HIV shunned stigma, raised awareness and sustained their income by recycling ARV bottles into artefacts. Lessons learned</b> <i>Poster Presenter:</i> Ruth Nakaboga, UG	09:00 - 09:00
<b>"Buddy Polska": community driven program for peer-to-peer support of people living with HIV</b> <i>Poster Presenter:</i> Grzegorz Jezierski, PL	09:00 - 09:00
<b>Analyzing the impact of COVID-19 during pandemic lockdowns on</b>	09:00 - 09:00

**women of Black African and Caribbean heritage living with HIV***Poster Presenter:* Sophie Strachan, GB**Community engagement in developing stigma reduction interventions to increase HIV testing and linkage to care/prevention for women who exchange sex and use drugs in Kazakhstan**

09:00 - 09:00

*Poster Presenter:* Meruyert Darisheva, KZ**Crowdsourcing among women who exchange sex and/or use drugs in Kazakhstan: developing community responsive interventions to address intersectional stigma in health care settings**

09:00 - 09:00

*Poster Presenter:* Meruyert Darisheva, KZ**New strategies for outreach are urgently needed to reach women who exchange sex and use drugs in the context of changing sex markets and high levels of stigma**

09:00 - 09:00

*Poster Presenter:* Meruyert Darisheva, KZ**Attitude of HIV-negative MSM towards functional cure of HIV infection**

09:00 - 09:00

*Poster Presenter:* Ngai Sze Wong, HK**Stigma in healthcare settings: a qualitative study on people with HIV in Cyprus**

09:00 - 09:00

*Poster Presenter:* Iliana Ntouriou, GR**Quality of life in young adults with perinatal hiv after transition to adult health care services in the Netherlands**

09:00 - 09:00

*Poster Presenter:* Annouschka Weijnsfeld, NL**Stigmatization towards People Living with HIV/AIDS in the Era of Test and Treat Policy in Kampala-Uganda**

09:00 - 09:00

*Poster Presenter:* Edward Mawejje, UG**How the use of Community-led Monitoring and Momentum (CLMM) tools improve service quality and support better client outcomes in OVC program in Akwa Ibom State, Nigeria**

09:00 - 09:00

*Poster Presenter:* Ifeyinwa Okereke, NG**Sexual health in a student population: knowledge and impact of COVID**

09:00 - 09:00

*Poster Presenter:* Dorsaf Slama, FR**Self-questionnaire on sexual-health collected from young people during a festival**

09:00 - 09:00

*Poster Presenter:* Dorsaf Slama, FR**Interrelations among depression and anxiety symptoms, CD4, and CD8 T-cell count in people living with HIV: a network analysis**

09:00 - 09:00

*Poster Presenter:* Lidija Popović Dragonjić, RS**Multilevel factors associated with HIV-related stigma among pregnant women living with HIV in China: an ecological model-informed study**

09:00 - 09:00

*Poster Presenter:* Yufan Xie, CN**Perceived benefits of long-acting injectable antiretroviral treatment go beyond pill-burden relief: a qualitative study (PANTER)**

09:00 - 09:00

*Poster Presenter:* Martin Duracinsky, FR**Validation of the HEALTHQUAL Questionnaire in Taiwan: A Pilot Study on Reducing HIV-Related Stigma and Discrimination in A Healthcare Settings**

09:00 - 09:00

*Poster Presenter:* Han Siong Toh, TW

<b>Routine Assessment of Life Satisfaction Patient Reported Outcomes (PROs) among People Living with HIV/AIDS (PLWHA) Indicate Maintenance of Overall Care Results at the Baylor Clinical Center of Excellence in Constanta, Romania over Four Years</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ana-Maria Schweitzer, RO	
<b>HIV in Italian hospitals between knowledge and stigma</b>	09:00 - 09:00
<i>Poster Presenter:</i> Antonella d'Arminio Monforte, IT	
<b>Patterns of Substance Use and their Consequences on Well-being among STI Clinic Patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> Matilde Sánchez-Conde, ES	
<b>Substance use among women engaged in sex work in Kazakhstan: typologies and implications for HIV risk</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tara McCrimmon, US	
<b>Non-neuropsychiatric complications of intravenous mephedrone in Chemsex users. Are we going back to the 80s?</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jesús Santos, ES	
<b>Substance use and multiple sexual risks in young adults: beyond the clinical concept of sexual risk assessment</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jiwon Jeong, FR	
<b>Why the IDUs' treatment is not working, assessing the relapse ratio</b>	09:00 - 09:00
<i>Poster Presenter:</i> Hameed ul Mehdi, PK	
<b>Initiatives to improve life span &amp; QOL in PLWHIV: Asian perspectives</b>	09:00 - 09:00
<i>Poster Presenter:</i> S. Pal, IN	
<b>Barriers access healthcare service among the hill tribe and stateless HIV/AIDS living in northern Thailand: a qualitative method</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tawatchai Apidechkul, TH	
<b>Perception of preventing gonorrhoea by vaccination among men who have sex with men: a mixed-methods study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tsz Ho Kwan, HK	
<b>PrEP knowledge among trans and/or non-binary participants of the TASG study, a participatory study in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Uwe Koppe, DE	
<b>D1. HIV and other health emergencies</b>	09:00 - 09:00
<b>UK Media responses to HIV through the lens of COVID-19: a study of multidirectional memory</b>	09:00 - 09:00
<i>Poster Presenter:</i> Frances Pheasant-Kelly, GB	
<b>Creation and Validation of an imported Malaria Predictive Model including People Living with HIV/AIDS (PLWHA)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Noemí Cabello-Clotet, ES	
<b>Linking and retaining HIV patients in care in Neuquén city, Patagonia, Argentina. A 4 Years' experience program</b>	09:00 - 09:00
<i>Poster Presenter:</i> Liliana Calanni, AR	
<b>HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in Central and Eastern Europe</b>	09:00 - 09:00
<i>Poster Presenter:</i> Cristiana Oprea, RO	
<b>Experience with Monkeypox (Mpox) in Belgrade, Serbia, between may and october 2022: a single center study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ivana Gmizic, RS	

<b>Acceptability of receiving a relatively low efficacy vaccine for gonorrhoea prevention among men who have sex with men</b> <i>Poster Presenter:</i> Tsz Ho Kwan, HK	09:00 - 09:00
<b>Effect on the HIV diagnosis rates of Integration of AIDS defining and indicator conditions into the hospital information system: HIV-IC study</b> <i>Poster Presenter:</i> Cigdem Hatipoglu, TR	09:00 - 09:00
<b>Mpox vaccination coverage across two high-risk cohorts: PLWHIV and PrEP-HIV users</b> <i>Poster Presenter:</i> Alberto Díaz-de Santiago, ES	09:00 - 09:00
<b>Sexual behavior of men who have sex with men who use PrEP in times of mpox threat</b> <i>Poster Presenter:</i> Zohar Mor, IL	09:00 - 09:00
<b>MPOX OUTBREAK AMONG PEOPLE LIVING WITH AND WITHOUT HIV IN ARGENTINA: THE VIHPOX STUDY</b> <i>Poster Presenter:</i> Romina Mauas, AR	09:00 - 09:00
<b>Risk perception and mpox vaccine acceptability among people living with HIV in northern Nigeria</b> <i>Poster Presenter:</i> Muktar Aliyu, US	09:00 - 09:00
<b>Supporting the mission of caring for patients during military conflicts: lessons from Ukraine</b> <i>Poster Presenter:</i> Vivian Avelino-Silva, US	09:00 - 09:00
<b>High mental resilience of displaced Ukrainian PLWH currently living in Hamburg, Germany</b> <i>Poster Presenter:</i> Anna Koval, UA	09:00 - 09:00
<b>AHF hotline in support of HIV care continuum for people living with HIV, including displaced populations in war-stricken Ukraine</b> <i>Poster Presenter:</i> Yaroslava Lopatina, UA	09:00 - 09:00
<b>The needs of people living with HIV displaced by war in Ukraine to Dublin</b> <i>Poster Presenter:</i> Annmarie White, IE	09:00 - 09:00
<b>Characteristics and recency of infection among people living with HIV from Ukraine migrating to Germany in 2022</b> <i>Poster Presenter:</i> Uwe Koppe, DE	09:00 - 09:00
<b>Clinical Cases</b>	09:00 - 09:00
<b>Histories, Heroina &amp; HIV. A case study of bio-psycho-social determinants and relationships of an Indigenous-Canadian woman living with HIV and her Polish &amp; Canadian clinical team from pasts to present</b> <i>Poster Presenter:</i> Piotr Klakowicz-Rodriguez-Szmaj, CA	09:00 - 09:00
<b>Challenges of treatment retention in times of social isolation leading to a catastrophic outcome</b> <i>Poster Presenter:</i> Marie-Angélique De Scheerder, BE	09:00 - 09:00
<b>A case report of HIV positive patient with two different malignancies (Nodular Lymphocyte predominant Hodgkin's Lymphoma and Adenocarcinoma)</b> <i>Poster Presenter:</i> Priyanka Khopkar-Kale, IN	09:00 - 09:00
<b>Symptomatic relapse of cryptococcal meningitis in a Late Presenter of HIV infection</b> <i>Poster Presenter:</i> Vasilis Petrakis, GR	09:00 - 09:00

<b>Unusual presentation of <i>Pneumocystis jirovecii</i> pneumonia: a case report</b>	09:00 - 09:00
<i>Poster Presenter:</i> Adelaide Maddaloni, IT	
<b>Neurosyphilis with multiple cranial neuropathy revealing HIV infection</b>	09:00 - 09:00
<i>Poster Presenter:</i> Magda Gonçalves, PT	
<b>Three cases of chronic hepatitis E infection (one HEV-A &amp; two HEV-C) among PLHIV in Hong Kong</b>	09:00 - 09:00
<i>Poster Presenter:</i> Chun Kwan Bonnie Wong, HK	
<b>Genital ulceration resistant to various treatments</b>	09:00 - 09:00
<i>Poster Presenter:</i> Martin Hartmann, DE	
<b>Limited therapeutic options in antiretroviral treatment in a male patient living with HIV during a 15-year follow-up</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carlo Bieńkowski, PL	
<b>Integrase inhibitor as cause of drug induced liver injury</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sanjay Bhagani, GB	
<b>Prolonged viral shedding of SARS-Cov-2 in a HIV-1 positive patient. A case report</b>	09:00 - 09:00
<i>Poster Presenter:</i> Clara de Angelis, DE	
<b>Young man with gastrointestinal bleeding: when things are not what they appear to be</b>	09:00 - 09:00
<i>Poster Presenter:</i> Samuel Estévez Alonso, ES	
<b>A rare case of <i>Rhodococcus equi</i> infection in a patient living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Fehmi Tabak, TR	
<b>Rare skin condition in HIV positive patient</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mikhail Savchenko, RU	
<b>Primary HIV Infection in an Adherent Pre-exposure Prophylaxis User with Limited Risk Factors</b>	09:00 - 09:00
<i>Poster Presenter:</i> Silvia Nozza, IT	
<b>Atypical cases of dermatophytosis as presenting sign of HIV infection, in Malagasy patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> Fandresena Arilala Sendrasoa, MG	
<b>Co-infection with <i>Cryptosporidium meleagridis</i> and <i>Enterocytozoon bieneusi</i> in an HIV+ Colombian patient</b>	09:00 - 09:00
<i>Poster Presenter:</i> Larry Lubert Martínez Rosado, CO	
<b>Cluster headache-like symptoms after tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) containing regimens initiation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Alberto Foncillas López, ES	
<b>Interleukin-1 inhibitor and <i>Toxoplasma spp</i> reactivation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Stefano Musumeci, CH	
<b>Complex diagnosis in elderly: A case report of HIV and Paroxysmal Nocturnal Hemoglobinuria</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Luis Parra Herrera, MX	
<b>Extensively Drug-resistant (XDR) <i>Shigella flexneri</i> bacteremia in a patient with severe Mpox and advanced HIV disease</b>	09:00 - 09:00
<i>Poster Presenter:</i> Héctor O. Rivera-Villegas, MX	
<b>Successful Management of a Patient with AIDS-related diffuse large B-cell lymphoma by Zanubrutinib and</b>	09:00 - 09:00

**Dolutegravir/Lamivudine***Poster Presenter:* Haiyan Min, CN**Jaundice and HIV: A patient with HIV-related cholangiopathy and a bilirubin metabolism genetic variation developing a rare paraneoplastic Vanishing Bile Duct Syndrome related to Hodgkin lymphoma**

09:00 - 09:00

*Poster Presenter:* Rita Patrocínio Jesus, PT**Unveiling the Uncommon: A Case Report of JCV Granule Cell Neuropathy**

09:00 - 09:00

*Poster Presenter:* Myrto Astriti, GR**Kaposi`s sarcoma and primary effusion lymphoma as first diagnoses in hidden HIV infection**

09:00 - 09:00

*Poster Presenter:* Alberto Díaz-de Santiago, ES**Pyoverdine syndrome due to Leishmania spp and Aspergillus fumigatus in a patient with HIV/AIDS infection**

09:00 - 09:00

*Poster Presenter:* Lily Soto, VE**Case of immunomodulatory therapy in advanced HIV-infection with disseminated non-tuberculosis mycobacteria**

09:00 - 09:00

*Poster Presenter:* Jan Vesterbacka, SE**Aortitis in early syphilis**

09:00 - 09:00

*Poster Presenter:* Tania Mudrikova, NL**Bilateral Syphilitic Optic Neuritis in a patient with Human Immunodeficiency Virus Infection**

09:00 - 09:00

*Poster Presenter:* Ligia Rodina, RO**Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV**

09:00 - 09:00

*Poster Presenter:* Lykke Larsen, DK**Fast track rechallenge after skin rash in a HIV-1 heavily treatment experienced patient with no alternative therapeutic options left**

09:00 - 09:00

*Poster Presenter:* Stefano Musumeci, CH**Sustained Mpox proctitis with primary syphilis and HIV seroconversion**

09:00 - 09:00

*Poster Presenter:* Rachel Burdon, AU**Gluteal subcutaneous cold abscesses complicating long acting injectable antiretroviral treatment with cabotegravir and rilpivirine: a case report**

09:00 - 09:00

*Poster Presenter:* Layla Pagnucco, IT**Syphilitic gumma as cause of cerebral and hepatic lesions, a case series**

09:00 - 09:00

*Poster Presenter:* Alexander Killer, DE**Unusual intersection: Adult-onset Langerhans Cell Histiocytosis and HIV Infection**

09:00 - 09:00

*Poster Presenter:* Myrto Astriti, GR**"Thrombotic Vasculopathy in an HIV-Positive Individual: A Detailed Diagnostic Odyssey and Resolution"**

09:00 - 09:00

*Poster Presenter:* Alexy Inciarte Portillo, ES**Unusual presentation of disseminated visceral leishmaniasis with lung and cutaneous involvement**

09:00 - 09:00

*Poster Presenter:* Lia Monsalve, CH**Mpox in advanced HIV: one of the few death cases**

09:00 - 09:00

Poster Presenter: Dan Veselý, CZ

**Painful proctitis secondary due to co-infection with mpox, syphilis, herpes simplex virus, lymphogranuloma venereum, *Neisseria gonorrhoeae*, and *Mycoplasma genitalium* in a person living with HIV vaccinated against mpox** 09:00 - 09:00

Poster Presenter: Rachel Burdon, AU

**Disseminated histoplasmosis and *Pneumocystis jirovecii* Pneumonia (PJP)-associated immune reconstitution inflammatory syndrome (IRIS) four weeks after ART initiation** 09:00 - 09:00

Poster Presenter: Alberto Díaz-de Santiago, ES

**Severe form of Mpox virus infection in a patient with AIDS and multiple opportunistic infections** 09:00 - 09:00

Poster Presenter: David Mangaloiu, RO

**Early treatment failure of Lenacapavir in a HIV-2 positive patient** 09:00 - 09:00

Poster Presenter: Olaf Degen, DE

**A case of co- infection of visceral leishmaniasis and HIV infection with multiple relapses: role of combination therapy to end the relapses** 09:00 - 09:00

Poster Presenter: Edjola Lulja, AL

**Early virological failure with Cabotegravir plus Rilpivirine in clinical practice** 09:00 - 09:00

Poster Presenter: Sofia Sábato, ES

**Limbic Encephalitis Following COVID-19 Vaccination in an HIV-Positive Patient** 09:00 - 09:00

Poster Presenter: Alexy Inciarte, ES

**Extensive virologic characterization in an HIV-infected individual with apparent HIV remission for 2 years after allogeneic stem cell transplantation with CCR5 wild-type cells: a case study** 09:00 - 09:00

Poster Presenter: Ilaria Vicenti, IT

**How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case** 09:00 - 09:00

Poster Presenter: Tommaso Clemente, IT

**The case of occult HBV infection in HIV infected patient from Eastern European country of Georgia** 09:00 - 09:00

Poster Presenter: Shorena DVALI, GE

Plenary lecture

09:30 - 10:05

POLONEZ

**The Limits of Antiretroviral Therapy**

Chair: Christine Katlama, FR

**The Limits of Antiretroviral Therapy** 09:30 - 10:00

Speaker: Jose Arribas, ES

**European Hector Research Award in HIV 2023 ceremony - Best clinical science and/or epidemiological paper** 10:00 - 10:05

Speaker: Esteban Martínez, ES

ePosters

10:00 - 10:45

ePoster

**ePosters exchange**



## Parallel session

10:45 - 11:45

POLONEZ

**PS1 - Antiretroviral therapy - Observational studies and clinical trials**

Chair: Cristina Mussini, IT

Chair: Milena Stevanovic, MK

**What to start with? A review of current guidelines (EACS, WHO, DHHS)**

10:45 - 10:55

Speaker: Cristiana Oprea, RO

**Switch to fixed-dose doravirine/islatravir (100/0.75 mg) once daily in adults with HIV-1 virologically suppressed on bicitgravir/emtricitabine/tenofovir alafenamide: week 96 results of a phase 3, randomized, double-blind, non-inferiority trial**

10:55 - 11:00

Abstract Presenter: Roger Paredes, ES

**Below 200: clinical relevance of low-level viremia in participants on ART in the Swiss HIV Cohort Study**

11:00 - 11:05

Abstract Presenter: Katharina Kusejko, CH

**Can we drug reduce antiretroviral regimen with dual NRTI regimen in naïve patients with viral load <50,000 copies/mL and CD4>300 cells/μL?: results from a randomized non-inferiority ANRS 173 ALTAR trial**

11:05 - 11:10

Abstract Presenter: Christine Katlama, FR

**Association between the timing of maternal anti-retroviral therapy, CD4 count and viraemia, and birth outcomes**

11:10 - 11:15

Abstract Presenter: Sisanda Siqithi, ZA

**Prevalence and clinical impact of doravirine-associated resistance mutations in a real-world population of NNRTI-naïve and NNRTI-experienced individuals**

11:15 - 11:20

Abstract Presenter: Chanson J. Brumme, CA

**Discussion**

11:20 - 11:45

## Parallel session

10:45 - 11:45

MAZUREK

**PS2 - Chemsex in 2023: Where are we now?**

Chair: Ben Collins, GB

Chair: Stéphan Vernhes, FR

**Chemsex in Kazakhstan: preliminary results of the qualitative study of reasons for engagement, motivation and demand for specific health services**

10:45 - 10:55

Speaker: Nikolay Lunchenkov, DE

**Stigma and other factors of HIV syndemic in MSM**

10:55 - 11:05

Speaker: Michal Pitoňák, CZ

**Drug related problems in gay and bisexual men living with HIV engaged in sexualized drug use: prevalence and warning signs**

11:05 - 11:10

Abstract Presenter: Pablo Ryan, ES

**Addressing the complex interplay between mental health, substance use, and sexual behavior among MSM in HIV care**

11:10 - 11:15

Abstract Presenter: Pablo Ryan, ES

**Toxic-Induced Encephalopathy Following Chemsex in a Young HIV-Positive Male: A Complex Case of Acute Cognitive Impairment with Anterograde Amnesia and Behavioral Alterations**

11:15 - 11:25

Case Presenter: Alexy Inciarte, ES

**Discussion**

11:25 - 11:45

## Parallel session

10:45 - 11:45

ETIUDA

**PS3 - Mechanisms of co-morbidities**

Chair: Antonella Castagna, IT

Chair: Casper Rokx, NL

**Potential mechanisms of long COVID**

10:45 - 10:55

Speaker: Mayte Coiras, ES

**Risk of major cardiovascular events after COVID-19 in people with HIV: the prospective PISCIS cohort study**

10:55 - 11:00

Abstract Presenter: Raquel Martin-Iguacel, DK

**Dolutegravir but not bictegravir exposure increases *in vitro* platelet aggregation**

11:00 - 11:05

Abstract Presenter: Renos Keniyopoullos, GB

**Gut microbiota changes - dysbiotic senescence pattern in the context of viral suppression**

11:05 - 11:10

Abstract Presenter: David Vydrář, CZ

**The persistent pro-inflammatory profile in very early ART treated individuals is associated with the inflammatory signature during acute HIV infection and viral reservoir dynamics**

11:10 - 11:15

Abstract Presenter: Jozefien De Clercq, BE

**Discussion**

11:15 - 11:45

## Oral presentations

10:45 - 11:45

SONATA

**Oral abstract session: Beyond survival**

Chair: Magdalena Rosińska, PL

Chair: Konstantinos Protopapas, GR

**Time trends in causes of death in people with HIV: insights from the Swiss HIV Cohort Study**

10:45 - 10:57

Abstract Presenter: Marc Stephan Renaat Weber, CH

**Effect of ART, immunologic-virologic status and prior tuberculosis on mortality among people with HIV in Europe**

10:57 - 11:09

Abstract Presenter: Erich Tusch, DK

**The status of social, professional, and intimate relations of people living with HIV in Central and Eastern Europe - Preliminary data from Go Holistic Go Beyond project**

11:09 - 11:21

Abstract Presenter: Dominik Bursa, PL

**PC-PTSD-5 self-reported screening tool introduced as part of routine clinical care detects high levels of clinically relevant PTSD symptoms in well-treated people with HIV**

11:21 - 11:33

Abstract Presenter: Kevin Moody, NL

**Temporal trends and impact of COVID-19 on the HIV cascade of care across Europe between 2016-2021**

11:33 - 11:45

Abstract Presenter: Lars Peters, DK

## ePosters

11:45 - 12:15

ePoster

**ePosters exchange**

## Industry sponsored session

12:15 - 13:45

POLONEZ

**Industry sponsored session**

*Special session*

12:15 - 13:15

MAZUREK

**Special session convened by Neat-ID***Chair:* Christine Katlama, FR*Chair:* Laura Waters, GB**Welcome (Chairs)**

12:15 - 12:17

*Speaker:* Christine Katlama, FR*Speaker:* Laura Waters, GB**Welcome and Introduction**

12:17 - 12:20

*Speaker:* Esteban Martínez, ES*Speaker:* Andrzej Horban, PL**Introduction, NEAT ID in Numbers, NEAT ID background**

12:20 - 12:25

*Speaker:* Nikos Dedes, GR**REPRIEVE**

12:25 - 12:32

*Speaker:* Esteban Martínez, ES**LAPTOP**

12:32 - 12:39

*Speaker:* Georg Behrens, DE**Panel discussion - Emerging Infections and the Role of NEAT ID, followed by Q&A**

12:39 - 12:59

*Moderator:* Jean-Michel Molina, FR*Discussant:* Paddy Mallon, IE*Discussant:* Marta Vasylyev, UA**NEAT ID Studies and Publications Update**

12:59 - 13:05

*Speaker:* Jean-Michel Molina, FR**NEAT ID Integration Grant Update**

13:05 - 13:15

*Speaker:* Jürgen Rockstroh, DE*Special session*

12:15 - 13:15

ETIUDA

**Special session convened by EATG - Empowering communities and clinicians for harm reduction and mental health***Chair:* Ann Piercy, IE*Chair:* Milosz Parczewski, PL**Welcome**

12:15 - 12:20

*Speaker:* Ann Piercy, IE*Speaker:* Milosz Parczewski, PL**Chemsex**

12:20 - 12:30

*Speaker:* Jorge Garrido, ES**Migration, HIV/HCV and drug use**

12:30 - 12:40

*Speaker:* Marios Atzemis, GR**Gender-transformative services**

12:40 - 12:55

*Speaker:* Paulie Amanita Calderón-Cifuentes, DK**Q&A and moderated discussion**

12:55 - 13:10

**Closing**

13:10 - 13:15

*Moderated ePosters*

12:15 - 13:00

ePoster

**ePoster Station 1****T1: Basic and translational science**

12:15 - 12:15

*Moderator:* Peter Reiss, NL

**Mitochondrial alterations in CD4 and CD8 T-cells as indicators of incomplete immune restoration** 12:15 - 12:22

*Poster Presenter:* Damian Vangelov, BG

**Prevalence of recent HIV infections among Key Populations (KP) using the Recent Infection Testing Algorithm (RITA) in southern states of Nigeria** 12:22 - 12:29

*Poster Presenter:* Mark Akhigbe, NG

**Investigational Studies to Understand the Decreases in Lymphocytes Seen Clinically with Islatravir (ISL) and Enabling the Initiation of New Clinical Trials** 12:29 - 12:36

*Poster Presenter:* Sandrine Ferry-Martin, US

**Immunological impact of switch towards 3TC/DTG after 48 weeks in the Rumba study** 12:36 - 12:43

*Poster Presenter:* Evy Blomme, BE

**HIV-1 gp120 exposure is associated with BDCA-2 receptor ligation and suppression of AKT phosphorylation and IRF-7 translocation causing IFN- $\alpha$  inhibition from plasmacytoid dendritic cells** 12:43 - 12:50

*Poster Presenter:* Ashwini Dhamanage, IN

*Moderated ePosters*

12:15 - 13:00

ePoster

### ePoster Station 3

**T3: Clinical science - Co-morbidities and ageing** 12:15 - 12:15

*Moderator:* Daniela Maric, RS

**Morbidity & Risk Factors of COVID-19 in People Living With HIV-1 in Europe: NEAT ID HIV-CoCo Study** 12:15 - 12:22

*Poster Presenter:* Casper Rokx, NL

**Real-world estimation of SARS-CoV-2 vaccination, infection and hospitalization in people living with HIV compared to people without HIV: a population-based cohort study by the CLHIP study group.** 12:22 - 12:29

*Poster Presenter:* Isabela Killander Möller, SE

**Change in blood pressure, weight and other cardiovascular disease risk factors after switch to dolutegravir versus staying on a protease inhibitor; post-hoc analysis of the 48-week randomised 2SD trial** 12:29 - 12:36

*Poster Presenter:* Loice Achieng Ombajo, KE

**PROM to identify gaps in the management of people living with HIV** 12:36 - 12:43

*Poster Presenter:* Marie-Angélique De Scheerder, BE

**Survival of individuals with HIV/HCV co-infection received liver transplantation in the post-DAA era in Modena** 12:43 - 12:50

*Poster Presenter:* Adriana Cervo, IT

**AIDS and non-AIDS-defining cancers in people living with HIV: a 28-year experience at Padua University Hospital (Italy)** 12:50 - 12:57

*Poster Presenter:* Maria Mazzitelli, GB

*Moderated ePosters*

12:15 - 13:00

ePoster

### ePoster Station 4

**T4 : Clinical science - CIS and trans women** 12:15 - 12:15

Moderator: Nina Weis, DK

**Do transgender women living with HIV experience different HIV outcomes?** 12:15 - 12:22

Poster Presenter: Déborah Konopnicki, BE

**Significant sex differences in antiretroviral treatment of young HIV patients - Results from the DONNA study (ART in women of Childbearing POteNtial)** 12:22 - 12:29

Poster Presenter: Svenja Spitzer, DE

**Determinants of intention to use pre-exposure prophylaxis (PrEP), high-risk sexual behaviors, and preferences on PrEP delivery options among transgender women engaged in prostitution in Madrid** 12:29 - 12:36

Poster Presenter: Jorge Valencia, ES

**Estimation and predictors of loss to follow-up in transgender women living with HIV: A multicenter observational study** 12:36 - 12:43

Poster Presenter: Andrea De Vito, IT

**Factors influencing discontinuation of care of women seeking Pre-Exposure Prophylaxis (PrEP)** 12:43 - 12:50

Poster Presenter: Tetiana Melnyk, FR

**Adults with perinatally acquired HIV in an upper middle-income country: what do we know?** 12:50 - 12:57

Poster Presenter: Violeta Zulema Ortiz, AR

Moderated ePosters

12:15 - 13:00

ePoster

#### ePoster Station 5

**T5: Combination prevention** 12:15 - 12:15

Moderator: Robert Hejzák, CZ

**Expansion of sub-subtype A6 in Belgium** 12:15 - 12:22

Poster Presenter: Virginie Mortier, BE

**Statutory health insurance-covered pre-exposure prophylaxis in Germany: changing trends in nationwide tenofovir disoproxil/emtricitabine prescriptions during the COVID-19 pandemic** 12:22 - 12:29

Poster Presenter: Daniel Schmidt, DE

**The Risk Factors of Mpox Among Men Who Have Sex With Men Contracting Sexually Transmitted Infections** 12:29 - 12:36

Poster Presenter: Chen-En Hsieh, TW

**HIV partner notification outcomes from the blood borne virus - ED testing programme in England** 12:36 - 12:43

Poster Presenter: Andrea Cartier, GB

**Reducing link-to-care and time-to-undetectability in a cohort of people with acute/recent HIV infection** 12:43 - 12:50

Poster Presenter: Lucia Bailón, ES

**Changing the molecular face of the HIV-1 epidemics in Poland: circulation dynamics of national A6 clades** 12:50 - 12:57

Poster Presenter: Karol Serwin, PL

Moderated ePosters

12:15 - 13:00

ePoster

#### ePoster Station 7

<b>T7: Social sciences and patients' perspective</b>	12:15 - 12:15
<i>Moderator:</i> Mario Cascio, IT	
<b>Turkish translation and cross-cultural validity of WHOQoL-HIV Bref Tool</b>	12:15 - 12:22
<i>Poster Presenter:</i> Hüsrev Diktaş, TR	
<b>Beliefs about medicines among people with HIV in Greece</b>	12:22 - 12:29
<i>Poster Presenter:</i> Iliana Ntourou, GR	
<b>Evolution of drug use, sexual practices and incidence of sexually transmitted infections in people with HIV who engage in chemsex in Barcelona: Results of a prospective cohort study (Care_ChemS_CliniC Study, CSC-Study)</b>	12:29 - 12:36
<i>Poster Presenter:</i> Lorena de la Mora Cañizo, ES	
<b>Assistance and/or autonomy, two principles supporting long-acting injectable antiretroviral treatment administrations in France: a qualitative study (PANTER)</b>	12:36 - 12:43
<i>Poster Presenter:</i> Martin Duracinsky, FR	
<b>Introducing telemedicine in HIV care in times of COVID-19 pandemic - patients' perspectives</b>	12:43 - 12:50
<i>Poster Presenter:</i> Justyna Kowalska, PL	
<b>The multifaceted illness attributions of people with HIV</b>	12:50 - 12:57
<i>Poster Presenter:</i> Konstantina Stavrogianni, GR	
<i>Moderated ePosters</i> 12:15 - 13:00	ePoster
<b>ePoster station 6</b>	
<b>T6: PrEP implementation across Europe</b>	12:15 - 12:15
<i>Moderator:</i> Aneta Cybula, PL	
<b>HIV seroconversions in the PrEP impact trial</b>	12:15 - 12:22
<i>Poster Presenter:</i> Andrea Cartier, GB	
<b>Slovenia's national HIV PrEP programme: evaluation of real-world implementation</b>	12:22 - 12:29
<i>Poster Presenter:</i> Jerca Ambrožič, SI	
<b>Preferences of injectable HIV pre-exposure prophylaxis in the men who have sex with men community</b>	12:29 - 12:36
<i>Poster Presenter:</i> Tsz Ho Kwan, HK	
<b>Cost-effectiveness analysis of a Safe Sex Programme with Pre-exposure Prophylaxis for the prevention of HIV-1 transmission in men that have sex with men</b>	12:36 - 12:43
<i>Poster Presenter:</i> Philip Wikman-Jorgensen, ES	
<b>Implementing PrEP in Switzerland: evaluation of the first 4 years of the SwissPrEPared program</b>	12:43 - 12:50
<i>Poster Presenter:</i> Benjamin Hampel, CH	
<i>ePosters</i> 12:15 - 13:00	ePoster
<b>Moderated ePoster Session</b>	
<i>Moderated ePosters</i> 12:15 - 13:00	ePoster
<b>ePoster Station 8</b>	

<b>T8: HIV and other health emergencies</b>	12:15 - 12:15
<i>Moderator:</i> Irina Cristiana Ianache, RO	
<b>Breakthrough COVID-19 infections after vaccination for Sars-CoV-2 in a greek cohort of people living with HIV (PLWH) during the Delta and Omicron wave. A single center experience</b>	12:15 - 12:22
<i>Poster Presenter:</i> Konstantinos Protopapas, GR	
<b>How to maintain the priority of HIV prevention (namely PrEP) in the context of russia's full-scale invasion of Ukraine</b>	12:22 - 12:29
<i>Poster Presenter:</i> Diana Shevchenko, UA	
<b>The outcome of COVID-19 among people living with HIV in European Union (EU) vs. non-European Union (non-EU) Countries - Data from the Euroguidelines in Central and Eastern Europe Network Group</b>	12:29 - 12:36
<i>Poster Presenter:</i> Agata Skrzat-Klapaczyńska, PL	
<b>Lasting impact of mpox infection on HIV-1 reservoir and antiviral immune response in people living with HIV</b>	12:36 - 12:43
<i>Poster Presenter:</i> Guiomar Casado-Fernández, ES	
<b>Asymptomatic infection and unexpected detection of anti-HMPXV antibodies before the declaration of the human monkeypox outbreak (2022) in newly diagnosed with HIV</b>	12:43 - 12:50
<i>Poster Presenter:</i> Maria J Vivancos-Gallego, ES	
<i>Moderated ePosters</i> 12:15 - 13:00	ePoster
<b>ePoster Station 2</b>	
<b>T2: Clinical science - Antiretroviral therapy</b>	12:15 - 12:15
<i>Moderator:</i> Rosa De Miguel Buckley, ES	
<b>Cabotegravir-rilpivirine long acting: data in real life setting in a large French cohort</b>	12:15 - 12:22
<i>Poster Presenter:</i> Clotilde Allavena, FR	
<b>Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in treatment-experienced people with HIV using real-world data: a systematic review and meta-analysis</b>	12:22 - 12:29
<i>Poster Presenter:</i> Juan Ambrosioni, ES	
<b>Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir+rilpivirine at 12-, 24-, and 48-weeks</b>	12:29 - 12:36
<i>Poster Presenter:</i> Khalil Nasser, US	
<b>OUTCOMES AFTER VIROLOGICAL FAILURE TO FIRST-LINE SECOND-GENERATION INSTI-BASED THERAPY IN A REAL-LIFE SETTING</b>	12:36 - 12:43
<i>Poster Presenter:</i> Rebecka Papaioannu Borjesson, IT	
<b>Trends in transmitted drug resistance among adults with a recently acquired HIV infection</b>	12:43 - 12:50
<i>Poster Presenter:</i> Anna Maria Geretti, GB	
<b>Inclusion of women, Black and People of Colour (BPoC) and older adults in real-world and implementation studies evaluating long-acting injectable (LA-I) Cabotegravir (CAB) and Rilpivirine (RPV): a rapid review</b>	12:50 - 12:57
<i>Poster Presenter:</i> Alexa Elias, GB	

## ePosters

13:00 - 14:15

ePoster

## ePosters exchange

## Parallel session

14:15 - 15:15

POLONEZ

**PS4 - Metabolic and cardiovascular co-morbidities among people living with HIV**

Chair: Gordana Dragović, RS

Chair: Paddy Mallon, IE

**Lessons from the Swiss Cohort study**

14:15 - 14:30

Speaker: Bernard Surial, CH

**The best of the year on metabolic and cardiovascular co-morbidities among people living with HIV (5 papers published in biomedical journals)**

14:30 - 14:45

Speaker: Jürgen Rockstroh, DE

**PERSISTENT LOW-LEVEL VIREMIA MAY INCREASE THE RISK OF CARDIOVASCULAR DISORDERS IN PEOPLE LIVING WITH HIV**

14:45 - 14:50

Abstract Presenter: Violeta Lara-Aguilar, ES

**Estimated risk of all-cause mortality and cardiovascular events in a cohort of women living with HIV and socio-demographically similar HIV-negative controls ≥40 years old**

14:50 - 14:55

Abstract Presenter: Tetiana Povshedna, CA

**Subclinical Coronary Artery Disease in Persons Living with HIV and Uninfected Controls**

14:55 - 15:00

Abstract Presenter: Andreas Dehlbæk Knudsen, DK

**BMI vs body composition changes to predict metabolic outcomes in people with HIV**

15:00 - 15:05

Abstract Presenter: Jovana Milic, IT

**Q&A / Discussion**

15:05 - 15:15

## Parallel session

14:15 - 15:15

MAZUREK

**PS5 - Vertical transmission and treatment for children: Missed opportunities across the European region 2023**

Chair: Karoline Aebi-Popp, CH

Chair: Maria Pokorska-Spiwak, PL

**Vertical transmission and treatment for children: Missed opportunities across the European region 2023**

14:15 - 14:25

Speaker: Jose Tomas Ramos Amador, ES

**Country on the way to elimination of vertical transmission - an example from Moldova**

14:25 - 14:35

Speaker: Oxana Turcanu, MD

**Changes in Preterm Birth Rates Among Pregnant Women Living with HIV in Switzerland: A 34-Year Cohort Analysis**

14:35 - 14:40

Abstract Presenter: Christian Kahlert, CH

**Particular aspects of pregnancy in a unique cohort of HIV-infected women by parenteral mode in early childhood**

14:40 - 14:45

Abstract Presenter: Irina Cristiana Ianache, RO

**Antiretroviral adherence among people living with HIV during the postpartum period: a retrospective cohort study at a PMTCT reference center in Rio de Janeiro before and during COVID-19 pandemic**

14:45 - 14:50



*Abstract Presenter:* Esaú João, BR

**Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir: The DOLOMITE-EPPICC Study** 14:50 - 14:55

*Abstract Presenter:* Vani Vannappagari, US

**Panel discussion** 14:55 - 15:15

*Parallel session*

14:15 - 15:15

ETIUDA

**PS6 - Mpox (un)limited**

*Chair:* Cristiana Oprea, RO

*Chair:* Ivailo Alexiev, BG

**How to re-set your clinic - Mpox example** 14:15 - 14:25

*Speaker:* Nicolo Girometti, GB

**Mpox control and treatment** 14:25 - 14:35

*Speaker:* Esteban Martínez, ES

**Monkeypox across countries from Central and Eastern Europe - ECEE network study group** 14:35 - 14:40

*Abstract Presenter:* Cristiana Oprea, RO

**Exploring associations between Mpox-related health outcomes and HIV status** 14:40 - 14:45

*Abstract Presenter:* Nicolo Girometti, GB

**Clinical course of Mpox among people with HIV: a 2022 cohort from Warsaw, Poland** 14:45 - 14:50

*Abstract Presenter:* Jacek Kowalski, PL

**No sign of viral shedding of Mpox virus in asymptomatic sexually highly active MSM in Austria** 14:50 - 14:55

*Abstract Presenter:* Katharina Grabmeier-Pfistershammer, AT

**Q&A / Discussion** 14:55 - 15:15

*Parallel session*

14:15 - 15:15

SONATA

**PS7 - The impact of the war in Ukraine on HIV epidemiology and care services**

*Chair:* Teymur Noori, SE

*Chair:* Monika Bociąga-Jasik, PL

**Successful approaches to the provision of HIV care to refugees from Ukraine** 14:15 - 14:25

*Speaker:* Miłosz Parczewski, PL

**The impact of war in Ukraine on the sustainability of HIV care and prevention services** 14:25 - 14:35

*Speaker:* Olga Gvozdetska, UA

**Impact of the COVID-19 pandemic and the war in Ukraine on late diagnosis of HIV infection** 14:35 - 14:40

*Abstract Presenter:* Tetiana Koval, UA

**Continuum of HIV and hepatitis C care in the times of war - Five Times Ninety project** 14:40 - 14:45

*Abstract Presenter:* Justyna Kowalska, PL

**Dynamics of coverage of HIV testing services, detection of new cases and bringing PLHIV under medical supervision in Ukraine before and during the pandemic COVID-19 and war (2019 to 2022)** 14:45 - 14:50

*Abstract Presenter:* Serhii Ryabokon, UA

<b>Impact of russia's full-scale military invasion in Ukraine on the non-governmental organization capacity of HIV prevention services for key population</b>		14:50 - 14:55
<i>Abstract Presenter:</i> Liudmyla Legkostup, UA		
<b>Discussion</b>		14:55 - 15:15
<i>ePosters</i>		
15:15 - 17:15		ePoster
<b>ePosters exchange</b>		
<i>Industry sponsored session</i>		
16:00 - 17:00		POLONEZ
<b>Industry sponsored session</b>		
<i>Special session</i>		
16:00 - 17:00		MAZUREK
<b>ECEE Network Group - Challenges and opportunities in Central and Eastern Europe</b>		
<i>Chair:</i> Andrzej Horban, PL		
<i>Chair:</i> Jens D. Lundgren, DK		
<b>Challenges and opportunities in Central and Eastern Europe</b>		16:00 - 16:00
<b>Introduction to ECEE World</b>		16:00 - 16:05
<i>Speaker:</i> Agata Skrzat-Klapaczyńska, PL		
<b>The forgotten Balcans</b>		16:05 - 16:20
<i>Speaker:</i> Milena Stevanovic, MK		
<b>The troubled Baltics</b>		16:20 - 16:35
<i>Speaker:</i> Kerstin Aimla, EE		
<b>The invincible Central East</b>		16:35 - 16:50
<i>Speaker:</i> Tetiana Koval, UA		
<b>Q&amp;A and discussion</b>		16:50 - 17:00
<i>Meet-the-expert</i>		
16:00 - 17:00		ETIUDA
<b>MTE4 - Mental health disorders in people living with HIV</b>		
<i>Moderator:</i> Paola Cinque, IT		
Introduction	<b>Mental health issues in HIV</b>	16:00 - 16:10
<i>Speaker:</i> Jordi Blanch, ES		
	<b>Roundtable discussion</b>	16:10 - 17:00
<i>Special session</i>		
16:00 - 17:00		SONATA
<b>Special session convened by the University of Liverpool - Pharmacology of ART: New drugs, different populations</b>		
<i>Chair:</i> Catia Marzolini, CH		
	<b>ART exposure and response in obese people living with HIV</b>	16:00 - 16:15
<i>Speaker:</i> Mattia Berton, CH		
	<b>Pharmacology of novel ART</b>	16:15 - 16:30
<i>Speaker:</i> Marta Boffito, GB		
	<b>HIV DDIs with OTC + other substances</b>	16:30 - 16:45

<i>Speaker:</i> José Moltó, ES	
<b>Q&amp;A</b>	16:45 - 17:00
<i>Special session</i> 17:15 - 18:15	POLONEZ
<b>EACS Guidelines session</b> <i>Chair:</i> Jürgen Rockstroh, DE <i>Chair:</i> Juan Ambrosioni, ES	
<b>Introduction</b>	17:15 - 17:21
<b>ART 2023</b> <i>Speaker:</i> Laura Levi, FR	17:21 - 17:27
<b>DDI and other prescribing issues 2023</b> <i>Speaker:</i> Catia Marzolini, CH	17:27 - 17:33
<b>Co-morbidities 2023</b> <i>Speaker:</i> Jasmini Alagaratnam, GB	17:33 - 17:39
<b>Viral Hepatitis co-infection 2023</b> <i>Speaker:</i> Kathrin Van Bremen, DE	17:39 - 17:45
<b>Opportunistic infections and COVID 2023</b> <i>Speaker:</i> Andrea Mastrangelo, CH	17:45 - 17:51
<b>Pediatric HIV management and Vertical Transmission 2023</b> <i>Speaker:</i> Steven Welch, GB	17:51 - 17:57
<b>Q&amp;A</b> <i>Speaker:</i> Jean-Michel Molina, FR <i>Speaker:</i> Steven Welch, GB	17:57 - 18:15
<i>Industry sponsored session</i> 18:45 - 19:45	POLONEZ
<b>Industry sponsored session</b>	

**Friday, 20. October 2023***Special session*

07:30 - 08:30

MAZUREK

**HIV Medicine: Language matters: the importance of using person-centred language***Chair:* Yvonne Gilleece, GB**Introduction**

07:30 - 07:35

*Speaker:* Yvonne Gilleece, GB**The importance of person-centred language - why does it matter?**

07:35 - 07:50

*Speaker:* Matthew Hodson, GB**The People First Charter - the past, the present and the future**

07:50 - 08:05

*Speaker:* Laura Waters, GB**Adopting person-centred language - simple steps for improving your papers and presentations? (Discussion)**

08:05 - 08:20

*Moderator:* Caroline Sabin, GB**Q&A**

08:20 - 08:30

*Meet-the-expert*

07:30 - 08:30

ETIUDA

**MTE5 - Different faces of TB/HIV - can we recognise them?***Moderator:* Nathalie de Castro, FR*Moderator:* Regina Podlasin, PL**Features of latent tuberculosis among Ukrainian migrants and refugees entering HIV care in Poland**

07:30 - 07:40

*Oral Presenter:* Bogusz Jan Aksak-Wąs, PL**Risk of tuberculosis disease in people living with HIV after initiating antiretroviral therapy: a Danish nationwide prospective cohort study**

07:40 - 07:50

*Oral Presenter:* Amrit Kaur Virdee, DK**Review of national guidelines for screening and management of Latent Tuberculosis Infection (LTBI) in People with HIV (PWH) from Central and Eastern Europe (CEE)**

07:50 - 08:00

*Oral Presenter:* Daria Podlekareva, DK**The simultaneous diagnosis of HIV, tuberculosis, and lymphoma - a case report. Authors: Maria Marczak, Magdalena Thompson, Regina Podlasin**

08:00 - 08:10

*Case Presenter:* Magdalena Thompson, PL**Panel discussion**

08:10 - 08:30

*Meet-the-expert*

07:30 - 08:30

SONATA

**MTE6 - How do we achieve 'zero' stigma, and how do we know when we have?***Moderator:* Fiona Burns, GB**Measuring HIV stigma in healthcare settings**

07:30 - 07:40

*Panelist:* Balnur Iskakova, KZ**Combating HIV stigma in Hungary - "what works"?**

07:40 - 07:50

*Panelist:* Ferenc Bagyinszky, DE**Scaling up zero stigma strategies in Finland**

07:50 - 08:00

*Panelist:* Sini Pasanen, FI

<b>Roundtable discussion</b>	08:00 - 08:30
<i>Plenary lecture</i> 09:00 - 09:30	POLONEZ
<b>Cases of HIV cure after stem cell transplantation: What do we know about the mechanisms?</b> <i>Chair:</i> Jens D. Lundgren, DK	
<b>Cases of HIV cure after stem cell transplantation: What do we know about the mechanisms?</b> <i>Speaker:</i> Monique Nijhuis, NL	09:00 - 09:30
<i>ePosters</i> 09:00 - 18:00	
<b>ePoster Exhibition</b>	
<b>A. Basic &amp; translational sciences</b>	09:00 - 09:00
<b>Targeting emtricitabine to HIV reservoir in mesenteric lymph nodes using lipophilic prodrug approach and lipidic formulation</b> <i>Poster Presenter:</i> Graziamarina Sinatra, GB	09:00 - 09:00
<b>Bictegravir and Dolutegravir influence leukocytes and/or platelets in a way that promotes a proinflammatory milieu which favors cardiovascular toxicity</b> <i>Poster Presenter:</i> Juan V Esplugues, ES	09:00 - 09:00
<b>Benefits of a change or ART to BIC/FTC/TAF in an HIV clinic in northern Mexico</b> <i>Poster Presenter:</i> Luis Gerardo Castillo, MX	09:00 - 09:00
<b>Cardiovascular disease prevalence in a cohort of HIV positive (PLWH) patients, over 50 years of age, in the era of the INSTI based regimen: a proof of concept retrospective analysis</b> <i>Poster Presenter:</i> Marco Di Gregorio, IT	09:00 - 09:00
<b>Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong</b> <i>Poster Presenter:</i> Man Chun, Jacky Chan, HK	09:00 - 09:00
<b>Fostemsavir in association with doravirine for the treatment of heavily treatment-experienced (HTE) PLWH with multi-drug resistant (MDR) HIV-1 infection: data from clinical practice</b> <i>Poster Presenter:</i> Pierluigi Francesco Salvo, IT	09:00 - 09:00
<b>Comparison of rapid ART versus delayed ART in viral load reduction and loss to follow-up in a cohort of naïve migrants living with HIV in a single tertiary care center in Florence, Italy</b> <i>Poster Presenter:</i> Sasha Trevisan, IT	09:00 - 09:00
<b>Real life evidence on dual therapy with dolutegravir and lamivudine</b> <i>Poster Presenter:</i> Ana Caroline Coutinho Iglessias, BR	09:00 - 09:00
<b>Bictegravir/Emtricitabine/Tenofovir Alafenamide use significantly improves CD4/CD8 ratio in women living with HIV over a 48-week treatment, with good safety and effectiveness</b> <i>Poster Presenter:</i> Manuela Ceccarelli, IT	09:00 - 09:00
<b>Assessment of the impact of the new blister packaging of Biktarvy® (B/F/TAF) on treatment satisfaction, in the treatment of people living with HIV-1</b> <i>Poster Presenter:</i> Filipa Palha, PT	09:00 - 09:00
<b>A shot in the dark: a review one year on after initiation of injectable HIV Treatment in a UK HIV outpatient clinic</b>	09:00 - 09:00

*Poster Presenter:* Jonathan Roberts, GB

**CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine Fixed Dose Combination (FDC) in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France. One-year interim analysis results**

09:00 - 09:00

*Poster Presenter:* Patrick Philibert, FR

**Bikswitch study: effectiveness and safety of switching to a bicitegravir-based antiretroviral therapy regimen from non-integrase inhibitor-based therapies in virologically suppressed HIV-infected patients**

09:00 - 09:00

*Poster Presenter:* Francisco Jover, ES

**Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks**

09:00 - 09:00

*Poster Presenter:* Christina Katerina Psomas, FR

**Intermittent three-drug regimens (i-3DR) as maintenance ART: a meta-analysis including individual participant data**

09:00 - 09:00

*Poster Presenter:* Jean-Jacques Parienti, FR

**DoraVIH: Observational study of the reasons for switch to Doravirine-based regimen in patients with virological success and the choice of a treatment correlated to PRO**

09:00 - 09:00

*Poster Presenter:* Olivier Robineau, FR

**HIV-2 in Germany: An observational study on the situation of people living with HIV-2 infection (PLHIV2) in Germany ("H2O")**

09:00 - 09:00

*Poster Presenter:* Dirk Berzow, DE

**Investigation of the Causes of Suboptimal CD4 Cell Response in Advanced Stage HIV Patients Receiving Antiretroviral Therapy**

09:00 - 09:00

*Poster Presenter:* HÜLYA Özkan Özdemir, TR

**Real-world 2-year weight changes among people with sustained HIV suppression : A multicenter French retrospective cohort study**

09:00 - 09:00

*Poster Presenter:* Arnaud De La Blanchardiere, FR

**Bicitegravir versus Dolutegravir-based three-drug regimen in the setting of Rapid ART Initiation**

09:00 - 09:00

*Poster Presenter:* Adriana Cervo, IT

**Weight and Body mass index gain among people living with HIV-1 switching to a single tablet of bicitegravir /emtricitabine/tenofovir alafenamide**

09:00 - 09:00

*Poster Presenter:* Luiz Buzón, ES

**Effectiveness and safety of a generic formulation of dolutegravir in clinical practice in a Latin American cohort: 18-month real-world data**

09:00 - 09:00

*Poster Presenter:* Diego Martin Cecchini, AR

**Effectiveness and timing of viral load measurement in real-world use of long-acting cabotegravir-rilpivirine in people with HIV**

09:00 - 09:00

*Poster Presenter:* Jose I Bernardino, ES

**CAB + RPV long-acting antiretroviral therapy: real world data from an Italian single center in Rome**

09:00 - 09:00

*Poster Presenter:* Valentina Iannone, IT

**Inflammation in HIV positive subjects on antiretroviral therapy: two-drug DTG based vs triple standard antiretroviral therapy**

09:00 - 09:00

*Poster Presenter:* Claudio Ucciferri, IT

<b>Changes in inflammation biomarkers after switching to TAF/FTC/BIC in experienced, virally suppressed People Living with HIV (PLHIV). Real world data</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vasilis Petrakis, GR	
<b>DOR-based therapy effectiveness as a switch regimen, real world study in Mexican population</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Antonio Mata-Marín, MX	
<b>Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people living with HIV who start a regimen with DTG/ABC/3TC compared to those who start BIC/FTC/TAF at 48-week follow-up at the Hospital de Infectología CMN "La Raza": a preliminary analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Antonio Mata-Marín, MX	
<b>Predictive capacity of the 7-item I-Score, a patient-reported measure of barriers to ART adherence for HIV care</b>	09:00 - 09:00
<i>Poster Presenter:</i> Bertrand Lebouché, CA	
<b>Bictegravir/emtricitabine/tenofovir alafenamide vs. other regimens for initial therapy in late presenters with AIDS-defining conditions.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ignacio Perez Valero, ES	
<b>Effects of albuvirtide intensification on CD4 T cell reconstitution in acquiring HIV clients with incomplete immune reconstitution</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ping Ma, CN	
<b>Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Maria Mazzitelli, GB	
<b>Potential Post Treatment HIV Controllers Have a Lower Burden of Comorbidities and of Non-antiretroviral Co-medications</b>	09:00 - 09:00
<i>Poster Presenter:</i> Micol Ferrara, IT	
<b>Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in Europe: Data from COMBINE-2 Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vani Vannappagari, US	
<b>HIV molecular epidemiology and resistance profiles in HIV-infected refugees from Ukraine in Hamburg, Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Anna Koval, UA	
<b>Real-world data on commercial long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results: findings from a University Hospital in Paris, France</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jade Ghosn, FR	
<b>Final results of VICDOR: Effectiveness of Switching to DOR-based antiretroviral therapy under real-world conditions in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Christoph Wyen, DE	
<b>Acceptability and health-related quality of life among HIV patients switching to a dual therapy with DTG/3TC: results from PROBI study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Martin Duracinsky, FR	
<b>Who wants to switch to injectables? Patients' preferences, perceptions and knowledge in the Swiss HIV Cohort Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Yonas Martin, CH	
<b>The two sides of doravirine-based regimens: a descriptive study focusing on kidney function and lipidic profile</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marianna Menozzi, IT	

<b>Durability and schedule compliance to cabotegravir/rilpivirine long acting: a retrospective analysis</b> <i>Poster Presenter:</i> Nicholas Brian Bana, IT	09:00 - 09:00
<b>Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir + Lamivudine (DTG + 3TC) in People With HIV-1 (PWH) Aged ≥50 Years</b> <i>Poster Presenter:</i> Emilio Letang, ES	09:00 - 09:00
<b>Dolutegravir + lamivudine 2-drug regimen is highly effective and well-tolerated in a real-world clinical setting in Europe: data from the COMBINE-2 Study</b> <i>Poster Presenter:</i> Cristina Mussini, IT	09:00 - 09:00
<b>Real-world Effectiveness of Dolutegravir + Lamivudine (DTG + 3TC) in Treatment-Naïve People With HIV-1 (PWH) and Low CD4+ Cell Count or High Viral Load at Baseline: A Systematic Literature Review</b> <i>Poster Presenter:</i> Emilio Letang, ES	09:00 - 09:00
<b>Assessing the effectiveness and safety of lamivudine/dolutegravir versus bicitegravir/emtricitabine/tenofovir alafenamide fumarate in adults living with Human immunodeficiency virus: one retrospective observational cohort study</b> <i>Poster Presenter:</i> Chien-Yu Cheng, TW	09:00 - 09:00
<b>EFFECTIVENESS, SAFETY AND TOLERABILITY OF DOLUTEGRAVIR/LAMIVUDINE VERSUS TENOFOVIR ALAFENAMIDE/EMTRICITABINE/BICTEGRAVIR IN A REAL-LIFE COHORT OF HIV-1 VIROLOGICALLY SUPPRESSED TREATMENT EXPERIENCED PEOPLE LIVING WITH HIV</b> <i>Poster Presenter:</i> Sara Tordi, IT	09:00 - 09:00
<b>Clinical Characteristics and Antiretroviral Treatment Patterns in HIV-2 Infected Patients: Insights from a Tertiary Hospital in Portugal</b> <i>Poster Presenter:</i> Carmela Piñeiro, PT	09:00 - 09:00
<b>Prospective assessment of viral rebound and associated risk factors in people living with HIV after achieving viral suppression in rural Tanzania</b> <i>Poster Presenter:</i> Amina Nyuri, TZ	09:00 - 09:00
<b>DOLAM-500: Efficacy and safety of Dolutegravir (DTG) plus Lamivudine (3TC) in ART-naïve PLWH with baseline viral load ≥500.000 copies/ml</b> <i>Poster Presenter:</i> Asuman Inan, TR	09:00 - 09:00
<b>UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net)</b> <i>Poster Presenter:</i> Kyle Ring, GB	09:00 - 09:00
<b>Performance of hepatic steatosis serological scores and lipid profile safety in a virologically suppressed population in DTG/3TC</b> <i>Poster Presenter:</i> Marcello Trizzino, IT	09:00 - 09:00
<b>Comparing lamivudine+dolutegravir and bicitegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve HIV-infected patients: preliminary results from clinical practice</b> <i>Poster Presenter:</i> Hai Long, CN	09:00 - 09:00
<b>Total HIV-DNA trend in complex ART-experienced PLWH switching to CAB+RPV long-acting injectable: 28-week results in a home-care assistance setting</b> <i>Poster Presenter:</i> Valentina Iannone, IT	09:00 - 09:00



<b>Real-world data on metabolic profile and renal function in a Latin American cohort of people living with HIV starting or switching to bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination: 48-week follow-up</b>	09:00 - 09:00
<i>Poster Presenter:</i> Diego Martin Cecchini, AR	
<b>Informing the design of HIV cure trials including antiretroviral treatment interruptions: the voices of people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ming Jie Lee, GB	
<b>Lipid profile in people living with HIV after one year of antiretroviral therapy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Agnieszka Lembas, PL	
<b>ORANGE STUDY: HIV Patients frOm UkRAine - ContiNuum of Care in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Annette Haberl, DE	
<b>Real-life data of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults living with VIH-1. 48-96 weeks results of RETROBIC study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jesús Troya, ES	
<b>BIC/FTC/TAF in PLWH with persistent low-level viremia: results of 48-96 weeks after switching</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ignacio Santos, ES	
<b>Real-life data of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed women with VIH-1.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Guillermo Pousada, ES	
<b>Real-world effectiveness and tolerability of doravirine-based antiretroviral therapy in people with HIV: a nationwide matched cohort study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Patrick G. A. Oomen, NL	
<b>Fostemsavir use in the OPERA cohort: immunologic and virologic response</b>	09:00 - 09:00
<i>Poster Presenter:</i> Vani Vannappagari, US	
<b>Marginalization related to material deprivation and ethnic concentration among patients receiving injectable ART at academic HIV clinics in Toronto</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ashan Wijesinghe, CA	
<b>Distinct lipidomic signatures in people living with HIV treated with EVG/c/FTC/TAF or BIC/FTC/TAF: a real-world prospective cohort study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Biao Zhu, CN	
<b>Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection</b>	09:00 - 09:00
<i>Poster Presenter:</i> Nicholas Brian Bana, IT	
<b>3-Year Outcomes for Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-treated People Living With HIV-1 (PLHIV) in Germany: Real-world Data From the German URBAN Cohort</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sebastian Noe, DE	
<b>Durability of two-drug antiretroviral regimens as maintenance therapy in people living with HIV and reasons for switch to a three-drug regimen: a real-life cohort study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Emmanuelle Bontemps, FR	
<b>HIV viremias among patients who discontinued Cabotegravir(CAB)/ Rilpivirine(RPV) Long acting(LA) intramuscular(IM) in real-life</b>	09:00 - 09:00

**setting***Poster Presenter:* Sophie Seang, FR

**Real life data on clinical and laboratory outcomes of long acting cabotegravir and rilpivirine in people with HIV** 09:00 - 09:00

*Poster Presenter:* Maria Mazzitelli, GB

**REAL-WORLD EXPERIENCE OF TAF/FTC/BIC IN PEOPLE WITH HIV-2** 09:00 - 09:00

*Poster Presenter:* Catarina Rodrigues, PT

**REAL-WORLD DATA ON PERSONS LIVING WITH HIV (PLWH) SWITCHING TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (BIC/FTC/TAF) WHILE VIROLOGICALLY SUPPRESSED: 96-WEEK DATA FROM THE ICONA COHORT** 09:00 - 09:00

*Poster Presenter:* Antonella d'Arminio Monforte, IT

**Real-life experience on dolutegravir and lamivudine as initial or switch treatment in a silver population living with HIV** 09:00 - 09:00

*Poster Presenter:* Maria Mazzitelli, GB

**Comparative observational study of darunavir/cobicistat/emtricitabine/tenofovir alafenamide versus bicittegravir/emtricitabine/tenofovir alafenamide in high-risk non-adherent people living with HIV** 09:00 - 09:00

*Poster Presenter:* Hernando Knobel, ES

**Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatment-naïve (TN) and -experienced (TE) people with HIV (PWH): 3-year effectiveness and safety outcomes in the BICSTaR observational cohort** 09:00 - 09:00

*Poster Presenter:* Michael Sabranski, DE

**Comparative efficacy and safety of TAF/FTC/BIC, TAF/FTC+DTG, and TDF/FTC+DTG in naive people with HIV: results from the SCOLTA cohort** 09:00 - 09:00

*Poster Presenter:* Andrea De Vito, IT

**Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virologically Suppressed Adults With HIV-1 Infection: a Multicenter, Randomized Controlled Study** 09:00 - 09:00

*Poster Presenter:* Yueming Shao, CN

**Bictegravir/Emtricitabine/Tenofovir Alafenamide comparing with Tenofovir/Lamivudine/Efavirenz as an initial regimen in late presenters of Chinese HIV patients: a 24-week randomised multicentered clinical trial study** 09:00 - 09:00

*Poster Presenter:* Wei Lyu, CN

**Efficacy and Safety of Fixed-dose Combination Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV-1—a Systematic Review and Meta-analysis** 09:00 - 09:00

*Poster Presenter:* Wenjing Wang, CN

**Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1** 09:00 - 09:00

*Poster Presenter:* Jason Hindman, US

**A randomised control trial of BIC/F/TAF vs DRV/c/F/TAF in context of HIV test-and-treat** 09:00 - 09:00

*Poster Presenter:* Arnold Xhikola, GB

**Evaluation of the viral reservoirs in people with HIV who start dual therapy: Results from the ANDES trial** 09:00 - 09:00

*Poster Presenter:* Yanina Ghiglione, AR

<b>Efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily in heavily treatment-experienced persons with HIV-1: week 49 results from a phase 3 trial</b>	09:00 - 09:00
<i>Poster Presenter:</i> Wayne Greaves, US	
<b>Subgroup analysis of week 48 efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily as initial HIV-1 treatment in a double-blind phase 3 trial</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mary Pisculli, US	
<b>Sustained Improvements in Biomarkers Observed With Fostemsavir in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 From the Phase 3 BRIGHT Study Through Week 240</b>	09:00 - 09:00
<i>Poster Presenter:</i> Antonella Castagna, IT	
<b>Long-term Safety and Impact of Immune Recovery in Heavily Treatment-Experienced Adults Receiving Fostemsavir for up to 5 Years in the BRIGHT Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Josep M. Llibre, ES	
<b>Switching to bicitgravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance - a Phase IV randomised, open-label pilot study (PIBIK study)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Collins Iwuji, GB	
<b>Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jean-Michel Molina, FR	
<b>Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bicitgravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mary Pisculli, US	
<b>Virologic Outcomes of Lamivudine/Dolutegravir in Virologically suppressed persons with expected or confirmed resistance to Lamivudine (VOLVER clinical trial-GESIDA 11820)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Rosa De Miguel, ES	
<b>Bicitgravir/Emtricitabine/Tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carmen Hidalgo-Tenorio, ES	
<b>Pharmacokinetics/Pharmacodynamics and Virological Activity of VH3810109 (N6LS) in Antiretroviral-Naïve Viremic Adults From the Phase IIa BANNER Study</b>	09:00 - 09:00
<i>Poster Presenter:</i> A. Yin Edwards, US	
<b>Cabotegravir + Rilpivirine long-acting efficacy and safety outcomes by sex at birth, age and race: a subgroup analysis of the CARISEL study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Kai Hove, GB	
<b>Efficacy, safety and implementation outcomes of Cabotegravir + Rilpivirine long-acting by country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Celia Jonsson-Oldenbüttel, DE	
<b>Efficacy and safety by subgroup at week 48 after switch to doravirine/islatravir (100 mg/0.75 mg) once daily in two phase 3</b>	09:00 - 09:00

**trials***Poster Presenter:* Jean-Michel Molina, FR

**No Relevant Difference in Incident Hypertension Observed by Gender, Race, Baseline BMI, or Other Key Subgroups Through Week 96 Among People Living With HIV-1 (PLWH) Receiving Dolutegravir (DTG)-Based Regimens or Comparator Antiretroviral Therapy (cART) in Pooled Randomized Clinical Trials**

09:00 - 09:00

*Poster Presenter:* Parul Patel, US

**Follow-up of injection site reactions in clinical studies of people using lenacapavir every 6 months for HIV treatment**

09:00 - 09:00

*Poster Presenter:* Antonella Castagna, IT

**SOLAR 12-Month European Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF**

09:00 - 09:00

*Poster Presenter:* Ignacio Santos, ES

**ANRS 177 DUETTO randomized, open-label and multicentric trial evaluating the non-inferiority of maintenance antiretroviral dual therapy taken 4 consecutive days per week versus dual therapy 7/7 days per week.**

09:00 - 09:00

*Poster Presenter:* Roland Landman, FR

**Analysis of transmitted HIV drug resistance and phylogenetic clusters in Bulgaria (2012-2020)**

09:00 - 09:00

*Poster Presenter:* Ivailo Alexiev, BG

**The Efficacy and Tolerability of Latency Reversing Agents in Reactivating the HIV-1 Reservoir in Clinical Studies: a Systematic Review**

09:00 - 09:00

*Poster Presenter:* Kathryn S. Hensley, NL

**Comparing viral re-suppression rates following antiretroviral therapy interruption in cure-related clinical studies: a systematic review and meta-analysis of intervention vs. non-intervention trials**

09:00 - 09:00

*Poster Presenter:* Ming Jie Lee, GB

**IMPACT OF ADMINISTRATION OF A LATENCY REVERSAL AGENT DURING INITIATION OF ANTIRETROVIRAL TREATMENT ON THE HIV RESERVOIR SIZE**

09:00 - 09:00

*Poster Presenter:* Erick De La Torre Tarazona, ES

**Identification of therapeutic targets for HIV cure through high-throughput screening in novel *in vitro* non-clonal HIV-1 latency models**

09:00 - 09:00

*Poster Presenter:* Edurne Garcia-Vidal, ES

**No Differences in HIV-1 Proviral Landscapes over 10 Years in Treated and Suppressed Individuals with Distinct HIV-1 Reservoir Dynamics**

09:00 - 09:00

*Poster Presenter:* Jasmin Tschumi, CH

**Performance Evaluation of two new molecular platforms for HIV-1 RNA measurement: the COBAS HIV-1 5800 and the NeuMoDx 96**

09:00 - 09:00

*Poster Presenter:* Eleni Papachristou, GR

**Heparin-Binding Protein as a proinflammatory biomarker in people living with HIV**

09:00 - 09:00

*Poster Presenter:* Agnieszka Lembas, PL

**Longitudinal immunophenotyping analysis of peripheral blood cells in PLWH on long-acting injectable HIV antiretroviral**

09:00 - 09:00

*Poster Presenter:* Raffaella Marocco, IT

**Characterization of specific T-cell responses to a Three-Doses**

09:00 - 09:00

**nonavalent HPV Vaccine Schedule in people living with HIV (PLWH) on antiretroviral therapy (ART)**

*Poster Presenter:* Miriam Lichtner, IT

**Mycobacterium tuberculosis infection associated immune perturbations correlate with antiretroviral immunity**

09:00 - 09:00

*Poster Presenter:* Katharina Kusejko, CH

**Platelet responses are comparable in participants taking BIC/F/TAF or DRV/c/F/TAF in context of HIV test-and-treat**

09:00 - 09:00

*Poster Presenter:* Akif A. Khawaja, GB

**Association of Susceptibility to Broadly Neutralizing Antibodies and Presence of Capsid CTL Epitopes During Acute HIV-1 Infection**

09:00 - 09:00

*Poster Presenter:* Laurie A. VanderVeen, US

**T-cell responses to an original/BA.4-5 bivalent 4<sup>th</sup> mRNA vaccine dose in people living with HIV (PLWH) on efficacious cART**

09:00 - 09:00

*Poster Presenter:* Matteo Augello, IT

**Development of highly conserved HIV-specific multiple CTL epitope vaccines based on the mRNA vaccine platform**

09:00 - 09:00

*Poster Presenter:* Zhihang Zheng, CN

**B1. Clinical science - Antiretroviral therapy**

09:00 - 09:00

**Switching to bictegravir/emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis**

09:00 - 09:00

*Poster Presenter:* Daniel Podzamczar, ES

**Surveillance programme to identify and reduce Drug-Drug Interactions (DDI) with Protease Inhibitors (PI) in PLHIV and darunavir/cobicistat (DRV/c) based ART. HIPI Cohort**

09:00 - 09:00

*Poster Presenter:* Veronica Rico Gonzalez, ES

**Outcomes of drug interactions between antiretrovirals and over-the-counter drugs: a real-world study**

09:00 - 09:00

*Poster Presenter:* Jose Molto, ES

**A study of pharmacist antiretroviral stewardship in relation to drug-drug interaction (DDI) checking**

09:00 - 09:00

*Poster Presenter:* Arlene Heekin, IE

**Polypharmacy, anticholinergic burden, and drug-drug interaction assessment in people living with HIV harboring a 4-class resistance: data from the PRESTIGIO Registry**

09:00 - 09:00

*Poster Presenter:* Maria Mazzitelli, GB

**Virological rebound and the use of dietary supplements in people living with HIV: results of a survey**

09:00 - 09:00

*Poster Presenter:* Adriana Cervo, IT

**Low level of HIV-1C integrase strand transfer inhibitor resistance mutations among recently diagnosed ART-naïve Ethiopians**

09:00 - 09:00

*Poster Presenter:* Mulugeta Kiros, ET

**Drug resistance mutations conferring resistance to integrase inhibitors among HIV patients in Tel Aviv, between 2010-2020, prevalence and risk factors**

09:00 - 09:00

*Poster Presenter:* Dan Turner, IL

**Assessing the Utilization of HIV Genotype Resistance Testing: Insights from Italian Infectious Diseases Units**

09:00 - 09:00

*Poster Presenter:* Andrea De Vito, IT

<b>Prevalence of doravirine (DOR) resistance associated mutations (RAMs) by algorithm in persons living with HIV (PLWH) and a history of failing a non-nucleoside reverse transcriptase inhibitor (NNRTI) in Haiti</b>	09:00 - 09:00
<i>Poster Presenter:</i> Rafael Campo, US	
<b>Prevalence of Doravirine Resistance-Associated Mutations in Pregnant Women Living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Javier Alejandro Sfalcin, AR	
<b>A cross-sectional analysis of HIV genotypic mutations and treatment efficacy; data from the All Ireland ID (AIID) Cohort</b>	09:00 - 09:00
<i>Poster Presenter:</i> Daragh Matthew McGee, IE	
<b>Real-world data on the use of the antiretroviral treatment (ART) regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c) and dolutegravir (DTG)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Amy Keane, IE	
<b>Prevalence of Resistance-Associated Mutations in Treatment-Naïve people with HIV-1 (PWH) Amid the Era of Integrase-Strand Transfer Inhibitors in Taiwan</b>	09:00 - 09:00
<i>Poster Presenter:</i> Guan-Jhou Chen, TW	
<b>Prevalence and Profile of Drug Resistance Mutations Among Irregular Migrants From Latin America Living With HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Samuel Manzano, ES	
<b>Sensitive HIV-1 DNA pol next generation sequencing (NGS) for the characterisation of archived antiretroviral drug resistance</b>	09:00 - 09:00
<i>Poster Presenter:</i> Johannes C Botha, GB	
<b>Impact of pre-existing HIV-1 primary and secondary reverse transcriptase and integrase resistance-associated mutations by next generation sequencing on virological response to dolutegravir (DTG)-containing regimens in antiretroviral-naïve patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Luis Blanco Arévalo, ES	
<b>Assessing phenotypic effect of integrase strand transfer inhibitor (INSTI)-based resistance substitutions linked to failures on cabotegravir</b>	09:00 - 09:00
<i>Poster Presenter:</i> Michelle L. D'Antoni, US	
<b>Unlocking Antiretroviral Treatment Potential: use of doravirine (DOR) in PLHIV with past NNRTI resistance associated mutations (RAMs)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Basma Abdi, FR	
<b>Dolutegravir/rilpivirine (DTG/RPV) therapy as a maintenance treatment in PLWH with past virological failures and resistance-associated mutations to NNRTIs and INSTIs</b>	09:00 - 09:00
<i>Poster Presenter:</i> Romain Palich, FR	
<b>High levels of resistance among HIV-1 treatment-naïve PLHIV in Greece: Evidence for ongoing NNRTI transmitted resistance within local transmission networks</b>	09:00 - 09:00
<i>Poster Presenter:</i> Evangelia-Georgia Kostaki, GR	
<b>3-year analysis of emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second generation INSTIs in 2- and 3-drug regimens (Virostar study)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Anne-Geneviève Marcelin, FR	
<b>Resistance to doravirine after virologic failure to a first-line Non-Nucleoside Reverse Transcriptase Inhibitor based regimen: Data from a real life cohort in a Latin American country</b>	09:00 - 09:00

*Poster Presenter:* Maria Veronica Mingrone, AR

**Do minority resistant variants in HIV-DNA predict virological rebound in highly treatment experienced PLWH under virological control? Data from the PRESTIGIO Registry** 09:00 - 09:00

*Poster Presenter:* Daniele Armenia, IT

**Proviral DNA for detection of HIV-1 subtype A drug resistance mutations** 09:00 - 09:00

*Poster Presenter:* Tal Levinson, IL

**DORAVIR: a French national survey of people with HIV-1 treated by an antiretroviral regimen including Doravirine** 09:00 - 09:00

*Poster Presenter:* Cathia Soulie, FR

**Comparative analysis of drug resistance among treatment-naïve Polish individuals and migrants living with HIV-1** 09:00 - 09:00

*Poster Presenter:* Kaja Scheibe, PL

**EFFICACY AND DURABILITY OF FOSTEMSAVIR-, IBALIZUMAB-, OR LENACAPAVIR-INCLUDING REGIMENS IN PEOPLE LIVING WITH A MULTIDRUG RESISTANT HIV: RESULTS FROM THE PRESTIGIO REGISTRY** 09:00 - 09:00

*Poster Presenter:* Vincenzo Spagnuolo, IT

**Transmitted drug resistance (TDR) surveillance in Croatia in period before and during COVID-19 pandemic** 09:00 - 09:00

*Poster Presenter:* Ana Planinic, HR

**Real life CABOTEGRAVIR (CAB) and RILPIVIRINE (RPV) pharmacokinetics among PLHIV treated with CAB RPV Long Acting (LA IM)** 09:00 - 09:00

*Poster Presenter:* Sophie Seang, FR

**Cabotegravir/Rilpivirine based long acting therapy with insufficient drug levels in routine drug monitoring** 09:00 - 09:00

*Poster Presenter:* Robert Ehret, DE

**Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 infection switching to long-acting cabotegravir and rilpivirine** 09:00 - 09:00

*Poster Presenter:* Jean-Michel Molina, FR

**Tenofovir plasma and intracellular pharmacokinetics IN Insti-based regimens** 09:00 - 09:00

*Poster Presenter:* Micol Ferrara, IT

**IMPACT OF DIFFERENT ANTIRETROVIRAL DRUGS ON ADIPOCYTE DIFFERENTIATION** 09:00 - 09:00

*Poster Presenter:* Maria Aurora Carleo, IT

**Use of the data mining algorithms for the analysis of adverse event risks associated with antiretroviral treatment** 09:00 - 09:00

*Poster Presenter:* Przemysław Kłesk, PL

**Subjective sleep quality evolution in patients starting or switching to dolutegravir or cabotegravir: a real-world longitudinal study** 09:00 - 09:00

*Poster Presenter:* Peter Messiaen, BE

**Dolutegravir discontinuation due to neuropsychiatric adverse events: a pharmacogenetic case-control study** 09:00 - 09:00

*Poster Presenter:* Julien De Greef, BE

**B2. Clinical science - Co-morbidities and ageing** 09:00 - 09:00

eP.B1.032

**Integrase strand-transfer inhibitor resistance in a tertiary hospital** 09:00 - 09:00

**in Portugal***Poster Presenter:* Josefina Méndez, PT**Lipid changes and its impact on CV risk after hepatitis C virus eradication in HIV-HCV co-infected persons**

09:00 - 09:00

*Poster Presenter:* Anna Castelli, ES**Role of optical coherence tomography to assess cognitive impairment in person living with HIV**

09:00 - 09:00

*Poster Presenter:* Agnès Libois, BE**Nonalcoholic fatty liver disease among people living with HIV (PLWH): a monocentric cross-sectional analysis**

09:00 - 09:00

*Poster Presenter:* Benedetto Maurizio Celesia, IT**The role of CYP450 families in the management of dyslipidemia in PLWHIV**

09:00 - 09:00

*Poster Presenter:* Elio Gentilini Cacciola, IT**Low levels of cortisol in people living with HIV infection in the OVER50 Cohort: a hormonal substudy**

09:00 - 09:00

*Poster Presenter:* Diana Hernandez-Sanchez, ES**Study of the Cardiovascular Disease Risk in People Living with HIV-1 in Portugal**

09:00 - 09:00

*Poster Presenter:* Isabel Casella, PT**Neuregulin 4 could be a new serum marker of insulin resistance, diabetes and lipid disorders development in people living with HIV on suppressive antiretroviral therapy**

09:00 - 09:00

*Poster Presenter:* Mariusz Sapała, PL**Cardiovascular risk assessment with SCORE, SCORE2 and D:A:D in people living with HIV with high prevalence of cardiovascular risk factors**

09:00 - 09:00

*Poster Presenter:* Inês Pintassilgo, PT**Prevalence and predictors of non-alcoholic fatty liver disease (NAFLD) among Egyptian people living with HIV: a cross-sectional study**

09:00 - 09:00

*Poster Presenter:* Rahma Mohamed, EG**Prevalence and predictors of erectile dysfunction in a contemporary cohort of greek people living with HIV (PLHIV) - a single center experience**

09:00 - 09:00

*Poster Presenter:* Konstantinos Protopapas, GR**Prevalence of Cardiovascular Disease Risk Factors and Calculation of Cardiovascular Disease Risk in a Cohort of People Living with HIV in Lebanon**

09:00 - 09:00

*Poster Presenter:* Remie El Helou, LB**Cognitive trajectories among people with HIV attending a dedicated memory clinic for people living with HIV**

09:00 - 09:00

*Poster Presenter:* Jaime Vera, GB**Characterization of transient elastography findings among Egyptian people living with HIV: a spotlight on steatotic liver disease**

09:00 - 09:00

*Poster Presenter:* Ahmed Cordie, EG**Awareness and acceptability of herpes zoster vaccination in people living with HIV**

09:00 - 09:00

*Poster Presenter:* Christian Motet, BE**ATTITUDE TOWARDS ALCOHOL INTAKE IN PLWHA:**

09:00 - 09:00



**IMPLICATION FOR DIETITIAN COUNSELLING***Poster Presenter:* Giancarlo Orofino, IT**The CYP2B6 Gene Polymorphism Is Associated with An Increased Risk of Cardiovascular Disease and Weight Gain in People Living with HIV on Antiretroviral Therapy**

09:00 - 09:00

*Poster Presenter:* Yuan-Ti Lee, TW**Humoral response 24 months after first COVID-19 vaccination in PWH with and without diabetes mellitus**

09:00 - 09:00

*Poster Presenter:* Louise Bering, DK**Incidence of bacterial respiratory infection and pneumonia in people with HIV with and without airflow limitation**

09:00 - 09:00

*Poster Presenter:* Safura-Luise Heidari, DK**Is there evidence for immunological alterations with GLP-1 agonists in people living with HIV?**

09:00 - 09:00

*Poster Presenter:* Sebastian Noe, DE**Socio-economic and demographic determinants of medication prescription in the Swiss HIV Cohort Study**

09:00 - 09:00

*Poster Presenter:* Chloé Pasin, CH**Intensive care unit treatment in people living with HIV in Croatia: a single Centre 25-year experience**

09:00 - 09:00

*Poster Presenter:* Filip Glavac, HR**Unmasking the Invisible Threat: Evaluating Cardiovascular Risks Among Smokers Living with HIV**

09:00 - 09:00

*Poster Presenter:* Bogusz Jan Aksak-Wąs, PL**The first two lung transplants in persons living with HIV at Puerta de Hierro Hospital (Madrid, Spain)**

09:00 - 09:00

*Poster Presenter:* Alberto Díaz-de Santiago, ES**Longitudinal Analysis of Cerebrospinal Fluid HIV RNA in Untreated People with HIV: Identification of Cerebrospinal fluid Controllers**

09:00 - 09:00

*Poster Presenter:* Mattia Trunfio, US**Incidence of Metabolic Syndrome in People living with HIV Starting ART with a Dolutegravir Based-Regimen vs Bictegravir Based-Regimen After 24 Weeks in Mexico**

09:00 - 09:00

*Poster Presenter:* Jose Antonio Mata Marín, MX**Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement**

09:00 - 09:00

*Poster Presenter:* Carmela Pinnetti, IT**CORRELATION OF ANTHROPOMETRIC PARAMETERS TO EPICARDIAL AND VISCERAL FAT IN PATIENTS RECEIVING ANTIRETROVIRAL TREATMENT**

09:00 - 09:00

*Poster Presenter:* Vanja Andric, RS**Statins and acetylsalicylic acid (ASA) use and LDL cholesterol value below 70 mg/dl in people living with HIV (PLWH): there is a gap between European AIDS Clinical Society guidelines and clinical practice**

09:00 - 09:00

*Poster Presenter:* Benedetto Maurizio Celesia, IT**The interplay between adipose tissue properties and levels of NT-proBNP in people with HIV**

09:00 - 09:00

*Poster Presenter:* Mads-Holger Bang Jacobsen, DK**Infectious disease events in people with HIV receiving kidney**

09:00 - 09:00

**transplantation - analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study***Poster Presenter:* Katharina Kusejko, CH**Weight gain and loss and stable weight in relation to fat and lean mass in PWH**

09:00 - 09:00

*Poster Presenter:* Nicole Barp, IT**LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study**

09:00 - 09:00

*Poster Presenter:* Giorgia Carrozzo, IT**Associations between multimorbidity burden and objective and patient-reported health outcomes among people living with HIV**

09:00 - 09:00

*Poster Presenter:* Caroline Sabin, GB**Bictegravir and Dolutegravir have no impact on glucose levels 12 months after initiation**

09:00 - 09:00

*Poster Presenter:* Nicola Squillace, IT**Divergent effects of SSRIs and SNRIs on blood and cerebrospinal fluid inflammatory markers in virally suppressed people with HIV**

09:00 - 09:00

*Poster Presenter:* Mattia Trunfio, US**Comparing the performance of cardiovascular risk models for a multicentre cohort of people living with HIV from the UK in an era of modern ART**

09:00 - 09:00

*Poster Presenter:* Ming Jie Lee, GB**NEW RISK FACTORS FOR FRAGILITY FRACTURES MUST BE CONSIDERED IN OLDER ADULTS WITH HIV**

09:00 - 09:00

*Poster Presenter:* Fátima Brañas, ES**The influence of COVID-19 pandemic on HIV care in Izmir, Turkiye**

09:00 - 09:00

*Poster Presenter:* Arzu Nazli, TR**Going virtual: Experience with conducting an HIV research study virtual visits during COVID-19 Lockdown in Kampala Uganda**

09:00 - 09:00

*Poster Presenter:* Sylvia Namanda, UG**Spike-specific CD8+ T cell responses after SARS-CoV-2 mRNA vaccination in people living with HIV**

09:00 - 09:00

*Poster Presenter:* Matthias Müller, DE**Immune response to routine COVID-19 vaccination amongst immunocompromised HIV patients**

09:00 - 09:00

*Poster Presenter:* Ludwig Apers, BE**The impact of COVID -19 pandemic on HIV national testing treatment and care services in the country of Georgia**

09:00 - 09:00

*Poster Presenter:* Otar Chokoshvili, GE**PREDICTORS OF SARS-COV2 INFECTION IN TREATMENT-EXPERIENCED PLWHIV: CASE-CONTROL STUDY**

09:00 - 09:00

*Poster Presenter:* Valentina Iannone, IT**Comparative analysis of primary and monovalent booster SARS-CoV-2 vaccination coverage in adults with and without HIV in Catalonia, Spain**

09:00 - 09:00

*Poster Presenter:* Daniel Kwakye Nomah, ES**CELLULAR AND HUMORAL RESPONSE AFTER mRNA SARS-CoV-2 VACCINATION IN KIDNEY TRANSPLANT RECIPIENTS LIVING WITH HIV**

09:00 - 09:00

*Poster Presenter:* Daniel Kwakye Nomah, ES

<b>Immunogenicity of a bivalent Omicron BA.1 COVID-19 booster vaccination in people with HIV in the Netherlands</b> <i>Poster Presenter:</i> Marlou J Jongkees, NL	09:00 - 09:00
<b>Humoral immunogenicity of mRNA SARS-COV-2 vaccines among people living with HIV</b> <i>Poster Presenter:</i> Daniel Kwakye Nomah, ES	09:00 - 09:00
<b>Interferon (IFN)-g release assay (IGRA) as a practical tool to measure SARS-CoV-2 specific cellular immunity and guide the management of people with a history of advanced HIV infection</b> <i>Poster Presenter:</i> Ludovica Ferrari, IT	09:00 - 09:00
<b>People living with HIV during the COVID-19 pandemic: Significant sex differences in health related quality of life - Results from the ANITA study</b> <i>Poster Presenter:</i> Johann Fabian Eberhardt, DE	09:00 - 09:00
<b>The effect of the COVID-19 epidemic on the epidemiological course of the HIV infection in Greece</b> <i>Poster Presenter:</i> Giota Touloumi, GR	09:00 - 09:00
<b>The mid-term effect of SARS-COV-2 on immune-oncology checkpoint inhibitors disruption in people living with HIV</b> <i>Poster Presenter:</i> Celia Crespo-Bermejo, ES	09:00 - 09:00
<b>Project 90 day ideal lifestyle modification onestep closer to the fourth 90</b> <i>Poster Presenter:</i> Ku Hsin Yen, TW	09:00 - 09:00
<b>Prevalence of and risk factors associated with poor quality of sleep in people living with HIV and the correlation of quality of sleep and CD4+ T lymphocyte reconstitution: cross-sectional study from Turkey</b> <i>Poster Presenter:</i> Özge Eren Korkmaz, TR	09:00 - 09:00
<b>HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH HIV WITH LOW CD4+ CELL COUNTS. CHANGES IN THE LAST 25 YEARS AROUND THE WORLD. A SYSTEMATIC REVIEW AND METAANALYSIS</b> <i>Poster Presenter:</i> Joaquin Portilla, ES	09:00 - 09:00
<b>Prevalence and Correlates of Depression among HIV-Positive Ethiopian Migrants in Israel</b> <i>Poster Presenter:</i> Hila Elinav, IL	09:00 - 09:00
<b>Sleep disorders and Inflammation Biomarkers in People Living with HIV (PLHIV) monitored in a tertiary University Hospital of Greece</b> <i>Poster Presenter:</i> Vasilis Petrakis, GR	09:00 - 09:00
<b>The Prevalence of Stigma, Depression and Anxiety in a Cohort of Treatment Controlled People Living with HIV in Lebanon: A Cross Sectional Study</b> <i>Poster Presenter:</i> Remie El Helou, LB	09:00 - 09:00
<b>Insomnia Assessment in PLWH: Utilizing the Soldatos Athens Insomnia Scale</b> <i>Poster Presenter:</i> Georgios Adamis, GR	09:00 - 09:00
<b>Health-related Quality of Life in Long-Term AIDS Survivors. A Co-Ris Study</b> <i>Poster Presenter:</i> Joaquin Portilla, ES	09:00 - 09:00
<b>Validation of a mobile health app as a health-related quality of life assessment instrument for people living with HIV</b> <i>Poster Presenter:</i> Joanna Cano-Smith, ES	09:00 - 09:00

<b>NO CHANGES IN THE IMPACT OF AIDS DIAGNOSIS IN HEALTH RELATED QUALITY OF LIFE DURING THE LAST 25 YEARS. A SYSTEMATIC REVIEW AND METAANALYSIS</b>	09:00 - 09:00
<i>Poster Presenter:</i> Joaquin Portilla, ES	
<b>The relationship of interleukin-6, cystatin C, D-dimer levels with depression and anxiety in people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Melike Nur Kultur, TR	
<b>Switching to bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Stefan Esser, DE	
<b>Patient reported outcomes in a Slovenian national cohort of people living with HIV; results of a cross-sectional study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jerca Ambrožič, SI	
<b>WELL-BEING IN PEOPLE LIVING WITH HIV (PLWH) STARTING LONG-ACTING THERAPY</b>	09:00 - 09:00
<i>Poster Presenter:</i> Francesca Alberton, IT	
<b>Implementing an electronic Patient-Reported Outcomes (ePROs) system for PLWH: experience of Icona cohort</b>	09:00 - 09:00
<i>Poster Presenter:</i> Antonella d'Arminio Monforte, IT	
<b>Screening for neurocognitive impairment in people living with HIV (PLHIV) through patient-reported outcome measures (PROMs) and cognitive assessment</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marie-Angélique De Scheerder, BE	
<b>Patient-reported outcomes among people living with HIV on bicitgravir/emtricitabine/tenofovir alafenamide fixed-dose combination: real-world data from Latin America</b>	09:00 - 09:00
<i>Poster Presenter:</i> Diego Martin Cecchini, AR	
<b>Symptomatic and "Asymptomatic" HIV-associated neurocognitive impairment, adherence to antiretroviral therapy, and viral control: a four-year observational study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Elisa Vuaran, IT	
<b>A quality of life indicator for HIV care beyond viral suppression in Spain</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carlos Iniesta, ES	
<b>The impact of the COVID-19 pandemic on cervical screening and outcomes for women living with HIV (WLHIV)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Harriet Mortimer, GB	
<b>Could DOL/LAM be a valid Dual-Therapy option even in onco-haematological patients? Data from a retrospective analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Layla Pagnucco, IT	
<b>Results of a survey conducted among Italian oncologists and infectious disease specialists evaluating the awareness about cancer in people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Eva Massari, IT	
<b>Lung cancer screening with loose dose CT scan in persons living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Alberto Díaz-de Santiago, ES	
<b>HIV-aviremic PLHIV with Kaposi's Sarcoma (KS) are prone to KS relapses and chemotherapy failure and toxicities: results from the French CancerVIH Network</b>	09:00 - 09:00

*Poster Presenter:* Sophie Bacquart, FR

**Increasing numbers of scabies in people living with HIV** 09:00 - 09:00

*Poster Presenter:* Oğuzhan Acet, TR

**Epidemiological features of viral hepatitis among patients with HIV/AIDS** 09:00 - 09:00

*Poster Presenter:* Olena Zubach, UA

**The use of polymerase chain reaction (PCR) and cycle threshold values in the diagnosis of *Pneumocystis jirovecii* pneumonia** 09:00 - 09:00

*Poster Presenter:* Karen Olshtain Pops, IL

**Identification of transdiagnostic HIV-related Cryptococcosis by machine learning** 09:00 - 09:00

*Poster Presenter:* Xuemin Fu, DE

**Seroprevalence of Monkeypox (MPX) IgG antibodies in a cohort of PLWH in Rome, during the 2022 outbreak** 09:00 - 09:00

*Poster Presenter:* Pierluigi Francesco Salvo, IT

**Syphilis in the Ege University HIV cohort: what was the impact of the pandemic?** 09:00 - 09:00

*Poster Presenter:* Oğuzhan Acet, TR

**Sexually transmitted dermatophytes may cause severe infection among men who have sex with men as *tinea genitalis*** 09:00 - 09:00

*Poster Presenter:* David Chromy, AT

**Incidence of syphilis among HIV-infected men in Busan, Korea, 2005-2022: a retrospective cohort study** 09:00 - 09:00

*Poster Presenter:* Sun Hee Lee, KR

**Azithromycin-resistant *Mycoplasma genitalium* is frequently detected in men who have sex with men in Austria** 09:00 - 09:00

*Poster Presenter:* David Chromy, AT

**Mpox-associated complications during the 2022 outbreak in Buenos Aires, Argentina: a case series in a referral HIV clinic** 09:00 - 09:00

*Poster Presenter:* Julián Vega, AR

**Lymphogranuloma venereum: the relevance of asymptomatic patients** 09:00 - 09:00

*Poster Presenter:* Cristina Gómez-Ayerbe, ES

**Clinical manifestations of Ocular Syphilis in people living with HIV at a specialized primary care clinic** 09:00 - 09:00

*Poster Presenter:* Andrea Calderón Suárez, MX

**Prevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), and syphilis co-infection among people living with HIV (PLHIV): An Egyptian cross-sectional study** 09:00 - 09:00

*Poster Presenter:* Rahma Mohamed, EG

**Recently acquired hepatitis C virus (RAHCV) infection in men who have sex with men (MSM) in Southern Spain** 09:00 - 09:00

*Poster Presenter:* Cristina Gómez-Ayerbe, ES

**Clinical Characteristics and Treatment Outcomes of Neurosyphilis in People Living with HIV: A Multicentric Retrospective Cohort Study** 09:00 - 09:00

*Poster Presenter:* Giulia Moi, IT

**Trends of sexually transmitted infections among MSM individuals over 2022 in a large teaching hospital in Milan, Italy** 09:00 - 09:00

*Poster Presenter:* Davide Moschese, IT

<b>Current patterns of unprotected sex, drug use, and prevalence of STIs among MSM on HIV care or taking PrEP in the region of Madrid</b>	09:00 - 09:00
<i>Poster Presenter:</i> Pablo Rayn, ES	
<b>Mycoplasma genitalium treatment and detection of 23S rRNA macrolide resistance mutations in PLWHIV and HIV-negative persons</b>	09:00 - 09:00
<i>Poster Presenter:</i> Alberto Díaz-de Santiago, ES	
<b>Diagnostic armamentaria for AIDS Defining Illnesses remains insufficient in the Central Eastern European region - data from ECEE Network Group</b>	09:00 - 09:00
<i>Poster Presenter:</i> Botond Lakatos, HU	
<b>Prevalence and clinical characteristics of late HIV presenters among persons who are enrolled in care at our clinic: an Egyptian cross-sectional study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Rahma Mohamed, EG	
<b>Pneumocystis jirovecii pneumonia - Immune reconstitution inflammatory syndrome: Evidence based therapeutic recommendations to fill the void</b>	09:00 - 09:00
<i>Poster Presenter:</i> Natasha Marcella Vaselli, AU	
<b>Risk factors for incident tuberculosis among people living with HIV after starting TB preventive therapy in South Africa, Mozambique, and Ethiopia</b>	09:00 - 09:00
<i>Poster Presenter:</i> Felex Ndebele, ZA	
<b>Latent tuberculosis infection screening and treatment in people living with HIV in a low tuberculosis incidence country</b>	09:00 - 09:00
<i>Poster Presenter:</i> Inès Charachon, FR	
<b>Risk factor predictions for three-year mortality among HIV-related patients with disseminated Cryptococcosis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Xuemin Fu, DE	
<b>Rilpivirine-based ART ameliorates liver fibrosis in persons with HIV (PWH) with MASLD (Metabolic dysfunction-associated steatitic liver disease) over a two-year period</b>	09:00 - 09:00
<i>Poster Presenter:</i> Maria Luisa Montes, ES	
<b>Clinical and laboratory features, and antiretroviral therapy in men living with HIV with hepatitis A</b>	09:00 - 09:00
<i>Poster Presenter:</i> Šime Zekan, HR	
<b>Changes in the prevalence of hepatitis B virus infection in people living with HIV in Seville from 2011 to 2022</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marta Santos, ES	
<b>Spontaneous clearance of HCV and its chronic infection alters the immunophenotypical T-cell profile in PLWH</b>	09:00 - 09:00
<i>Poster Presenter:</i> Manuel Llamas-Adán, ES	
<b>To the liver and beyond: the impact of HCV clearance with direct antiviral agents in people living with HIV/HCV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mauro Bertolini, AR	
<b>THE SHIP: Testing Hepatitis E Seroprevalence among PLWHIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Karolina Akinosoglou, GR	
<b>Efficacy of Tenofovir Alafenamide- or Tenofovir Disoproxil Fumarate-containing Regimens in Adults with HIV-HBV Coinfection</b>	09:00 - 09:00
<i>Poster Presenter:</i> Fehmi Tabak, TR	

<b>The status of hepatitis C micro-elimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group</b> <i>Poster Presenter:</i> Agata Skrzat-Klapaczyńska, PL	09:00 - 09:00
<b>Molecular and serological survey of rat hepatitis E virus (<i>Rocahepevirus rattii</i>) in people living with HIV in Spain</b> <i>Poster Presenter:</i> Antonio Rivero-Juarez, ES	09:00 - 09:00
<b>Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany</b> <i>Poster Presenter:</i> Patrick Ingiliz, DE	09:00 - 09:00
<b>Prevalence of NAFLD and risk factors associated with liver fibrosis in a cohort of people with HIV in Barcelona (Spain)</b> <i>Poster Presenter:</i> Alberto Foncillas López, ES	09:00 - 09:00
<b>Long-term durability of immune response to hepatitis A vaccination among people living with HIV</b> <i>Poster Presenter:</i> Takashi Muramatsu, JP	09:00 - 09:00
<b>Assessing and improving the quality of guideline-adherent hepatitis B virus care in people with HIV: a cross-sectional study</b> <i>Poster Presenter:</i> Patrick G. A. Oomen, NL	09:00 - 09:00
<b>FibroScan screening on detecting NAFLD in PLWH: the prevalence in our cohort and the role of high BMI as risk factor</b> <i>Poster Presenter:</i> Caterina Candela, IT	09:00 - 09:00
<b>Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study</b> <i>Poster Presenter:</i> Antonella Castagna, IT	09:00 - 09:00
<b>Evidence generation on ageing women living with HIV in Zimbabwe. An investment case to close the gap in ending AIDS</b> <i>Poster Presenter:</i> Tendayi Westerhof, ZW	09:00 - 09:00
<b>The prevalence and prognostic of poor immunological recovery in viral suppressed elderly HIV-infected individuals</b> <i>Poster Presenter:</i> Ping Ma, CN	09:00 - 09:00
<b>Frailty and quality of life for people with HIV in Cyprus: re-visiting the cascade of care</b> <i>Poster Presenter:</i> Konstantina Stavrogianni, GR	09:00 - 09:00
<b>"Everyone seems already satisfied because people with HIV do not die from AIDS": iCOPE HIV's stakeholder survey to identify the unmet needs of ageing and older people living with HIV globally</b> <i>Poster Presenter:</i> Mario Cascio, IT	09:00 - 09:00
<b>Predictors of Quality of Life among Older People Living with HIV in Kampala, Uganda</b> <i>Poster Presenter:</i> Elizabeth Senkoro, TZ	09:00 - 09:00
<b>Neurocognitive impairment, and anxiety symptoms may influence the development of prefrailty/frailty in Japanese people living with HIV aged over 40 years</b> <i>Poster Presenter:</i> Hideta Nakamura, JP	09:00 - 09:00
<b>One-year frailty transitions among persons living with HIV aged 70 years or more on ART</b> <i>Poster Presenter:</i> Clotilde Allavena, FR	09:00 - 09:00
<b>B3. Clinical science - Sex, gender and sexuality</b>	09:00 - 09:00

<b>SEXUALLY TRANSMITTED INFECTIONS (STIs) IN OROPHARYNGEAL MUCOSA of ASYMPTOMATIC PEOPLE LIVING WITH HIV (PLHIV)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carmen Hidalgo-Tenorio, ES	
<b>Asymptomatic extragenital gonorrhea among transgender women: prevalence, bacterial resistance and clonal types involved</b>	09:00 - 09:00
<i>Poster Presenter:</i> Pedro Cahn, AR	
<b>How are trans women doing with HIV care and the UNAIDS 95-95-95 targets? A Look back at twelve years of data</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mauro Bertolini, AR	
<b>EFFECTS OF A SPECIALIZED HEALTHCARE PROGRAM FOR WOMEN WITH HIV ON THEIR RETENTION</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jessica Mejía-Castrejón, MX	
<b>HIV infection in female patients from Ukraine in Wroclaw, Poland</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mateusz Bożejko, PL	
<b>Efficacy and safety of doravirine-based regimens by sex and race: long-term results from three phase 3 clinical trials</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sharon Walmsley, CA	
<b>B4. Clinical science - Pregnancy, children and adolescents</b>	09:00 - 09:00
<b>Anthropometric characteristics of infants born to HIV-infected mothers</b>	09:00 - 09:00
<i>Poster Presenter:</i> E.N. Serhiyenka, BY	
<b>Pediatric participation in HIV cure research: a systematic review of clinical studies</b>	09:00 - 09:00
<i>Poster Presenter:</i> Yusuf Hassan Wada, NG	
<b>Efficacy of raltegravir for virological suppression at delivery in HIV positive pregnant women: a systematic review and meta-analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Huanmei Wu, CN	
<b>Before and after transition to adult care: the path of people living with perinatally acquired HIV in an upper middle-income country</b>	09:00 - 09:00
<i>Poster Presenter:</i> Julián Vega, AR	
<b>Sources of information on HIV knowledge for youth living with HIV in a refugee setting in Uganda</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mackline Hope, UG	
<b>C1. Epidemiology / public health / models of care</b>	09:00 - 09:00
<b>Comparison between patients who interrupted ART and those with late HIV diagnosis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Dagny Krankowska, PL	
<b>COCOVIIH: New data on cascade of care in France up to 2019. Fewer PLWHIV treated than expected</b>	09:00 - 09:00
<i>Poster Presenter:</i> Catherine Majerholc, FR	
<b>Implementation of telemedicine for HIV care in the public health system of Buenos Aires: A study based on surveys of physicians to assess the acceptability of this strategy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tomas Kierszenowicz, AR	
<b>HCV cascade of care in HIV/HCV coinfecting individuals: missed opportunities for micro-elimination</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giota Touloumi, GR	
<b>Reducing HIV-related maternal mortality through strengthening</b>	09:00 - 09:00



**Maternal Surveillance and Response (MPDSR) systems in Uganda***Poster Presenter:* Brenda Kharono, UG**Influence of indicator conditions on the late presenter and all-cause mortality among PLWH: a nationwide, retrospective cohort study from 2009 to 2015**

09:00 - 09:00

*Poster Presenter:* Chun-Yuan Lee, TW**Late presenters among people newly diagnosed with HIV infection during the COVID-19 pandemic**

09:00 - 09:00

*Poster Presenter:* Adriana Violeta Topan, RO**Survival of late HIV-presenters on DTG-based regimen ART in Ukraine**

09:00 - 09:00

*Poster Presenter:* Olena Marchenko, UA**Anchor drug associated with the odds of immunological recovery: a nation-wide register-based study between 2000 and 2022**

09:00 - 09:00

*Poster Presenter:* Josefin Nilsson, SE**Evolving trends in mortality patterns and predictors among people living with HIV in Catalonia and the Balearic Islands, Spain, 1998-2020: a multisite cohort study**

09:00 - 09:00

*Poster Presenter:* Sergio Moreno-Fornés, ES**Suicide mortality trends and predictors in the PISICS cohort of people living with HIV in Catalonia and the Balearic Islands, Spain**

09:00 - 09:00

*Poster Presenter:* Daniel Kwakye Nomah, ES**Trends of HIV mortality rate and its associated factors among people who inject drugs in Mizoram, Northeast India**

09:00 - 09:00

*Poster Presenter:* Lucy Ngaihbanglovi, AU**Evolution of causes of death in people living with HIV: a retrospective single-center observational study**

09:00 - 09:00

*Poster Presenter:* Giorgia Carrozzo, IT**Comparative analysis of abnormal cervical cytology among HIV positive & negative women in a Tertiary Hospital in Southern Nigeria**

09:00 - 09:00

*Poster Presenter:* Abuchi Okpara, NG**Estimation of the time of infection and missed opportunities for an early HIV diagnosis in Greece: The MORFEAS Program**

09:00 - 09:00

*Poster Presenter:* Mina Psychogiou, GR**Differential characteristics of newly diagnosed HIV cases since COVID-19 pandemic**

09:00 - 09:00

*Poster Presenter:* Tsz Ho Kwan, HK**Risk factors associated with non-condom use among people living with HIV in Brazzaville, Republic of Congo**

09:00 - 09:00

*Poster Presenter:* Martin Herbas Ekati, CG**HIV subtypes**

09:00 - 09:00

*Poster Presenter:* Claudia Afonso, PT**Analysis HIV-1 genetic diversity among MSM living in Russia in 2008-2023**

09:00 - 09:00

*Poster Presenter:* Anastasia Shlykova, RU**First regional HIV recent infection surveillance in Krasnodar region, Russia, 2021**

09:00 - 09:00

*Poster Presenter:* Anastasia Shlykova, RU**ACUTE HIV INFECTION IN GREECE: RESULTS FROM THE**

09:00 - 09:00

**"MORFEAS" PROJECT (Missed Opportunities For an Early diagnosis)***Poster Presenter:* Mina Psychogiou, GR**CQI Institutionalization to achieve optimal HIV Recency Testing Targets amidst COVID 19 resurgence: Busia HC IV Experience-Busia District**

09:00 - 09:00

*Poster Presenter:* Edward Mawejje, UG**HIV transmission dynamics networks - a molecular epidemiology study in Hong Kong between 2016 and 2022**

09:00 - 09:00

*Poster Presenter:* Tsz Ho Kwan, HK**Unveiling Patient Profiles: Insights into Functionality and Switching Perspectives of HIV Patients**

09:00 - 09:00

*Poster Presenter:* Roberto Caldera, IT**Late Diagnosis in HIV with New and Old Definitions; Data from a Regional Hospital in Turkey**

09:00 - 09:00

*Poster Presenter:* Yesim Tasova, TR**Molecular investigation of HIV-1 transmission patterns among people who inject drugs in Thessaloniki: Evidence for a recent outbreak in Greece**

09:00 - 09:00

*Poster Presenter:* Evangelia-Georgia Kostaki, GR**HIV care in Ukrainian migrants in two European countries-all the same?**

09:00 - 09:00

*Poster Presenter:* Kathrin Van Bremen, DE**Integration of HIV Recent Infection Testing Algorithm into HIV surveillance among Key Populations Across Six United States Agency for International Development (USAID) supported States in Nigeria: An Observational Study**

09:00 - 09:00

*Poster Presenter:* Ughweroghene Kingston Omo-Emmanuel, NG**Clinical characteristics, epidemiological trends and prognostic factors among people with HIV admitted to ICU due to an OI in Spain: a retrospective study**

09:00 - 09:00

*Poster Presenter:* Alberto Foncillas, ES**Pretreatment HIV-1 Resistance in Argentina: results from the second surveillance study following WHO guidelines (2019-2021)**

09:00 - 09:00

*Poster Presenter:* Sergio Martini, AR**Self-reported HIV diagnoses among trans and/or non-binary participants of the TASG study, a participatory study in Germany**

09:00 - 09:00

*Poster Presenter:* Uwe Koppe, DE**High proportion of post-migration HIV acquisition in immigrant men who have sex with men receiving HIV care in France, and association with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study**

09:00 - 09:00

*Poster Presenter:* Romain Palich, FR**Usability of a mobile health app aimed at people living with HIV to prepare for the next physician's visit**

09:00 - 09:00

*Poster Presenter:* Joanna Cano-Smith, ES**VAX-EMPOWERMENT PROJECT: IDENTIFYING PLWHA GROUP AT GREATEST RISK OF NON-ADHERENCE TO BEST ADAPT VACCINE HESITANCY INTERVENTIONS**

09:00 - 09:00

*Poster Presenter:* Giancarlo Orofino, IT**Impact of methadone substitution therapy on antiretroviral treatment efficacy. Ewa Pietraszkiewicz, Andrzej Horban, Ewa Firląg-**

09:00 - 09:00

**Burkacka, Justyna Kowalska***Poster Presenter:* Ewa Pietraszkiewicz, PL**Study on the Quality of Life of people living with HIV in Romania**

09:00 - 09:00

*Poster Presenter:* Mariana Mardarescu, RO**Clinical complexity of a cohort of PLWH based on Spanish Gesida/National Policy stratification system**

09:00 - 09:00

*Poster Presenter:* Ines Armenteros, ES**Management of metabolic syndrome by HIV physicians in the Central and Eastern Europe**

09:00 - 09:00

*Poster Presenter:* Daniela Maric, RS**Building a HIV combination prevention services checklist to assess their availability and access by key populations**

09:00 - 09:00

*Poster Presenter:* Ann Isabelle von Lingen, BE**Unleashing the power of proximity: early ART initiation in East Kazakhstan's remote regions**

09:00 - 09:00

*Poster Presenter:* Nadezhda Ryapolova, KZ**Levels of tetanus seroprotection in a cohort of Ukrainian PLWHA**

09:00 - 09:00

*Poster Presenter:* Kateryna Lytvyn, UA*Poster Presenter:* Heorhii Revenko, UA**HIV Testing in the Emergency Department: an effective strategy to increase new diagnoses**

09:00 - 09:00

*Poster Presenter:* Francesco Romano, IT**Preferences, motivations, and barriers to HIV self-testing uptake among men and women enrolled in a six-month PrEP dispensing program in Kenya**

09:00 - 09:00

*Poster Presenter:* Esther Rugendo, DE**Delay between primary care access and antiretroviral therapy initiation in the most precarious people living with HIV in Northern France: a monocentric study**

09:00 - 09:00

*Poster Presenter:* Ava Diarra, FR**HIV infection and linkage to care in migrants settling in Northern France: Data from associations providing initial health and social care services**

09:00 - 09:00

*Poster Presenter:* Ava Diarra, FR**Improving HIV Self-Test (HVST) Coverage and Case Finding among Adolescents in an OVC Preventive Program in Akwa-Ibom State**

09:00 - 09:00

*Poster Presenter:* Oluwaseyi Adeyemi, NG**HIV-positive patients with chronic total occlusion (CTO) face the dilemma of percutaneous coronary interventions**

09:00 - 09:00

*Poster Presenter:* H.S Natraj Setty, IN**Percutaneous Transvenous Mitral Commissurotomy (PTMC) in HIV positive patients with severe Mitral Stenosis (MS) - challenges and dilemmas**

09:00 - 09:00

*Poster Presenter:* H.S Natraj Setty, IN**Fostering Patient-Clinician communication to promote rapid HIV, HBV, and HCV diagnostic testing: the conceptual development of a multilingual application**

09:00 - 09:00

*Poster Presenter:* Martin Duracinsky, FR**Evaluation of the information level and attitude of people living with HIV, towards conduction of tele-health systems in healthcare,**

09:00 - 09:00

**and its relationship with their sociodemographic attributes***Poster Presenter:* Hayat Kumbasar Karaosmanoğlu, TR**Insights and experiences from the CAPELLA trial: perspectives of healthcare professionals and study coordinators on lenacapavir use amongst heavily treatment-experienced people with HIV**

09:00 - 09:00

*Poster Presenter:* Megan Dunbar, US**Treatment outcomes among children and adolescents living with HIV (CALHIV) receiving 1,3,6 months ART refills: a program data review in Eastern Uganda**

09:00 - 09:00

*Poster Presenter:* Bridget Ainembabazi, UG**ART access programme at Checkpoint BLN: High rate of late presentation among people living with HIV without health insurance in Berlin, Germany**

09:00 - 09:00

*Poster Presenter:* Christoph Weber, DE**Vaccination against COVID-19 among Healthcare Workers as a Cocoon Strategy for HIV-Positive Patients**

09:00 - 09:00

*Poster Presenter:* Agata Skrzat-Klapaczyńska, PL**The burden of CHEMSEX in Normandy, France: results of a systematic screening of drugs use in STI centers**

09:00 - 09:00

*Poster Presenter:* Guillemette Unal, FR**Benefit of a systematic health checkup for migrants at arrival: the example of Ukrainian refugees in Rouen, France**

09:00 - 09:00

*Poster Presenter:* Anaïs Lesourd, FR**Engagement of Role Model Fathers to improve male partner participation in the prevention of mother-to-child transmission of HIV in Tanzania**

09:00 - 09:00

*Poster Presenter:* Neema Makyao, TZ**A Prospective Assessment From Kenya of The HIV Enhanced Access Testing in the Emergency Department (HEATED) Program: A Pragmatic Evidence-based Approach to Increased Service Delivery Among High-Risk Groups For HIV**

09:00 - 09:00

*Poster Presenter:* Joshua Smith-Sreen, US**Temporal trends in the pattern of antiretroviral therapy prescription before and during COVID-19, Croatia, 2017-2022**

09:00 - 09:00

*Poster Presenter:* Šime Zekan, HR**Telemedicine Implementation in Buenos Aires during COVID-19 outbreak: implementation outcomes using implementation facilitation as a core strategy**

09:00 - 09:00

*Poster Presenter:* Tomas Kierszenowicz, AR**Barriers to HIV testing and possible interventions to improve healthcare among migrants, especially migrant women, in Europe**

09:00 - 09:00

*Poster Presenter:* Dagny Krankowska, PL**COCOVIIH: decrease in healthcare consumption by French PLHIV in 2019 over the last decade, comparison with other European countries**

09:00 - 09:00

*Poster Presenter:* François PrevotEAU du Clary, FR**Integrated assessment and management of non-communicable diseases (NCDs): a survey of HIV centers in the WHO European Region**

09:00 - 09:00

*Poster Presenter:* Christian Kraef, DK**Ensuring the continuity of ART during significant internal migration and disruption of the sustainable functioning of HCFs in**

09:00 - 09:00

	<b>the frontline and occupied territories of Ukraine</b>	
	<i>Poster Presenter:</i> Serhii Riabokon, UA	
	<b>What impact does ART packaging have on the daily lives of PLWH: results from the French national survey CONCERTO</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Romain Palich, FR	
	<b>ART access programme at Checkpoint BLN: High prevalence of sexually transmitted infections among people living with HIV without health insurance in Berlin, Germany</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Christoph Weber, DE	
	<b>Improving HIV testing and treatment using non-health facility HIV service: a mixed-methods study from Yogyakarta, Indonesia</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Yanri Wijayanti Subronto, ID	
	<b>Role of the Advanced Pharmacist Practitioner (APP)</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Marta Boffito, GB	
	<b>Management of Sexually Transmitted Infections in Central and Eastern Europe: Route to Improvement</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Deniz Gökengin, TR	
	<b>Impact of hiding HIV positive status on PLWH treatment with ART: results from the French national survey CONCERTO</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Romain Palich, FR	
eP.C1.077	<b>Time to ART initiation: temporal trends and challenges from a single-center cohort</b>	09:00 - 09:00
	<b>Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: a prospective study in out-patient clinics of the Parisian region.</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Agnieszka Kolakowska, FR	
	<b>Experience and barriers of counseling, testing and prevention of HIV in the practice of general practitioners in Ukraine</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Yulia Kvasnevskaya, UA	
	<b>What is the profile of patients on the same oral ART for over 10 years: results from the French national survey CONCERTO</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Romain Palich, FR	
	<b>MSM seeking care in free STI / HIV testing Checkpoints in Ukraine and Germany: comparative analysis of clinical and epidemiological characteristics</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Yaroslav Basarab, UA	
	<b>Predictors of retention in care among people living with HIV: an Egyptian cross-sectional study</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Ahmed Cordie, EG	
	<b>Access to care among asylum seekers living with HIV</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Pablo Ryan, ES	
	<b>Impact of Rapid ART initiation amongst people newly diagnosed with HIV on retention in care and time to HIV viral load suppression in a diverse London cohort</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Jozef Shaw, GB	
	<b>Screening of HPV-related anogenital cancers in women living with HIV in Europe: results from a systematic review</b>	09:00 - 09:00
	<i>Poster Presenter:</i> Dagny Krankowska, PL	
	<b>C2. Combination prevention</b>	09:00 - 09:00

<b>Co-developing a novel campaign for Amsterdam's MSM at risk of late diagnosis of HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Muhammad Sharjeel, NL	
<b>AEGIDA: An Intervention to Support Uptake of HIV Self-testing and PrEP among Women who Exchange Sex and/or Use Substances in Kazakhstan</b>	09:00 - 09:00
<i>Poster Presenter:</i> Victoria Frye, US	
<b>Improving HIV testing efficiency and New Positive identification through Sexual Index Case Testing and Tracking Recency Outcome Across Three United States for International Development (USAID) Supported States in Nigeria.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ughweroghene Kingston Omo-Emmanuel, NG	
<b>Evaluating the impact of strategic weekend approach to HIV testing, Kwara State, North Central, Nigeria experience</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ikenna Onyejiaka, NG	
<b>The Impact of Empirical quantification for implementing partners (EQUIP) tool on human resources for health for HIV case finding, Kwara State, North Central, Nigeria</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ikenna Onyejiaka, NG	
<b>Free HIV, HCV and syphilis testing in Warsaw. Who is tested at stationary checkpoints and who at social and cultural events?</b>	09:00 - 09:00
<i>Poster Presenter:</i> Agnieszka Świdorska, PL	
<b>HIV prevalence among females and males in 26 potential HIV indicator conditions in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Frederik Valbert, DE	
<b>Recent real-life data of non- occupational (NO) post-exposure prophylaxis(PEP) from 4 Greek HIV clinics and national gaps in HIV prevention</b>	09:00 - 09:00
<i>Poster Presenter:</i> Giota Lourida, GR	
<b>Blood and body fluids exposure, post-exposure prophylaxis, and HIV self-testing among healthcare workers in northern Nigeria</b>	09:00 - 09:00
<i>Poster Presenter:</i> Muktar Aliyu, US	
<b>VICTIMS OF SEXUAL VIOLENCE, POST-EXPOSURE PROPHYLAXIS: 7 YEARS EXPERIENCE AT THE CONDESA SPECIALIZED IZTAPALAPA CLINIC</b>	09:00 - 09:00
<i>Poster Presenter:</i> Teresita de J. Cabrera López, MX	
<b>Improving Oral PreP initiation and continuation using EPOA and Pre-appointment reminders among female sex workers in Busia - East Central Uganda</b>	09:00 - 09:00
<i>Poster Presenter:</i> Edward Mawejje, UG	
<b>Willingness to participate in a long-acting injectable cabotegravir pre-exposure prophylaxis study among men who have sex with men followed in the French ANRS-PREVENIR cohort</b>	09:00 - 09:00
<i>Poster Presenter:</i> Luis Sagaon-Teyssier, FR	
<b>A collaborative approach for introducing pre-exposure prophylaxis for HIV (PrEP) in the Western Balkans: case studies from North Macedonia and Bosnia and Herzegovina</b>	09:00 - 09:00
<i>Poster Presenter:</i> Pietro Leone Giovanni Vinti, DK	
<b>Reimbursed PrEP is not enough: what are the continuing barriers to PrEP accessibility in Italy? Lessons from community-led monitoring</b>	09:00 - 09:00
<i>Poster Presenter:</i> Marco Stizioli, IT	

<b>Disparities in HIV PrEP engagement and continuum of care among cisgender males, and transgender and cisgender women who engage in prostitution</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jorge Valencia, ES	
<b>Uptake of PrEP among MSM in a city without formal PrEP access: comparison of PrEP-experienced and naïve MSM in case-control analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ngai Sze Wong, HK	
<b>Drivers of discontinuation of oral PrEP within Europe: Findings from a real-world survey of PrEP use</b>	09:00 - 09:00
<i>Poster Presenter:</i> Paul O'Brien, GB	
<b>Knowledge, attitude, and willingness towards HIV Pre-Exposure Prophylaxis (PrEP) among men who have sex with men (MSM) in Yogyakarta, Indonesia</b>	09:00 - 09:00
<i>Poster Presenter:</i> Dwi Kartika Rukmi, ID	
<b>Factors influencing the willingness to use bi-monthly long-acting injectable PrEP among MSM using oral PrEP: results from a mixed-method study in Belgium</b>	09:00 - 09:00
<i>Poster Presenter:</i> Thijs Reyniers, BE	
<b>Nurse-Led PrEP with tenofovir alafenamide fumarate/emtricitabine (TAF/FTC) achieves better outcomes compared to physician-led PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) among cis-gender women in Zambia at 24 weeks: results from the NLPPrEP Trial</b>	09:00 - 09:00
<i>Poster Presenter:</i> Lloyd Mulenga, ZM	
<b>Complex PrEP: outcomes from a complex clinical PrEP referral service in the UK</b>	09:00 - 09:00
<i>Poster Presenter:</i> Rachel Gallagher, GB	
<b>Extremely limited knowledge and moderate interest in HIV pre-exposure prophylaxis among people who inject drugs in Madrid, Spain</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jorge Valencia, ES	
<b>What we know about knowledge, attitudes and use of Pre-exposure prophylaxis (PrEP) among MSM in the Russian Federation: Data from the European MSM Internet Survey</b>	09:00 - 09:00
<i>Poster Presenter:</i> Rigmor C Berg, NO	
<b>Perceived impact of digital health instruments on the uptake of HIV Pre-Exposure Prophylaxis among gay, bisexual, and other men who have sex with men in the UK. A discrete choice experiment on the use of digital health for PrEP initiation.</b>	09:00 - 09:00
<i>Poster Presenter:</i> Igor Kuchin, AT	
<b>HIV home testing in Poland - underappreciated approach despite huge potential</b>	09:00 - 09:00
<i>Poster Presenter:</i> Bartosz Szetela, PL	
<b>Early pre-exposure prophylaxis users in Belgium, their PrEP use trajectories and incidence of HIV and STI: a cohort analysis of insurance claims data from 2017 to 2019</b>	09:00 - 09:00
<i>Poster Presenter:</i> Anke Rotsaert, BE	
<b>Looking forward in Pre-Exposure Prophylaxis (PrEP): comparing preference and acceptability of novel modalities in a cohort of men who have sex with men (MSM) in a community centre in Barcelona, Spain</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jose Miguel Cabrera Guarin, ES	

<b>Prevalence and factors associated with pre-exposure prophylaxis uptake among men who have sex with men</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tsz Ho Kwan, HK	
<b>Pre-exposure prophylaxis in men who have sex with men and new HIV infections in Croatia</b>	09:00 - 09:00
<i>Poster Presenter:</i> Šime Zekan, HR	
<b>Informal PrEP for HIV prevention: The case of Greece</b>	09:00 - 09:00
<i>Poster Presenter:</i> Konstantinos Protopapas, GR	
<b>Outcomes of a PrEP service model from 56 Dean Street</b>	09:00 - 09:00
<i>Poster Presenter:</i> Victoria Tittle, GB	
<b>Pre-exposure prophylaxis for HIV in Austria: a prospective observational study</b>	09:00 - 09:00
<i>Poster Presenter:</i> David Chromy, AT	
<b>C3. Social sciences</b>	09:00 - 09:00
<b>An hospital-based integrated Healthy Life Programme among PLWH: preliminary data from a service including Infectious Disease specialist, nutritionist, personal trainer and psychologist at "D. Cotugno" hospital, Naples, Italy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Francesco Maria Fusco, IT	
<b>Favorable effect of karate on self-esteem, anxiety, anger and fatigue in people living with HIV: a pilot study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Lucia Grandiere Perez, FR	
<b>Assessment of Anti-Pneumococcal Vaccination Health Beliefs Among Patients Living With HIV and Viral Hepatitis In Constanta, Romania</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ana-Maria Schweitzer, RO	
<b>Efficacy and safety of bariatric surgery in people living with HIV: a retrospective matched cohort analysis</b>	09:00 - 09:00
<i>Poster Presenter:</i> Leena Zino, NL	
<b>Tracking of PLHIV who had a clinical missed ART due to Russia's war with Ukraine based on data from the medical information system</b>	09:00 - 09:00
<i>Poster Presenter:</i> Olha Klymova, UA	
<b>Characterization of new HIV diagnoses in the migrant population in a tertiary hospital in Portugal</b>	09:00 - 09:00
<i>Poster Presenter:</i> Maria João Miguel, PT	
<b>Migrants' (un)equal access to health: Where do national policies of European countries stand?</b>	09:00 - 09:00
<i>Poster Presenter:</i> Varsha Srivatsan, US	
<b>Patients' fears and expectations related to HIV infection and its treatment in Poland. A Positive Perspective 2 (PP2) substudy</b>	09:00 - 09:00
<i>Poster Presenter:</i> Maciej Moskwa, PL	
<b>COVID 19 effects: how young people living with HIV shunned stigma, raised awareness and sustained their income by recycling ARV bottles into artefacts. Lessons learned</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ruth Nakaboga, UG	
<b>"Buddy Polska": community driven program for peer-to-peer support of people living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Grzegorz Jezierski, PL	
<b>Analyzing the impact of COVID-19 during pandemic lockdowns on</b>	09:00 - 09:00



**women of Black African and Caribbean heritage living with HIV***Poster Presenter:* Sophie Strachan, GB**Community engagement in developing stigma reduction interventions to increase HIV testing and linkage to care/prevention for women who exchange sex and use drugs in Kazakhstan**

09:00 - 09:00

*Poster Presenter:* Meruyert Darisheva, KZ**Crowdsourcing among women who exchange sex and/or use drugs in Kazakhstan: developing community responsive interventions to address intersectional stigma in health care settings**

09:00 - 09:00

*Poster Presenter:* Meruyert Darisheva, KZ**New strategies for outreach are urgently needed to reach women who exchange sex and use drugs in the context of changing sex markets and high levels of stigma**

09:00 - 09:00

*Poster Presenter:* Meruyert Darisheva, KZ**Attitude of HIV-negative MSM towards functional cure of HIV infection**

09:00 - 09:00

*Poster Presenter:* Ngai Sze Wong, HK**Stigma in healthcare settings: a qualitative study on people with HIV in Cyprus**

09:00 - 09:00

*Poster Presenter:* Iliana Ntouriou, GR**Quality of life in young adults with perinatal hiv after transition to adult health care services in the Netherlands**

09:00 - 09:00

*Poster Presenter:* Annouschka Weijnsfeld, NL**Stigmatization towards People Living with HIV/AIDS in the Era of Test and Treat Policy in Kampala-Uganda**

09:00 - 09:00

*Poster Presenter:* Edward Mawejje, UG**How the use of Community-led Monitoring and Momentum (CLMM) tools improve service quality and support better client outcomes in OVC program in Akwa Ibom State, Nigeria**

09:00 - 09:00

*Poster Presenter:* Ifeyinwa Okereke, NG**Sexual health in a student population: knowledge and impact of COVID**

09:00 - 09:00

*Poster Presenter:* Dorsaf Slama, FR**Self-questionnaire on sexual-health collected from young people during a festival**

09:00 - 09:00

*Poster Presenter:* Dorsaf Slama, FR**Interrelations among depression and anxiety symptoms, CD4, and CD8 T-cell count in people living with HIV: a network analysis**

09:00 - 09:00

*Poster Presenter:* Lidija Popović Dragonjić, RS**Multilevel factors associated with HIV-related stigma among pregnant women living with HIV in China: an ecological model-informed study**

09:00 - 09:00

*Poster Presenter:* Yufan Xie, CN**Perceived benefits of long-acting injectable antiretroviral treatment go beyond pill-burden relief: a qualitative study (PANTER)**

09:00 - 09:00

*Poster Presenter:* Martin Duracinsky, FR**Validation of the HEALTHQUAL Questionnaire in Taiwan: A Pilot Study on Reducing HIV-Related Stigma and Discrimination in A Healthcare Settings**

09:00 - 09:00

*Poster Presenter:* Han Siong Toh, TW

<b>Routine Assessment of Life Satisfaction Patient Reported Outcomes (PROs) among People Living with HIV/AIDS (PLWHA) Indicate Maintenance of Overall Care Results at the Baylor Clinical Center of Excellence in Constanta, Romania over Four Years</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ana-Maria Schweitzer, RO	
<b>HIV in Italian hospitals between knowledge and stigma</b>	09:00 - 09:00
<i>Poster Presenter:</i> Antonella d'Arminio Monforte, IT	
<b>Patterns of Substance Use and their Consequences on Well-being among STI Clinic Patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> Matilde Sánchez-Conde, ES	
<b>Substance use among women engaged in sex work in Kazakhstan: typologies and implications for HIV risk</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tara McCrimmon, US	
<b>Non-neuropsychiatric complications of intravenous mephedrone in Chemsex users. Are we going back to the 80s?</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jesús Santos, ES	
<b>Substance use and multiple sexual risks in young adults: beyond the clinical concept of sexual risk assessment</b>	09:00 - 09:00
<i>Poster Presenter:</i> Jiwon Jeong, FR	
<b>Why the IDUs' treatment is not working, assessing the relapse ratio</b>	09:00 - 09:00
<i>Poster Presenter:</i> Hameed ul Mehdi, PK	
<b>Initiatives to improve life span &amp; QOL in PLWHIV: Asian perspectives</b>	09:00 - 09:00
<i>Poster Presenter:</i> S. Pal, IN	
<b>Barriers access healthcare service among the hill tribe and stateless HIV/AIDS living in northern Thailand: a qualitative method</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tawatchai Apidechkul, TH	
<b>Perception of preventing gonorrhoea by vaccination among men who have sex with men: a mixed-methods study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Tsz Ho Kwan, HK	
<b>PrEP knowledge among trans and/or non-binary participants of the TASG study, a participatory study in Germany</b>	09:00 - 09:00
<i>Poster Presenter:</i> Uwe Koppe, DE	
<b>D1. HIV and other health emergencies</b>	09:00 - 09:00
<b>UK Media responses to HIV through the lens of COVID-19: a study of multidirectional memory</b>	09:00 - 09:00
<i>Poster Presenter:</i> Frances Pheasant-Kelly, GB	
<b>Creation and Validation of an imported Malaria Predictive Model including People Living with HIV/AIDS (PLWHA)</b>	09:00 - 09:00
<i>Poster Presenter:</i> Noemí Cabello-Clotet, ES	
<b>Linking and retaining HIV patients in care in Neuquén city, Patagonia, Argentina. A 4 Years' experience program</b>	09:00 - 09:00
<i>Poster Presenter:</i> Liliana Calanni, AR	
<b>HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in Central and Eastern Europe</b>	09:00 - 09:00
<i>Poster Presenter:</i> Cristiana Oprea, RO	
<b>Experience with Monkeypox (Mpox) in Belgrade, Serbia, between may and october 2022: a single center study</b>	09:00 - 09:00
<i>Poster Presenter:</i> Ivana Gmizic, RS	

<b>Acceptability of receiving a relatively low efficacy vaccine for gonorrhoea prevention among men who have sex with men</b> <i>Poster Presenter:</i> Tsz Ho Kwan, HK	09:00 - 09:00
<b>Effect on the HIV diagnosis rates of Integration of AIDS defining and indicator conditions into the hospital information system: HIV-IC study</b> <i>Poster Presenter:</i> Cigdem Hatipoglu, TR	09:00 - 09:00
<b>Mpox vaccination coverage across two high-risk cohorts: PLWHIV and PrEP-HIV users</b> <i>Poster Presenter:</i> Alberto Díaz-de Santiago, ES	09:00 - 09:00
<b>Sexual behavior of men who have sex with men who use PrEP in times of mpox threat</b> <i>Poster Presenter:</i> Zohar Mor, IL	09:00 - 09:00
<b>MPOX OUTBREAK AMONG PEOPLE LIVING WITH AND WITHOUT HIV IN ARGENTINA: THE VIHPOX STUDY</b> <i>Poster Presenter:</i> Romina Mauas, AR	09:00 - 09:00
<b>Risk perception and mpox vaccine acceptability among people living with HIV in northern Nigeria</b> <i>Poster Presenter:</i> Muktar Aliyu, US	09:00 - 09:00
<b>Supporting the mission of caring for patients during military conflicts: lessons from Ukraine</b> <i>Poster Presenter:</i> Vivian Avelino-Silva, US	09:00 - 09:00
<b>High mental resilience of displaced Ukrainian PLWH currently living in Hamburg, Germany</b> <i>Poster Presenter:</i> Anna Koval, UA	09:00 - 09:00
<b>AHF hotline in support of HIV care continuum for people living with HIV, including displaced populations in war-stricken Ukraine</b> <i>Poster Presenter:</i> Yaroslava Lopatina, UA	09:00 - 09:00
<b>The needs of people living with HIV displaced by war in Ukraine to Dublin</b> <i>Poster Presenter:</i> Annmarie White, IE	09:00 - 09:00
<b>Characteristics and recency of infection among people living with HIV from Ukraine migrating to Germany in 2022</b> <i>Poster Presenter:</i> Uwe Koppe, DE	09:00 - 09:00
<b>Clinical Cases</b>	09:00 - 09:00
<b>Histories, Heroína &amp; HIV. A case study of bio-psycho-social determinants and relationships of an Indigenous-Canadian woman living with HIV and her Polish &amp; Canadian clinical team from pasts to present</b> <i>Poster Presenter:</i> Piotr Klakowicz-Rodriguez-Szmaj, CA	09:00 - 09:00
<b>Challenges of treatment retention in times of social isolation leading to a catastrophic outcome</b> <i>Poster Presenter:</i> Marie-Angélique De Scheerder, BE	09:00 - 09:00
<b>A case report of HIV positive patient with two different malignancies (Nodular Lymphocyte predominant Hodgkin's Lymphoma and Adenocarcinoma)</b> <i>Poster Presenter:</i> Priyanka Khopkar-Kale, IN	09:00 - 09:00
<b>Symptomatic relapse of cryptococcal meningitis in a Late Presenter of HIV infection</b> <i>Poster Presenter:</i> Vasilis Petrakis, GR	09:00 - 09:00

<b>Unusual presentation of <i>Pneumocystis jirovecii</i> pneumonia: a case report</b>	09:00 - 09:00
<i>Poster Presenter:</i> Adelaide Maddaloni, IT	
<b>Neurosyphilis with multiple cranial neuropathy revealing HIV infection</b>	09:00 - 09:00
<i>Poster Presenter:</i> Magda Gonçalves, PT	
<b>Three cases of chronic hepatitis E infection (one HEV-A &amp; two HEV-C) among PLHIV in Hong Kong</b>	09:00 - 09:00
<i>Poster Presenter:</i> Chun Kwan Bonnie Wong, HK	
<b>Genital ulceration resistant to various treatments</b>	09:00 - 09:00
<i>Poster Presenter:</i> Martin Hartmann, DE	
<b>Limited therapeutic options in antiretroviral treatment in a male patient living with HIV during a 15-year follow-up</b>	09:00 - 09:00
<i>Poster Presenter:</i> Carlo Bieńkowski, PL	
<b>Integrase inhibitor as cause of drug induced liver injury</b>	09:00 - 09:00
<i>Poster Presenter:</i> Sanjay Bhagani, GB	
<b>Prolonged viral shedding of SARS-Cov-2 in a HIV-1 positive patient. A case report</b>	09:00 - 09:00
<i>Poster Presenter:</i> Clara de Angelis, DE	
<b>Young man with gastrointestinal bleeding: when things are not what they appear to be</b>	09:00 - 09:00
<i>Poster Presenter:</i> Samuel Estévez Alonso, ES	
<b>A rare case of <i>Rhodococcus equi</i> infection in a patient living with HIV</b>	09:00 - 09:00
<i>Poster Presenter:</i> Fehmi Tabak, TR	
<b>Rare skin condition in HIV positive patient</b>	09:00 - 09:00
<i>Poster Presenter:</i> Mikhail Savchenko, RU	
<b>Primary HIV Infection in an Adherent Pre-exposure Prophylaxis User with Limited Risk Factors</b>	09:00 - 09:00
<i>Poster Presenter:</i> Silvia Nozza, IT	
<b>Atypical cases of dermatophytosis as presenting sign of HIV infection, in Malagasy patients</b>	09:00 - 09:00
<i>Poster Presenter:</i> Fandresena Arilala Sendrasoa, MG	
<b>Co-infection with <i>Cryptosporidium meleagridis</i> and <i>Enterocytozoon bieneusi</i> in an HIV+ Colombian patient</b>	09:00 - 09:00
<i>Poster Presenter:</i> Larry Lubert Martínez Rosado, CO	
<b>Cluster headache-like symptoms after tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) containing regimens initiation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Alberto Foncillas López, ES	
<b>Interleukin-1 inhibitor and <i>Toxoplasma spp</i> reactivation</b>	09:00 - 09:00
<i>Poster Presenter:</i> Stefano Musumeci, CH	
<b>Complex diagnosis in elderly: A case report of HIV and Paroxysmal Nocturnal Hemoglobinuria</b>	09:00 - 09:00
<i>Poster Presenter:</i> José Luis Parra Herrera, MX	
<b>Extensively Drug-resistant (XDR) <i>Shigella flexneri</i> bacteremia in a patient with severe Mpox and advanced HIV disease</b>	09:00 - 09:00
<i>Poster Presenter:</i> Héctor O. Rivera-Villegas, MX	
<b>Successful Management of a Patient with AIDS-related diffuse large B-cell lymphoma by Zanubrutinib and</b>	09:00 - 09:00

**Dolutegravir/Lamivudine***Poster Presenter:* Haiyan Min, CN**Jaundice and HIV: A patient with HIV-related cholangiopathy and a bilirubin metabolism genetic variation developing a rare paraneoplastic Vanishing Bile Duct Syndrome related to Hodgkin lymphoma**

09:00 - 09:00

*Poster Presenter:* Rita Patrocínio Jesus, PT**Unveiling the Uncommon: A Case Report of JCV Granule Cell Neuropathy**

09:00 - 09:00

*Poster Presenter:* Myrto Astriti, GR**Kaposi`s sarcoma and primary effusion lymphoma as first diagnoses in hidden HIV infection**

09:00 - 09:00

*Poster Presenter:* Alberto Díaz-de Santiago, ES**Pyoverdine syndrome due to Leishmania spp and Aspergillus fumigatus in a patient with HIV/AIDS infection**

09:00 - 09:00

*Poster Presenter:* Lily Soto, VE**Case of immunomodulatory therapy in advanced HIV-infection with disseminated non-tuberculosis mycobacteria**

09:00 - 09:00

*Poster Presenter:* Jan Vesterbacka, SE**Aortitis in early syphilis**

09:00 - 09:00

*Poster Presenter:* Tania Mudrikova, NL**Bilateral Syphilitic Optic Neuritis in a patient with Human Immunodeficiency Virus Infection**

09:00 - 09:00

*Poster Presenter:* Ligia Rodina, RO**Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV**

09:00 - 09:00

*Poster Presenter:* Lykke Larsen, DK**Fast track rechallenge after skin rash in a HIV-1 heavily treatment experienced patient with no alternative therapeutic options left**

09:00 - 09:00

*Poster Presenter:* Stefano Musumeci, CH**Sustained Mpox proctitis with primary syphilis and HIV seroconversion**

09:00 - 09:00

*Poster Presenter:* Rachel Burdon, AU**Gluteal subcutaneous cold abscesses complicating long acting injectable antiretroviral treatment with cabotegravir and rilpivirine: a case report**

09:00 - 09:00

*Poster Presenter:* Layla Pagnucco, IT**Syphilitic gumma as cause of cerebral and hepatic lesions, a case series**

09:00 - 09:00

*Poster Presenter:* Alexander Killer, DE**Unusual intersection: Adult-onset Langerhans Cell Histiocytosis and HIV Infection**

09:00 - 09:00

*Poster Presenter:* Myrto Astriti, GR**"Thrombotic Vasculopathy in an HIV-Positive Individual: A Detailed Diagnostic Odyssey and Resolution"**

09:00 - 09:00

*Poster Presenter:* Alexy Inciarte Portillo, ES**Unusual presentation of disseminated visceral leishmaniasis with lung and cutaneous involvement**

09:00 - 09:00

*Poster Presenter:* Lia Monsalve, CH**Mpox in advanced HIV: one of the few death cases**

09:00 - 09:00

Poster Presenter: Dan Veselý, CZ

**Painful proctitis secondary due to co-infection with mpox, syphilis, herpes simplex virus, lymphogranuloma venereum, *Neisseria gonorrhoeae*, and *Mycoplasma genitalium* in a person living with HIV vaccinated against mpox** 09:00 - 09:00

Poster Presenter: Rachel Burdon, AU

**Disseminated histoplasmosis and *Pneumocystis jirovecii* Pneumonia (PJP)-associated immune reconstitution inflammatory syndrome (IRIS) four weeks after ART initiation** 09:00 - 09:00

Poster Presenter: Alberto Díaz-de Santiago, ES

**Severe form of Mpox virus infection in a patient with AIDS and multiple opportunistic infections** 09:00 - 09:00

Poster Presenter: David Mangaloiu, RO

**Early treatment failure of Lenacapavir in a HIV-2 positive patient** 09:00 - 09:00

Poster Presenter: Olaf Degen, DE

**A case of co- infection of visceral leishmaniasis and HIV infection with multiple relapses: role of combination therapy to end the relapses** 09:00 - 09:00

Poster Presenter: Edjola Lulja, AL

**Early virological failure with Cabotegravir plus Rilpivirine in clinical practice** 09:00 - 09:00

Poster Presenter: Sofia Sábato, ES

**Limbic Encephalitis Following COVID-19 Vaccination in an HIV-Positive Patient** 09:00 - 09:00

Poster Presenter: Alexy Inciarte, ES

**Extensive virologic characterization in an HIV-infected individual with apparent HIV remission for 2 years after allogeneic stem cell transplantation with CCR5 wild-type cells: a case study** 09:00 - 09:00

Poster Presenter: Ilaria Vicenti, IT

**How to choose the optimized background therapy with fostemsavir in viremic people with multidrug-resistant HIV? A clinical case** 09:00 - 09:00

Poster Presenter: Tommaso Clemente, IT

**The case of occult HBV infection in HIV infected patient from Eastern European country of Georgia** 09:00 - 09:00

Poster Presenter: Shorena DVALI, GE

Plenary lecture

09:30 - 10:00

POLONEZ

**Ageing and cardio-pulmonary co-morbidities. The intersection of age, gender, and social determinants of health**

Chair: Juan Berenguer, ES

**Ageing and cardio-pulmonary co-morbidities. The intersection of age, gender, and social determinants of health** 09:30 - 10:00

Speaker: Susanne Dam Nielsen, DK

**European Hector Research Award in HIV 2023 ceremony - Best basic science, translational paper** 10:00 - 10:05

Speaker: Georg Behrens, DE

ePosters

10:00 - 10:45

ePoster

ePosters exchange

## Parallel session

10:45 - 11:45

POLONEZ

**PS8 - Long acting Antiretroviral therapies: Present and future**

Chair: Catia Marzolini, CH

Chair: Nicky Mackie, GB

<b>Implementation challenges and long-term efficacy</b>	10:45 - 10:55
<i>Speaker:</i> Christoph Spinner, DE	
<b>Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: results from the Dutch ATHENA national observational cohort</b>	10:55 - 11:00
<i>Abstract Presenter:</i> Vita Jongen, NL	
<b>Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: preliminary analysis on cabotegravir plus rilpivirine</b>	11:00 - 11:05
<i>Abstract Presenter:</i> Jessy Jomary Duran Ramirez, CH	
<b>Failure following switch from long-term suppressive oral ART to long-acting cabotegravir/rilpivirine injections</b>	11:05 - 11:10
<i>Abstract Presenter:</i> Annemarie Wensing, NL	
<b>Resistance analysis of long-acting lenacapavir in heavily treatment-experienced people with HIV after 104 weeks of treatment</b>	11:10 - 11:15
<i>Abstract Presenter:</i> Nicolas Margot, US	
<b>Safety and Tolerability of VH3810109 (N6LS) Among Antiretroviral Therapy-Naive Adults Living With HIV-1: Results From the Monotherapy Phase of the Phase IIa BANNER Study</b>	11:15 - 11:20
<i>Abstract Presenter:</i> Peter Leone, US	
<b>Q&amp;A / Panel discussion</b>	11:20 - 11:45

## Parallel session

10:45 - 11:45

MAZUREK

**PS9 - Meet the (s)experts - sexual wellbeing, identity, and stigma (roundtable)**

Chair: Gus Cairns, GB

Chair: Umbelina Caixas, PT

<b>Community Introduction: What is sexual wellbeing?</b>	10:45 - 10:50
<i>Speaker:</i> Iza Jąderek, PL	
<b>Sexual safety - how does it work in practice for sex workers in Europe?</b>	10:50 - 11:00
<i>Speaker:</i> Harriet Langanke, DE	
<b>Stigma related to HIV and sexual orientation - why we should care (more)</b>	11:00 - 11:10
<i>Speaker:</i> Rigmor C Berg, NO	
<b>Heterosexual identifying MSM - who are they, what do they do, and what are their health needs?</b>	11:10 - 11:20
<i>Speaker:</i> Tyrone Curtis, GB	
<b>Why is addressing stigma and sexual wellbeing essential to ending HIV by 2030 ? [focus on European region]</b>	11:20 - 11:30
<i>Speaker:</i> Kai J Jonas, NL	
<b>Q&amp;A / Discussion</b>	11:30 - 11:45

## Parallel session

10:45 - 11:45

ETIUDA

**PS10 - HIV cure intervention - New approaches**

Chair: Simon Collins, GB

Chair: Michaela Müller-Trutwin, FR

**Update on treatment interruption trials**

10:45 - 10:55

Speaker: Sarah Fidler, GB

**Novel approaches in the pipeline toward HIV cure**

10:55 - 11:05

Speaker: Asier Sáez-Cirión, FR

**Gut barrier damage and reservoirs, yet not peripheral inflammation, are contained in PHI-treated PLWH**

11:05 - 11:10

Abstract Presenter: Valeria Bono, IT

**Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers of rhesus macaques.**

11:10 - 11:15

Abstract Presenter: Karsten Eichholz, US

**Safety, Pharmacokinetics, and Exploratory Efficacy of the PD-1 Inhibitor Budigalimab in Antiretroviral Treatment-suppressed People Living With HIV-1: Preliminary Analysis of 2 Phase 1b Studies Including an Analytical Treatment Interruption**

11:15 - 11:20

Abstract Presenter: Jean-Pierre Routy, CA

**Q&A / Discussion**

11:20 - 11:45

## Oral presentations

10:45 - 11:45

SONATA

**Oral abstract session: HIV, ART and co-morbidities**

Chair: Daria Podlekareva, DK

Chair: Karine Lacombe, FR

**Lymph node dendritic cells harbor inducible replication competent HIV despite years of suppressive ART**

10:45 - 10:57

Abstract Presenter: Riddhima Banga, CH

**Evolution of patterns and cost of antiretroviral strategies over 8 years among people living with HIV (PHIV): experience of Pitié-Salpêtrière HIV clinical center in France**

10:57 - 11:09

Abstract Presenter: Luis Sagaon-Teyssier, FR

**Cardiovascular risk assessment after continuing or switching to a doravirine-based regimen using the atherosclerotic cardiovascular disease (ASCVD) risk score model**

11:09 - 11:21

Abstract Presenter: Georg Behrens, DE

**Evolution of cancers risk in PWH over 20 years and risks when immunity is restored and viral load is controlled. Results from the ANRS CO4 FHDH cohort**

11:21 - 11:33

Abstract Presenter: Sophie Grabar, FR

**Modifiable risk factors and their population attributable fractions for TB in people with HIV across Europe**

11:33 - 11:45

Abstract Presenter: Christian Kraef, DK

## ePosters

11:45 - 14:15

ePoster

**ePosters exchange**



*Industry sponsored session*

12:15 - 13:45

POLONEZ

**Industry sponsored session***Oral presentations*

12:15 - 13:15

MAZUREK

**Rapid Abstract Presentations: From basics to clinics***Chair:* Silvia Nozza, IT*Chair:* Josip Begovac, HR**Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure**

12:15 - 12:22

*Abstract Presenter:* Mariangela Cavarelli, FR**Non-T cell tissue niches for HIV reservoirs in human macrophages in vivo mediated by S100A8 metabolic adaptation**

12:22 - 12:29

*Abstract Presenter:* Morgane Bomsel, FR**Bictegravir alters glucose tolerance and metabolism**

12:29 - 12:36

*Abstract Presenter:* Laura Gisbert Ferrándiz, ES**Early and Durable Reductions in Soluble CD14 Concentrations Among Treatment-Experienced Persons With HIV-1 Through 96 Weeks of Fostemsavir Treatment in a Phase 2b Clinical Trial**

12:36 - 12:43

*Abstract Presenter:* Andrew Clark, GB**Risk of virological failure after drug burden reduction in non-viremic people with 4-class drug-resistant HIV: data from the PRESTIGIO Registry**

12:43 - 12:50

*Abstract Presenter:* Tommaso Clemente, IT**Prevalence and incidence of hepatitis D virus infection in HIV-HBV coinfecting patients in the French nationwide Dat'AIDS cohort**

12:50 - 12:57

*Abstract Presenter:* Dulce Alfaiate, FR**Assessing the landscape and implementation of HIV-relevant policies on uptake of treatment and care among key populations in the WHO European Region**

12:57 - 13:04

*Abstract Presenter:* Patrick J. Campbell, US**Identifying the unknown: application of molecular epidemiology tool to characterise clustering and HIV transmission routes in Poland**

13:04 - 13:11

*Abstract Presenter:* Marcin Horecki, PL*Oral presentations*

12:15 - 13:15

ETIUDA

**Rapid Abstract Presentations: Evolving ART***Chair:* Agnès Libois, BE*Chair:* Georg Behrens, DE**Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + 2 NRTIs in Treatment-Naive Adults: 24-Week Results From the Phase IIb, Dose-Range Finding DOMINO Study**

12:15 - 12:22

*Abstract Presenter:* Samit R. Joshi, US**Efficacy and Safety of the HIV-1 Maturation Inhibitor GSK3640254 + Dolutegravir as a 2-Drug Regimen in Treatment-Naive Adults: 24-Week Results From the Phase IIb DYNAMIC Study**

12:22 - 12:29

*Abstract Presenter:* Samit R. Joshi, US**Real-world retrospective observational study on the use of Doravirine (DOR) based regimens in clinical practice in Europe**

12:29 - 12:36

*Abstract Presenter:* Laura Levi, FR

<b>Doravirine plus dolutegravir two-drug regimen as a maintenance ART: results from a French cohort study</b>	12:36 - 12:43
<i>Abstract Presenter:</i> Olivier Robineau, FR	
<b>Penetration of doravirine combined to raltegravir in semen: preliminary results of the DORAL switch study</b>	12:43 - 12:50
<i>Abstract Presenter:</i> Romain Palich, FR	
<b>Dual therapy with DTG+3TC or DTG+RPV vs. triple therapy with B/F/TAF in virologically suppressed adults living with HIV-1: immunological outcomes in real-life experience</b>	12:50 - 12:57
<i>Abstract Presenter:</i> Mariano Matarranz, ES	
<b>HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG</b>	12:57 - 13:04
<i>Abstract Presenter:</i> Vincenzo Malagnino, IT	
<b>Rates and reasons for antiretroviral switches with implicated drug associations: a post-COVID 10-year comparison</b>	13:04 - 13:11
<i>Abstract Presenter:</i> Nicklas Brown, GB	

*Oral presentations*

12:15 - 13:15

SONATA

**Rapid Abstract Presentations: Continuum of care***Chair:* María Jesús Pérez Elías, ES*Chair:* Agata Skrzat-Klapaczyńska, PL

<b>Psychosocial and sexual health in men with and without HIV, who have sex with men, in Denmark: a cross-sectional nationwide study</b>	12:15 - 12:22
<i>Abstract Presenter:</i> Ditte Scofield, DK	
<b>Comparative Analysis of Sexually Transmitted Infections among People Living with HIV and Pre-exposure Prophylaxis Users</b>	12:22 - 12:29
<i>Abstract Presenter:</i> Jose I Bernardino, ES	
<b>Decreasing trend in standardised mortality rate among HIV positive individuals in Poland</b>	12:29 - 12:36
<i>Abstract Presenter:</i> Magdalena Rosińska, PL	
<b>The Effect of U=U Awareness on Relationship Status, HIV Status Disclosure and Mental Health in People Living with HIV: A Preliminary Study</b>	12:36 - 12:43
<i>Abstract Presenter:</i> Ceren Atasoy Tahtasakal, TR	
<b>Unmet sexual and reproductive health needs in women living with HIV: results from the Marilyn study</b>	12:43 - 12:50
<i>Abstract Presenter:</i> Maria Luisa Cosmaro, IT	
<b>Disruptions in testing and treatment services for hepatitis C virus during the SARS-CoV-2 epidemic among individuals with HIV susceptible for HCV reinfection: results from the EuroSIDA study</b>	12:50 - 12:57
<i>Abstract Presenter:</i> Anders Boyd, NL	
<b>Manifestations of stigma suffered by people living with HIV in Spain</b>	12:57 - 13:04
<i>Abstract Presenter:</i> Carlos Prats-Silvestre, ES	
<b>Continuum of HIV care by key populations in Belgium: cross-sectional and longitudinal views</b>	13:04 - 13:11
<i>Abstract Presenter:</i> Rémy Demester, BE	

## Parallel session

14:15 - 15:15

POLONEZ

**PS11 - STI/HIV syndemics in Europe: Combination prevention barriers, new implementation and treatment strategies**

Chair: Maximilian C. Aichelburg, AT

Chair: David Jilich, CZ

**State of the art: STI epidemiology, treatment in the European setting**

14:15 - 14:25

Speaker: Anna Maria Geretti, GB

**Clinical manifestations of Monkeypox (mpox) and impact of vaccination in people with and without HIV in Catalonia: a population-wide study**

14:25 - 14:30

Abstract Presenter: Raquel Martin-Iguacel, DK

**Factors associated with uptake of cervical cancer screening among women in the Swiss HIV Cohort Study**

14:30 - 14:35

Abstract Presenter: Mailin Waldecker, CH

**Efficacy and safety of topical trichloroacetic acid vs. electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive patients (TECAIN) - a randomized controlled trial**

14:35 - 14:40

Abstract Presenter: Stefan Esser, DE

**Panel discussion**

14:40 - 15:15

## Parallel session

14:15 - 15:15

MAZUREK

**PS12 - How to implement new integrated testing strategy (including home based testing and POC)? - lessons learned**

Chair: Dorthe Raben, DK

Chair: Laura Fernández López, ES

**Challenges and successes**

14:15 - 14:25

Speaker: Daniel Simões, PT

**Are projects between NGO and HIV centres the solution?**

14:25 - 14:35

Speaker: Bartosz Szetela, PL

**Opt out Blood Borne Virus (BBV) testing in 33 Emergency Departments (EDs) in areas of high and extremely high HIV prevalence in England**

14:35 - 14:40

Abstract Presenter: Ann Sullivan, GB

**Implementing HIV teams sustainably improves HIV testing rates in patients with HIV indicator conditions: a multicenter study**

14:40 - 14:45

Abstract Presenter: Carlijn C.E. Jordans, NL

**Designing a Sex-Positive "Do-It-Yourself" Intervention Condition to Promote Sexual Pleasure and Health for Gay/Bisexual/Same-gender Loving, Black/African-American Men in New York City**

14:45 - 14:50

Abstract Presenter: Victoria Frye, US

**Discussion**

14:50 - 15:15

## Parallel session

14:15 - 15:15

ETIUDA

**PS13 - Providing HIV prevention and care to migrant populations - successes and challenges**

Chair: Panagioti Lourida, GR

Chair: Tetiana Koval, UA

**Access of migrating people to healthcare**

14:15 - 14:25

Speaker: Melvina Woode-Owusu, GB

<b>Perspectives of HIV/HBV/HCV cascade of care among migrants and refugees</b>	14:25 - 14:35
<i>Speaker:</i> Pavel Khaykin, DE	
<b>Psychological distress in HIV-Infected Undocumented Migrants recently arrived to Spain: a higher vulnerability of people with HIV-related stigma and early adverse events</b>	14:35 - 14:40
<i>Abstract Presenter:</i> Alicia González-Baeza, ES	
<b>Designing a community-based, migrant-sensitive HIV testing programme for migrants in precarious circumstances in Europe</b>	14:40 - 14:45
<i>Abstract Presenter:</i> Anne Flaherty-Gupta, GB	
<b>UNAIDS 90-90-90 target and retention in care of a cohort of migrants living with HIV in a tertiary referral hospital in Florence, Italy</b>	14:45 - 14:50
<i>Abstract Presenter:</i> Giuseppe Gasparro, IT	
<b>Clinical characteristics and antiretroviral treatment efficacy among newly diagnosed migrants and refugees from Ukraine</b>	14:50 - 14:55
<i>Abstract Presenter:</i> Milosz Parczewski, PL	
<b>Q&amp;A / Discussion</b>	14:55 - 15:15
<i>Parallel session</i> 14:15 - 15:15	SONATA
<b>PS14 - Integrating approaches to older people living with HIV</b>	
<i>Chair:</i> Giovanni Guaraldi, IT <i>Chair:</i> Monika Bociąga-Jasik, PL	
<b>Community Speak</b>	14:15 - 14:20
<i>Speaker:</i> Grzegorz Jezierski, PL	
<b>What are we learning from cohorts of older people living with HIV?</b>	14:20 - 14:30
<i>Speaker:</i> Paddy Mallon, IE	
<b>Challenges in the clinical management of older people living with HIV</b>	14:30 - 14:40
<i>Speaker:</i> Fátima Brañas, ES	
<b>HIV in the elderly is becoming an easily manageable pathology: reality is contradictory</b>	14:40 - 14:45
<i>Abstract Presenter:</i> Frederico Duarte, PT	
<b>Cognitive frailty in people living with HIV and its association with geriatric syndromes</b>	14:45 - 14:50
<i>Abstract Presenter:</i> Jovana Milic, IT	
<b>Implementation of frailty screening in older people living with HIV in Brighton, UK</b>	14:50 - 14:55
<i>Abstract Presenter:</i> Jaime Vera, GB	
<b>Supporting practitioners to identify, assess and manage frailty in people living with HIV: introducing a practical, co-created guide</b>	14:55 - 15:00
<i>Abstract Presenter:</i> Tristan Barber, GB	
<b>Q&amp;A / Discussion</b>	15:00 - 15:15
<i>ePosters</i> 15:15 - 16:00	ePoster
<b>ePosters exchange</b>	

*Special session*

16:00 - 17:00

POLONEZ

**EACS Special session: EACS goes East- Vulnerable populations and vulnerable topics in Central and Eastern Europe***Chair:* Maka Gogia, GE*Chair:* Mike Youle, GB*Chair:* Magdalena Ankiersztejn-Bartczak, PL**Why do we need harm reduction in Central and Eastern Europe**

16:00 - 16:15

*Speaker:* Maka Gogia, GE**Barriers to HCV treatment in Polish prisons**

16:15 - 16:30

*Speaker:* Jerzy Jaroszewicz, PL**HIV and hepatitis harm reduction and treatment in prisons in Moldova**

16:30 - 16:45

*Speaker:* Serghei Craveti, MD**Gender sensitivities in harm reduction services**

16:45 - 16:55

*Speaker:* Aisuluu Bolotbaevaa, KG**Q&A and discussion**

16:55 - 17:00

*Meet-the-expert*

16:00 - 17:00

MAZUREK

**MTE7 - Management of low level viraemia***Moderator:* Annemarie Wensing, NL**Management of low level viraemia**

16:00 - 16:10

*Speaker:* Anna Maria Geretti, GB**PERSISTENT LOW-LEVEL VIREMIA LEADS TO IMMUNE T-CELL EXHAUSTION IN PEOPLE LIVING WITH HIV**

16:10 - 16:20

*Abstract Presenter:* Violeta Lara-Aguilar, ES**Panel discussion**

16:20 - 17:00

*Meet-the-expert*

16:00 - 17:00

ETIUDA

**MTE8 - Gender Identity - Exemplars of best practice, and how to deliver integrated care across the EACS region (roundtable)***Moderator:* Erika Castellanos, NL**The clinical, sexual health and healthcare system needs of trans people at risk of HIV and STIs**

16:00 - 16:10

*Speaker:* Paulie Amanita Calderón-Cifuentes, DK**The trans community in EECA: Sexual health, sex work and stigma**

16:10 - 16:20

*Speaker:* Beka Gabadadze, GE**Research on the inclusivity of clinical trials for trans people, as a follow up of the manifesto 'No Data no more'**

16:20 - 16:30

*Speaker:* Cindra Feuer, FR**Transgender people living with HIV integral assessment**

16:30 - 16:40

*Speaker:* Martin Viehweger, DE**Roundtable discussion**

16:40 - 17:00

*Special session*

16:00 - 17:00

SONATA

**Special session convened by ESCMID - Beyond STIs: Bacterial infections in specific populations with HIV**

<b>The captain of the men of death: invasive pneumococcal diseases across the span of life</b> <i>Speaker:</i> Silvio Brugger, CH	16:00 - 16:20
<b>Antibiotic resistance crisis: impact on people with HIV</b> <i>Speaker:</i> Ioana-Diana Olaru, GB	16:20 - 16:40
<b>Pathogen spectrum of community-acquired pneumonia (CAP) in people living with HIV (PLWH) - consequences for empiric therapy</b> <i>Speaker:</i> Benjamin T. Schleenvoigt, DE	16:40 - 17:00

*Industry sponsored session*  
17:30 - 18:30

POLONEZ

**Industry sponsored session**

**Saturday, 21. October 2023***Meet-the-expert*

08:00 - 09:00

POLONEZ

**MTE9 - Emerging infections in people living with HIV***Moderator:* Sanjay Bhagani, GB*Moderator:* Cristiana Oprea, RO

**Challenges in the clinical management of a HIV/HCV-coinfected Ukrainian refugee with complicated course of MDR-tuberculosis during the first months of the humanitarian crisis following the Russian attack: a case study in a tertiary referral centre in Germany**

08:00 - 08:10

*Case Presenter:* Stefan Schlabe, DE

**Pulmonary Cryptococcosis Presenting as Pleural Effusion in an Untreated HIV Patient with Amphetamine Abuse: A Rare Clinical Presentation**

08:10 - 08:20

*Case Presenter:* Alexy Inciarte Portillo, ES

**Malignant Syphilis mimicking lymphoma in HIV patient: a diagnostic challenge**

08:20 - 08:30

*Case Presenter:* Chiara Maci, IT**Panel discussion / Q&A**

08:30 - 09:00

*Parallel session*

09:15 - 10:15

POLONEZ

**PS15 - On the way towards elimination of vertical HIV transmission***Chair:* Igor Codreanu, MD*Chair:* Justyna Kowalska, PL

**The last mile costs the most - National MTCTP program in the Republic of Moldova. Lessons learned**

09:15 - 09:30

*Speaker:* Maia Ribacova, MD

**The fulfilment of PMTCT measures in the context of a full-scale Russian invasion**

09:30 - 09:45

*Speaker:* Diana Shevchenko, UA

**Best practices and common bottlenecks of eMTCT in countries of Eastern Europe and Central Asia region**

09:45 - 10:00

*Speaker:* Justyna Kowalska, PL**Panel discussion and Q&A**

10:00 - 10:15

*Special session*

10:30 - 11:25

POLONEZ

**ECDC/EACS Standard of Care Workshop (Part 1)***Chair:* Cristiana Oprea, RO*Chair:* Ann Sullivan, GB**Welcome**

10:30 - 10:35

*Speaker:* Cristiana Oprea, RO**Introduction to the European standards of HIV care in Europe**

10:35 - 10:45

*Speaker:* Teymur Noori, SE**Implementation and utility of Standards of Care**

10:45 - 10:55

*Speaker:* Fiona Burns, GB**HIV testing module**

10:55 - 11:05

<i>Speaker:</i> Ann Sullivan, GB	
<b>Panel discussion, Q&amp;A</b>	11:05 - 11:25
<i>Moderator:</i> Jürgen Rockstroh, DE	
<i>Panelist:</i> Jose I Bernardino, ES	
<i>Panelist:</i> Deniz Gökengin, TR	
<i>Panelist:</i> Caroline Hurley, IE	
<i>Panelist:</i> Omar Syarif, NL	
 <i>Special session</i> 11:40 - 13:10	 POLONEZ
<b>ECDC/EACS Standard of Care Workshop (Part 2)</b>	
<i>Chair:</i> Cristiana Oprea, RO	
<i>Chair:</i> Ann Sullivan, GB	
<b>PrEP module</b>	11:40 - 11:50
<i>Speaker:</i> Milosz Parczewski, PL	
<b>Panel discussion, Q&amp;A</b>	11:50 - 12:10
<i>Moderator:</i> Jean-Michel Molina, FR	
<i>Panelist:</i> Alma Cicic, ME	
<i>Panelist:</i> Bartosz Szetela, PL	
<i>Panelist:</i> Ferenc Bagyinszky, DE	
<b>Prevention and access to treatment</b>	12:10 - 12:20
<i>Speaker:</i> Jean-Michel Molina, FR	
<b>Access to treatment: PrEP (structural barriers)</b>	12:20 - 12:35
<i>Speaker:</i> Deniz Gökengin, TR	
<b>Access to treatment: ART, including Long Acting drugs</b>	12:35 - 12:50
<i>Speaker:</i> Marco Vitoria, CH	
<b>Panel discussion, Q&amp;A and conclusions</b>	12:50 - 13:10
 <i>Ceremony</i> 13:10 - 13:40	 POLONEZ
<b>Closing remarks</b>	
<i>Chair:</i> Esteban Martínez, EACS President, EACS Conference Co-Chair, ES	
<i>Chair:</i> Justyna Kowalska, Local Conference Co-chair, PL	
<i>Chair:</i> Magdalena Ankiersztejn-Bartczak, Local Community Co-Chair, PL	
<b>EACS 2023 conference closing remarks</b>	13:10 - 13:15
<b>Rapid Abstract awards</b>	13:15 - 13:20
<b>Art exhibition awards</b>	13:20 - 13:30
<b>Introduction on the 20th European AIDS Conference/EACS 2025</b>	13:30 - 13:40